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ELISA: enzyme-linked immunosorbent assay 
EU: ELISA units
GCF: gingival crevicular fluid 
(M)GI: (modified) gingival index 
ISH: in situ hybridisation 
(L )JP: (localized) juvenile periodontitis 
LF: lactoferrin
MANOVA: multivariate analysis of variance 
MHC: major histocompatibility complex 
PBS: phoshate-buffered saline
PBSE: phosphate-buffered saline containing 1% EDTA 
PCR: polymerase-chain reaction 
PD: probing depth
RCE: relative coefficient of excretion 
RPP: rapidly progressive periodontitis 
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SUMMARY
The precise role of the humoral immune response in 
periodontal diseases is not known. Previous workers have 
investigated the relationship between systemic antibody 
levels and disease status in great detail. However, areas 
such as local antibody levels, antibody avidity, 
differentiation of specific disease states, treatment 
effects and oral implants have been investigated to a much 
lesser extent. Therefore, in this study, these and other 
aspects were investigated in order to further elucidate the 
effects of the humoral immune response on the initiation 
and progression of periodontal disease.
An early study investigated systemic antibody levels 
to Gram-positive organisms during the course of 
experimental gingivitis. No significant changes in
antibody levels were detected. However, at this stage, the 
ELISA technology employed was not sensitive enough to 
permit estimation of gingival crevicular fluid (GCF)
antibody levels. Levels of a2-macroglobulin (a2-M) and 
transferrin were assayed to monitor the progression of 
inflammation.
Because many studies of the humoral immune response 
in periodontal disease have concentrated on antibody titre 
and very little has been published on antibody avidity, or 
binding strength, three studies were conducted into the 
relationship between antibody avidity and disease
progression, disease state and response to treatment
xiv
respectively.
The first study assayed antibody avidities to 
Porphyromonas gingivalis and Actinobacillus 
actinomycetemcomitans in adult periodontitis (AP) patients 
on a longitudinal basis. IgM antibodies to P. gingivalis 
were found to be higher in patients who did not go on to 
experience further attachment loss than in those who did. 
IgG avidities to P. gingivalis were significantly higher 
in AP patients than in control subjects, confirming a 
previous finding.
The second of these studies investigated the 
relationship between antibody avidity and periodontal 
disease classification, i.e. AP or rapidly progressive 
periodontitis (RPP). It had previously been shown that 
antibody avidities were lower in RPP patients than in 
controls, in complete contrast to the earlier finding for 
AP patients. However, this study demonstrated that IgG and 
IgM avidities to P. gingivalis were lower in RPP patients 
than in AP, when directly compared.
The third of these studies investigated the effect of 
periodontal treatment on antibody avidity. The scope of 
previous studies in this area was increased to include IgG, 
IgM and IgA avidities to both P. gingivalis and A. 
actinomycetemcomitans. The avidity of IgG antibodies to P. 
gingivalis and IgG, IgM and IgA titres to A. 
actinomycetemcomitans increased after therapy. Overall, 
the data suggest that therapy induces the production of 
higher avidity antibodies.
xv
Modification of the ELISA technology by utilising 
biotin-avidin amplification increased sensitivity allowing 
antibody levels in GCF to be quantified. Four studies were 
conducted. Two of these were cross-sectional studies 
investigating healthy, gingivitis and periodontitis sites 
in periodontitis patients. Two compared cross-sectionally 
matched oral implant and natural tooth sites in oral 
implant patients.
The first of these studies demonstrated a strong 
correlation between IgG antibody levels to P. gingivalis 
in serum and GCF, confirming earlier findings. IgG levels 
to P. gingivalis were found to be significantly different 
in sites with different disease status, i.e. sites with 
deeper pockets and more inflammation had lower antibody 
levels than sites with shallower pockets and less 
inflammation.
The second of these studies focused on a comparison 
of IgG levels to P. gingivalis around oral implants and 
natural teeth. This is a field in which no previous work 
has been conducted on the humoral immune response, and very 
little on the inflammatory response. Therefore, assays of 
the acute-phase proteins, a2-M and al-antitrypsin (al-AT), 
and the iron-binding proteins, TF and lactoferrin (LF), 
were also performed. This study indicated great similarity 
between oral implants and natural teeth. However, there 
was also a suggestion that implants and natural teeth may 
differ in their local plasma cell infiltrate.
Because of the provocative conclusion of the first
xvi
study, that antibody levels were paradoxically lower in 
deeper pockets and more inflamed sites, it was decided to 
conduct another cross-sectional study in periodontitis 
patients. This differed in that three sites were sampled 
in each patient - one healthy, one gingivitis and one 
periodontitis. Paired comparisons were performed by 
multivariate repeated measures analysis of variance 
(MANOVA). In addition, levels of the tissue
metalloproteinase, stromelysin, and tissue inhibitor of 
metalloproteinases (TIMP) were assayed to provide an 
indication of local tissue degradation.
IgG levels against P. gingivalis alone showed a 
significant difference between health and gingivitis. 
Additionally, there was a definite trend towards specific 
IgG levels being lower in periodontitis sites than in 
gingivitis sites; bearing out the findings of the previous 
study and suggesting that specific antibody levels may 
provide a more sensitive indicator of local disease 
progression than other parameters, e.g. metalloproteinases 
or TIMP.
A further comparative study of matched implants and 
natural teeth was extended in its scope to include all 
three main immunoglobulin classes directed against both P. 
gingivalis and A. actinomycetemcomitans. The findings 
accorded generally with those of the previous implant study 
and show that there is a tendency towards IgG titres to P. 
gingivalis and A. actinomycetemcomitans being higher in 
natural teeth and IgA titres to A. actinomycetemcomitans
being higher in implants.
Finally, a pilot study was conducted in which the 
relative coefficient of excretion (RCE) ratio was applied 
to assess the extent of local immunoglobulin production. 
The findings showed definite tendencies towards increased 
local IgG and IgA production and decreased IgM production 
in periodontitis.
In conclusion, this study has demonstrated that levels 
and avidities of systemic antibodies directed against 
particular suspected periodontopathogens are influenced by 
periodontal disease classification, disease status and the 
effect of treatment. GCF IgG titres to P. gingivalis may 
allow discrimination between gingivitis and periodontitis 
sites. The comparative studies of gingival tissue around 
implants and natural teeth have suggested, despite 
remarkable similarities in humoral response, that there may 
be differences in the plasma cell infiltrate around these 
fixtures. All of these topics would benefit from further 
research, involving advanced technologies such as in situ 
hybridization (ISH) and polymerase chain reaction (PCR), 




1.1. Summary of relevant aspects of contemporary immunology
1.1.1. Introduction
Immunology has advanced at a rapid pace in recent years and 
many of these developments have impacted significantly on 
research into chronic immune and inflammatory diseases such 
as periodontal disease. These developments have been 
synthesized in a number of recent textbooks (1-5) and only 
a summary of the relevant points is presented here.
1.1.2. Innate immunity
Immunity to infection falls into two main categories, 
innate or non-specific immunity and acquired or specific 
immunity.
Mechanisms of innate immunity operate regardless of 
any prior contact with the invading organism. The simplest 
and most basic of these mechanisms are physical barriers 
preventing access to the body. These include skin which 
is impermeable, when intact, to most micro-organisms. In 
addition, mucus is secreted by membranes lining the inner 
surfaces of the body and this not only prevents adherence 
of micro-organisms to epithelial cells but also traps them 
allowing them to be eliminated mechanically by e.g. 
movement of cilia within the lungs.
The washing action of fluids such as tears, saliva and
urine also help keep epithelial surfaces clear of invading 
organisms and many of the secreted body fluids contain 
bactericidal agents e.g. lysozyme in tears, saliva and 
nasal mucus, lactoferrin and lactoperoxidase in milk, and 
hydrochloric acid secreted by the stomach. A similar 
beneficial washing function might be attributed to gingival 
crevicular fluid (GCF) also. This will be discussed at a 
later stage.
The normal bacterial flora of the body can also act 
as an effective buffer against infection by both passive 
and active mechanisms. They can inhibit the growth of 
pathogenic organisms by competition for nutrients or 
production of inhibitors. Commensal organisms in the gut 
can produce colicins. These bactericidins bind to the 
negatively-charged surface of susceptible bacteria and 
insert a hydrophobic, helical molecule into the membrane. 
This molecule then becomes completely hydrophobic and forms 
a voltage-dependent channel in the membrane, destroying the 
cell's electrical energy potential and leading to cell 
death.
1.1.3. Innate Immunity - Molecular Factors
If this first cohort of defence strategies is circumvented, 
the two main remaining innate mechanisms are those 
dependent on molecular factors and those dependent on 
cells.
Lysozyme is probably the most ubiquitous and abundant
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of secreted anti-bacterials, a muraminidase which can split 
the peptidoglycan cell wall of susceptible bacteria.
Endotoxins produced by micro-organisms during 
infection stimulate the production of the cytokines, 
interleukin-1 (IL-1) and IL-6. IL-1 is an endogenous
pyrogen (a general increase in body temperature being 
another innate defence mechanism), and can also, along with 
IL-6, stimulate the liver and other organs to produce 
molecules such as al-antitrypsin (al-AT), a2-macroglobulin 
(a2-M), both potent inhibitors of bacterial proteases, and 
C-reactive protein (CRP); proteins produced in this way as 
a response to infection are known as acute-phase proteins.
CRP binds in a Ca-dependent way to micro-organisms 
which contain membrane phosphorylcholine. Once complexed, 
the CRP-bound particle activates complement through the 
classical pathway resulting in binding of complement C3b 
to the membrane. This process, called opsonization 
(literally "making ready for the table"), renders the cell 
susceptible to adherence of phagocytes. Both phagocytic 
cells and complement will be discussed later. 
Interestingly, molecules such as CRP appear to be highly 
conserved in evolutionary terms, since the horseshoe crab's 
haemolymph contains a very similar analogue, limulin.
Finally, interferons are a group of broad-spectrum 
anti-viral agents. They are so named because they were 
first recognized by the phenomenon of viral interference. 
This is the mechanism by which an animal infected with one 
virus is rendered capable of resisting superinfection by
3
another virus.
Cells produce interferon when infected by a virus and 
secrete it into the extracellular fluid. The interferon 
then binds to uninfected cells. This promotes derepression 
of two genes in the target cell, permitting the synthesis 
of two enzymes. One of these is a protein kinase which 
catalyses the phosphorylation of a ribosomal protein and 
an initiation factor necessary for protein synthesis, 
thereby preventing mRNA translation to a large extent . The 
other catalyses the formation of a short adenylic acid 
polymer which activates a latent endonuclease. The latter 
has the ability to degrade both viral and host mRNA. The 
overall effect of this mechanism is to create a "cordon 
sanitaire" of uninfected and uninfectable cells around the 
locus of infection, thus ensuring containment.
However, as this mechanism can also inhibit host cell 
division as effectively as viral replication, it could have 
implications also in immune surveillance of neoplastic 
cells. By the same token, interferons could conceivably 
have a role in the healing phase of periodontal disease by 
"damping down" the immune and inflammatory reactions to 
bacterial products once the challenge has been removed.
1.1.4. Innate Immunity - Cells
Interferons may also modulate the activity of natural 
killer (NK) cells, which brings us to a discussion of the 
cellular components of innate immunity.
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NK cells are large granular lymphocytes which have 
membrane receptors thought to be capable of recognizing 
structures on high molecular weight glycoproteins expressed 
on the surface of virally infected cells. Via these 
receptors, the NK cell is brought close to the target cell 
and becomes activated leading to polarization of granules 
between nucleus and target, and extracellular release of 
their contents into the intercellular space. Among the 
proteins released is perforin or cytolysin which bears some 
structural homology to complement C9. It can bind to the 
target cell membrane and form a transmembrane pore 
effecting apoptosis (programmed cell death) via a Ca- 
dependent endonuclease.
Another cell which effects extracellular killing is 
the eosinophil, a polymorphonuclear leucocyte which can 
bind to large parasites, e.g. helminths, coated with C3b. 
Most of these parasites are resistant to C9. The 
eosinophil granules contain a cationic protein and a major 
basic protein, both capable of damaging the parasite 
membrane, and also a protein capable of forming a 
transmembrane pore similarly to C9 or perforin.
The two main cells involved in killing of micro­
organisms by phagocytosis, a form of total encirclement by 
the cell followed by intracellular destruction and 
digestion, are macrophages and neutrophils, the so-called 
"professional phagocytes".
Promonocytes in the bone marrow differentiate into 
mature monocytes which disseminate through the bloodstream
to locate in a number of tissues as mature macrophages. 
These macrophage populations make up the mononuclear 
phagocyte system, which comprises alveolar macrophages in 
the lung, cells in the lining of spleen sinusoids and lymph 
node medullary sinuses, Kupffer cells in the liver, and 
also macrophages throughout the connective tissue and 
around the basement membrane of capillaries. They also 
exist as osteoclasts in bone, mesangial cells in the kidney 
glomerulus and microglia in the brain. Macrophages are 
long-lived cells which can phagocytose invading bacteria 
directly. However, their particular specialism is their 
ability to phagocytose host cells infected with bacteria, 
protozoa or viruses.
The polymorphonuclear neutrophil (PMN) is a 
polymorphonuclear cell similar to the eosinophil but 
considerably more abundant, constituting about 70% of the 
leucocytes in the peripheral blood. These are short-lived 
cells produced in vast numbers in the bone marrow and 
spending about 36 hours in the bloodstream upon maturation 
before migrating into the tissues. PMNs contain three 
types of granules. The primary azurophilic granules 
contain myeloperoxidase, a group of cationic proteins and 
also some lysozyme. The secondary, so-called "specific", 
granules contain lactoferrin and large amounts of lysozyme. 
Acid hydrolases are contained in the tertiary granules. 
Since PMNs contain large glycogen stores which can be 
metabolized by glycolysis, these cells are ideally suited 
to operate under anaerobic conditions; a factor of crucial
importance in periodontal disease.
However, these cells do not operate in isolation. For 
example, activation and emigration of PMNs into a site of 
infection, e.g. a periodontal pocket, involves interaction 
between PMNs, macrophages and the complement system.
1.1.5. Complement
Complement comprises a complex series of 20 plasma proteins 
which constitute a triggered enzyme system similar in 
mechanism to the blood clotting, fibrinolytic and kinin- 
forming systems. Like these,it operates as a cascade where 
the product of one reaction then acts as an enzyme in the 
next. The net effect of this is to produce a rapid and 
highly amplified response to an initial trigger stimulus.
1.1.6. Neutrophil Activation and Emigration
Since the classical pathway is not an example of innate 
immunity, alternative pathway activation will be dealt with 
here to elucidate neutrophil activation and emigration. 
Lipopolysaccharides (LPS) and carbohydrates produced by 
bacteria react with receptors on the membranes of 
macrophages, e.g. the mannose/fucose receptor and the 
complement receptor. The mannose/fucose receptor binds 
surface carbohydrates of the bacterium whereas the CR3 
complement receptor binds bacteria which have been 
opsonized with C3b via the alternative pathway.
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Macrophages so stimulated release IL-1 and tumour necrosis 
factor (TNF), and synthesize and release neutrophil 
chemotactic factor (NCF; also designated IL-8).
These factors diffuse into the local vasculature and 
stimulate vascular endothelial cells to express the 
endothelial leucocyte adhesion molecule, ELAM-1, and up- 
regulate the concentrations of the adhesion molecules, 
ICAM-1 and ICAM-2. PMNs in the adjacent circulation are 
then bound by these adhesion molecules via their own 
adhesin, LFA-1. Movement of the PMN through the vascular 
endothelium and the basement membrane is modulated by IL-1 
and TNF, this action being independent of any existing 
chemotactic gradient. However, the neutrophil's further 
journey through the subendothelial extracellular matrix 
occurs by chemotaxis through a chemotactic gradient, a form 
of directed migration. Chemotaxins involved here include 
IL-8, C5a, bacterially-derived formyl peptides, e.g. 
formyl-methionyl-leucyl-phenylalanine, and the leukotriene, 
B4 •
These chemotaxins also activate the PMNs which can 
then destroy opsonized bacteria (i.e. with bound 
antibody/complement or complement only) by a number of 
oxygen-dependent mechanisms involving lipid peroxidation 
and the peroxide-myeloperoxidase system. As previously 
mentioned, PMNs can also kill using oxygen-independent 
mechanisms, e.g. neutral serine proteases (proteinases, 
elastase, cathepsin G), lactoferrin, lysozyme and 
defensins. These latter mechanisms are probably of much
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greater relative importance in the anaerobic micro­
environment of the periodontal pocket.
1.1.7. Acquired Immunity - B-lvmphocvtes
The cells mainly involved in specific or acquired immunity 
are antigen-presenting cells and lymphocytes. The former 
include macrophages, dendritic cells in the follicles of 
the lymph nodes, Langerhan's cells of the skin and mucous 
membranes, and B-lymphocytes themselves. These cells 
present antigen to B-lymphocytes and T-helper lymphocytes. 
The activated T-helper cells then produce cytokines which 
stimulate B-cells to differentiate into antibody-producing 
plasma cells.
Early workers in the field of antibody production 
postulated that antibody was produced as a malleable, 
uniform molecule which could be moulded to a specific 
structure by using the antigen as a template. However, 
Ehrlich (6), even a century ago, anticipated the mechanism 
which is accepted today, that of clonal selection by 
antigen. B-cells differentiate in the bone-marrow and are 
programmed to produce only one antibody. They display this 
on their surface as a receptor (about 105 molecules) but 
produce no further antibody (i.e. they are quiescent). 
When these antibody receptors are bound by antigen a 
triggering signal causes the B-cell to develop into an 
antibody-producing plasma cell.
The second step in this process is that the activated
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B-cell proliferates to produce a clone i.e. a large number 
of identical cells producing identical antibody. This is 
known as clonal expansion and allows a high level of serum 
antibody to be produced within a few days.
A third feature of this process is that clonal 
expansion not only produces antibody-producing plasma cells 
but also a proportion of quiescent cells expressing 
antibody on their surface. These memory cells provide a 
relatively large pool ready to produce a much more rapid 
and intense antibody response on further antigen challenge.
1.1.8. Acquired Immunity - T-lymphocytes
T-cells act by another mechanism to destroy invading 
viruses, mycobacteria and protozoa which attempt to evade 
host defences by proliferating inside host cells. T-cells 
differentiate within the thymus and will only recognize 
foreign antigen when it is on the surface of a host cell 
in association with cell surface markers of the major 
histocompatibility complex (MHC)• These regulatory cell 
surface molecules will be discussed in depth later.
Killing of virally-infected cells can be achieved by 
two mechanisms, one involving NK cells and the other 
cytotoxic T-cells. Apart from their direct effect on 
virally-infected cells, as already discussed, NK cells can 
also kill these cells by the process of antibody-dependent 
cell-mediated cytotoxicity (ADCC). NK cells have a 
receptor for the Fc portion of antibody and can thus bind
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to antibodies directed against virally-coded surface 
antigens. The ADCC mechanism works well in vitro, but its 
relevance in vivo is difficult to assess.
However, a subpopulation of cytotoxic T-cells produces 
a wide range of surface receptors similar to the surface 
antigen receptors on B-cells. Similarly, these T-cells are 
programmed to recognize only one antigen when it is found 
in association with a class I MHC receptor. The cytotoxic 
T-cell can thus bind to the infected cell and destroy it.
T-helper cells will bind to an antigen for which they 
are programmed when it is found in association with a class 
II MHC receptor on the surface of an infected macrophage. 
They then produce lymphokines, including y-interferon and 
other macrophage activating factors, re-triggering the 
microbiocidal mechanisms of the macrophage which had been 
repressed by the intracellular pathogen. Cytotoxic T-cells 
are also capable of acting in this way by producing y- 
interferon. These actions of T-lymphocytes are referred 
to as cell-mediated immunity. In a similar fashion to that 
which pertains for B-cells, T-cells are selected and 
activated by antigen and expanded by clonal proliferation 
to produce a large clone of activated T-cells and also a 
pool of quiescent memory cells.
1.1.9. Regulatory Cell Surface Receptors
As previously discussed, the interactions between immune 
cells are not only influenced and controlled by soluble
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agents, e.g. cytokines, complement and immunoglobulins, but 
also by regulatory cell surface molecules. These fall into 
four categories on immune cells: 1) MHC receptors; 2) cell 
surface receptors; 3) cluster of differentiation (CD) 
antigens; and 4) adhesins.
MHC ; antigens are transmembrane heterodimers. MHC 
class I molecules consist of a 43kDa peptide heavy chain 
non-covalently linked to a smaller llkDa peptide called p~ 
microglobulin. Most of the heavy chain is organized into 
three globular domains which protrude from the cell 
surface. A hydrophobic domain anchors the molecule in the 
membrane and a short hydrophilic sequence carries the C- 
terminus into the cytoplasm. Class II MHC receptors are 
also transmembrane glycoproteins, consisting of an a-chain 
of 34kDa and a p-chain of 28kDa. Class I receptors are 
found on virtually all cells, whereas class II receptors 
are found in B-cells and macrophages, and can be induced 
by y-interferon on capillary endothelial and epithelial 
cells. In addition, a number of other genes within the MHC 
chromosome 6 region are known as MHC class III. These 
include genes coding for complement factors C2, C4 and 
factor B, and also TNF-a and -p. The MHC system has 
evolved as a highly polymorphic system based on multiple 
alleles (i.e. alternative genes at each locus). These 
multiple allelic forms are produced by various means 
including recombination, homologous but unequal cross-over, 
point mutation and gene conversion. This latter mechanism 
involves transfer of short nucleotide sequences from
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apparently non-functional genes, e.g Qa, into functional 
ones.
The importance of MHC receptors in immunological 
phenomena has already been discussed, but they also have 
influence in developmental and hormonal events.
The T-cell receptor (TCR) merits further discussion. 
Like the MHC receptor it is also a heterodimer, comprising 
two chains of 40-50kDa each. Unlike B-cell receptors which 
exist as membrane-bound immunoglobulin M monomer, the TCR 
is obviously not synthesized by immunoglobulin genes.
Functional T-cells display the TCR on their surface non-
covalently bound to CD3 (one of the cluster of 
differentiation antigens). The seven-peptide chain CD3 
transduces the antigen recognition signal into the cell.
Although the a and p chains of the TCR are not related
to immunoglobulin, they share the same function. Each
chain folds into two domains, one having a relatively 
invariant structure, the other displaying great variability 
akin to that of the immunoglobulin Fab fragment.
The CD antigens were discovered by immunizing animals 
with human lymphocytes. The antibodies produced recognize 
particular lymphocyte sub-populations. For example, CD3 
is present on all T-cells but not on B-cells. CD4 is 
expressed on T-helper cells and CD8 on cytotoxic T-cells. 
These latter CD antigens act as co-receptors for class II 
MHC-antigen complex and class I MHC-antigen complex 
respectively, and are part of the TCR complex. CD4 is also 
a receptor for the human immunodeficiency virus.
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The adhesins fall into four main groups: 1) integrins; 
2) adhesion molecules of the immunoglobulin supergene 
family; 3) lectin-like adhesion molecules, the selectins; 
and 4) the CD44, or Hermes group, which interact with 
ligands called addressins on vascular endothelium.
Important integrins include CR3 and CR4 which bind to 
complement C3b and LFA which binds to ICAM-1 and ICAM-2. 
ICAM-1 and ICAM-2 are both found on capillary endothelium, 
and ICAM-1 is also expressed on B-cells and T-cells, and 
is probably involved in the interaction between antigen- 
presenting cells and lymphocytes. ICAM-1 is also probably 
, important in transendothelial migration of PMNs.
Selectins include endothelial/leucocyte adhesion 
molecule (ELAM). Binding of neutrophils to ELAM is thought
t
I
| to be a crucial first step in neutrophil emigration across
j the capillary endothelium.
The CD44 homing receptors expressed on lymphocytes 
appear to be important in the binding of these cells to the 
high endothelial venules (HEV) of peripheral lymph nodes. 
The ligands for the CD44 antigen found on lymphocytes have 
been called vascular addressins. It is thought that there 
are other homing receptors selective for other lymphoid 
tissues, e.g. Peyer's Patch HEV, and, therefore, these 




An antibody, or immunoglobulin, molecule is made up of four 
peptide chains, two identical heavy chains and two 
identical light chains linked by interchain disulphide 
bonds. Immunoglobulin G (IgG) can be split by proteolytic 
enzymes to produce fragments giving clues to their 
function. The Fab fragment is now recognized as the 
antigen-binding fragment and the Fc as having other 
functions, e.g. complement binding. The Fab fragment 
contains considerable variability whereas the Fc fragment 
is relatively constant, and analysis of amino-acid 
variability has identified three hypervariable sequences 
on the heavy chain and three on the light chain in the Fab 
fragment.
Five different types of heavy chain exist in humans 
and these define the immunoglobulin classes, IgG, IgA, IgM, 
IgD and IgE. These are termed the immunoglobulin classes. 
IgG is the principal immunoglobulin produced in the 
secondary immune response. IgG diffuses more easily than 
the other immunoglobulins into the extracellular spaces 
where it has the predominant role in neutralizing bacterial 
toxins and binding to micro-organisms to promote complement 
fixation followed by phagocytosis.
The unique biological function of different 
immunoglobulin classes is mediated by the Fc portion. In 
the case of IgG, monocytes and macrophages contain 
receptors for Fey (FcyRI) • FcyRII is found on monocytes,
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neutrophils, eosinophils, platelets and B-cells. IgG 
complexes can bind to platelets causing thrombosis. 
Stimulation of B-cell Fc receptor leads to downregulation 
of IgG production, a possible mechanism whereby IgG and IgG 
immune complexes exert a negative feedback effect on 
antibody production.
The Fey region of IgG is responsible for complement 
activation via the classical pathway, binding to Clq and 
causing its activation.
Another low-affinity Fc receptor, FcyRIII, which is 
found on NK cells, macrophages, PMNs and eosinophils, is 
thought to be responsible for mediating ADCC by NK cells 
and immune complex clearance by macrophages.
IgG possesses the unique property among immunoglobulin 
classes of being able to cross the placenta providing 
considerable protection to the newborn in the first weeks 
of life, further supplemented by IgG in milk. The 
transport processes required here involve translocation of 
IgG across the cell barrier by complexing with another Fey 
receptor. A recent study has shown that the FcyRn receptor 
in the gut cells of the newborn rat complexes with IgG at 
relatively low pH in the gut lumen. This complex 
dissociates at the higher pH of the basal layer once the 
IgG has been transported across the intestinal cell (7).
IgA is adapted to defend the exposed external and 
internal surfaces of the body against micro-organisms. It 
is found predominantly in sero-mucous secretions, e.g. lung
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secretions, saliva and secretions of the gastrointestinal 
and genito-urinary tracts. In these fluids it is present 
as a dimer which is stabilized against proteolysis by 
combination with the secretory component, which is 
synthesized by local epithelial cells. Dimerization occurs 
intracellularly via a joining sequence (J-chain), to 
prevent association of monomers with differing specificity. 
Essentially, IgA antibodies coat micro-organisms and 
thereby inhibit their adherence to mucosal cells. 
Aggregated IgA can also bind PMNs and can activate the 
alternative complement pathway. Monomeric IgA is also 
found in relatively high levels in the circulation 
indicating an additional systemic role for IgA.
IgM exists as a pentamer joined by a J-chain. IgM 
antibodies, although of low affinity as measured against 
single determinants, can demonstrate relatively high 
avidity, i.e. overall binding strength with molecules 
containing multiple epitopes. This is because the 
multivalency of IgM confers a synergistic effect whereby 
the binding of the molecule to two epitopes is of many 
times greater strength than the sum of the two 
interactions. In fact, the avidity is determined by a 
multiplication of the two binding strengths. This bonus 
effect of multivalency can be thought of as a vast 
reduction in the probability of simultaneous dissociation 
of several interactions as opposed to a single interaction.
IgM appears in the primary immune response and is 
extremely efficient in agglutination and cytolysis of
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invading cells. As such it is thought to play a vital role 
in control of bacteraemia.
Immunoglobulins are further grouped into subclasses. 
IgG, for example, exists as IgGl, IgG2, IgG3 and IgG4, the 
difference being in the heavy chains which exist as y 1,2,3 
and 4 respectively. These heavy chain differences give 
rise to differences in biological properties. IgG2, for 
example, is relatively inefficient in placental transfer, 
whereas IgG3 is a very avid binder of complement, and IgG4 
is a poor fixer of complement. IgGl and IgG3 are both 
strong binders of monocytes. Some of these differences 
between different IgG subclasses may have an impact on the 
course of periodontal disease, and this will be discussed 
later.
The hypervariable regions on the immunoglobulin 
molecules which form the antigen-binding site are 
themselves, by definition, unique antigens which can be 
recognized by antibodies raised against them. In this 
context, these regions are referred to as idiotypic 
determinants? these compare with the isotypic determinants 
which define the various class and subclass variants and 
allotypes which define genetic variants of various regions.
Jerne's network hypothesis (8) states that because 
lymphocytes can recognize a vast array of foreign antigens, 
they should also be able to recognize the idiotypes of 
other lymphocytes. It is thought that a network may be 
formed which relies on idiotype-anti-idiotype recognition 
between lymphocytes of different subsets. The response to
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foreign antigen would then affect the equilibrium of this 
network and provoke an appropriate response.
1.1.11. Generation of Diversity of Antibodies
Since the immune system must be capable of producing 
millions of different antibodies, the dedication of a 
single gene to programme for each antibody is clearly not 
an option as the mechanism producing such diversity.
To illustrate how such diversity is generated from a 
limited gene pool, the genes coding for heavy chains will 
be discussed here. The first element is that there are 
several genes coding for these; a single cluster is formed 
by the subclass constant region genes, and there is also 
a group of twelve highly variable D segments inserted 
between the V segment coding for the hypervariable regions 
and the J segment coding for a joining sequence to the 
constant region.
The diversity latent in this pool is considerably 
amplified by various mechanisms. The first of these 
involves rearrangement of these genes as the precursor cell 
differentiates into a mature B-lymphocyte. For example, 
there are 500 different V segments, 15 different D segments 
and 4 different J segments coding for heavy chain 
hypervariable region. Possible VxDxJ combinations generate 
thirty thousand rearrangements.
A second mechanism involves splicing out of base 
triplets upon recombination of V, D and J genes resulting
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in removal of one amino-acid from the protein sequence. 
Splicing out of single base pairs and doublets can also 
occur resulting in a frame shift which thereafter codes for 
a completely different protein sequence.
A third mechanism involves random association between 
heavy chains and light chains, both of which have 
hypervariable regions. Since possible light chain 
combinations are on the order of 103, total heavy/light 
chain combinations are on the order of 107-108.
Other mechanisms amplify this diversity yet further, 
e.g. V gene swapping and reading of D genes in three 
different reading frames.
A final mechanism which deserves specific attention 
is that of somatic mutation. The V region rate of somatic 
mutation as a result of single base substitutions has been 
assessed at 2-4%, with mutations being more prevalent in 
IgG and IgA than in IgM. It is thought that somatic 
mutation is more involved in class switching and affinity 
maturation in association with immunological memory 
generation than simply in the generation of greater 
antibody diversity.
These and other mechanisms which tune the humoral 
immune response to pathogens in terms of avidity, subclass 
etc. during the course of periodontal disease will be 
further discussed later.
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1.2. Microbiology of Periodontal Disease
1.2.1. Historical Perspective
Although references to periodontal diseases can be traced 
back to Roman physicians, oral microbiology can be said to 
date back to van Leeuwenhoek in 1772 (9). Later W.D.
Miller, whose work was reprinted in 1973 (10), proposed his 
acidogenic theory of dental caries and, in addition, 
proposed that "pyorrhoea alveolaris" is not caused by a 
specific bacterium occurring in every case (as in classical 
single-pathogen infections e.g. tuberculosis), but that 
various bacteria may be responsible.
As such this was one of the earliest expressions of 
what is now known as the non-specific plaque hypothesis. 
This postulates that dental plaque can be considered a 
homogeneous mass which causes periodontal disease once it 
has accreted to a point where it can overwhelm host defence 
mechanisms. Similarly, one of the first suggestions of the 
specific plaque hypothesis was that of Bass who suggested 
a specific micro-organism, "Endoameba buccalis" as the 
cause of periodontal disease, even going so far as to 
suggest a vaccine to this organism as a form of therapy 
(11).
1.2.2. Infectious Nature of Periodontal Disease
Since the periodontal diseases, comprising gingivitis and
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periodontitis, are caused by bacterial plaque, they are, 
therefore infectious diseases as borne out by much evidence 
summarized by Socransky (12). Notably, the classic 
experimental gingivitis study of Loe et al (13) 
demonstrated a correlation between the build up of plaque 
and the development of clinically demonstrable gingivitis.
Secondly, periodontal treatment which reduces plaque 
mass and removes some key species altogether can be 
correlated with clinical improvement.
Thirdly, in vivo and in vitro studies of plaque micro­
organisms provide further evidence of the infectious nature 
of periodontal disease, especially with regard to the 
specific plaque hypothesis. A number of case reports have 
demonstrated various infections caused by oral micro­
organisms in extra-oral sites (14, 15). Oral implantation 
into animals has been shown to cause periodontal disease 
with similar histopathology to that seen in humans (16, 
17). Mixed infections have also been shown to have 
synergistic effects (18).
In vitro studies of pathogenicity have investigated 
the ability of plaque bacteria to produce virulence 
factors. Since Gram-negative bacteria tend to predominate 
in periodontal pockets, high concentrations of 
lipopolysaccharide (LPS) endotoxin tend to build up. This 
causes a cytotoxic effect on host cells, promotes 
osteoclastic bone resorption and results in a localized 
Schwartzman reaction with tissue necrosis.
Additionally, toxic metabolic end products are
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released and there are indirect effects such as activation 
of the alternative complement pathway (19).
Certain bacteria, notably Porphyromonas gingivalis, 
also produce enzymes capable of destroying host proteins 
(20). P. gingivalis and Actinobacillus actinomycetem- 
comitans both produce collagenase which is capable of 
degrading host collagen. P. gingivalis also produces 
enzymes capable of degrading host immunoglobulins (21) and 
this organism, along with Prevotella ssp., has been shown 
to be able to coat itself with Fab fragments of degraded 
IgAl thus evading host defences (22). Another example of 
this sort of strategy is the bacterial capsule which can 
inhibit phagocytosis by polymorphonuclear leucocytes (PMNs) 
and macrophages.
By the production of enzymes such as collagenase, 
hyaluronidase, gelatinase, aminopeptidase, proteinase etc., 
plaque bacteria can increase the permeability of the 
epithelium lining the gingival sulcus, destroy connective 
tissue and thereby cause proliferation of the junctional 
epithelium apically along the root surfaces.
1.2.3. Specific Microorganisms
The infectious nature of periodontal diseases having been 
clearly established, a number of studies have implicated 
specific micro-organisms in the aetiology of these diseases 
(23-27). Classically, a pathogen has been defined by 
Koch's postulates (28). Briefly, these three requirements
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demand that 1) the agent must be isolated from every case 
of the disease, 2) the agent must not be isolated from 
cases of other disease states or from non-pathogenic 
(healthy) states and 3) after isolation and repeated growth 
in pure culture the agent must induce disease in 
experimental animals. However, Koch was required to 
abandon the third requirement in 1884 when he failed to 
induce cholera in animals, and in 1890 the second criterion 
was relaxed when the possibility of the carrier state was 
recognized.
Recent workers in periodontal microbiology have 
modified and extended Koch's postulates (27). The relevant 
criteria can be discussed under five headings. First, the 
criterion of association requires that the suspected 
pathogen be detected more frequently and at higher levels 
in disease cases than in controls. This would mean that 
the organism should be present in higher levels in actively 
progressing sites than in non-progressing sites, healthy 
sites or sites showing improvement. It might also be 
expected that a system of longitudinal monitoring would 
show an increase in the pathogen prior to or concomitant 
with clinically assessed disease progression.
Secondly, the criterion of elimination is based on the 
premise that periodontal treatment should influence not 
only the clinical course of the disease but also the 
associated micro-flora. A corollary of this view is that 
failure to eliminate or at least reduce the level of the 
pathogen would eventually lead to further progression at
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that site.
Thirdly, the animal pathogenicity criterion continues 
to be used in the elucidation of possible pathogens, 
despite concerns about the use of animal models. They have 
been shown to produce valuable supportive evidence 
concerning the roles of certain micro-organisms in 
periodontal disease (29-31).
Fourthly, the response of the host to potential 
pathogens has been applied in attempts to differentiate the 
importance of various species in different forms of 
periodontal disease. This will be discussed in greater 
detail at a later stage.
Finally, some suspected organisms have the capability 
to produce virulence factors and these may not only be 
important in disease initiation and progression, but may 
also be useful as indicators of the pathogenic potential 
of the organism (32).
1.2.4. Porphvromonas gingivalis and Actinobacillus actino- 
mvcetemcomitans
Two organisms that have been particularly implicated in 
periodontal disease using these criteria are P. gingivalis 
and A. actinomycetemcomitans. Both of these organisms 
have been found in elevated numbers in periodontitis sites. 
However, A. actinomycetemcomitans has been associated 
particularly with the early-onset forms of periodontitis, 
localized juvenile periodontitis (LJP) and rapidly
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progressive periodontitis (RPP). It has also been detected 
in prospective studies of disease progression. Further 
evidence of association is that P. gingivalis has been 
shown to bind to epithelial cells (27).
Elimination of both organisms results in successful 
therapy and recurrent lesions were found to harbour these 
species. Both species have been shown to induce 
periodontal disease in animal studies (27). The host 
response in terms of specific antibody production, both 
local and systemic, has been shown to be elevated with both 
organisms in different types of periodontal disease, a high 
titre to A. actinomycetemcomitans being associated with 
LJP • Both organisms also produce a number of virulence 
factors including enzymes such as collagenase, numerous 
proteases in the case of P. gingivalis capable of 
destroying most host proteins, endotoxin, leucotoxin and 
epitheliotoxin in the case of A. actinomycetemcomitans, 
and also factors inducing bone resorption and inhibiting 
PMN function (27).
1.2.5. Other Suspected Microorganisms
A number of other micro-organisms have also been implicated 
in periodontal disease. However, of these only 
spirochaetes, Prevotella intermedia and Fusobacterium 
nucleatum have been suggested as possibly causative 
satisfying all of the extended postulates (27). 
Spirochaetes are found in "superficial layers" of plaque
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near host tissues, as evidenced by electron microscopy, 
where they are actively motile, suggesting that they have 
a strong affinity for host tissue. Indeed, they have been 
shown to invade gingiva in acute ulcerative gingivitis 
(AUG) (33). However, since spirochaetes do not form 
colonies on agar media but instead form "spirochaetal haze" 
as they move through the agar when cultured by membrane- 
filter and agar-well techniques, and are also sensitive to 
mechanical forces during sample dispersion or dilution and 
particularly to atmospheric oxygen, the laboratory culture 
of spirochaetes has been fraught with problems.
F. nucleatum is a Gram-negative obligate anaerobe 
which is frequently isolated from subgingival dental plaque 
in patients with adult periodontitis. Indeed, high numbers 
are often detected in sites undergoing active periodontal 
destruction. However, high numbers of F.nucleatum can also 
be isolated in inactive sites and, therefore, the role of 
this organism in periodontitis is equivocal (27).
Prevotella intermedia, like P. gingivalis, is 
frequently isolated from periodontitis sites. A recent 
study has demonstrated Prevotella intermedia in 88% of 
periodontitis subjects and P. gingivalis in 94% of these 
subjects. However, Prevotella intermedia was also detected 
in 42% of gingivitis subjects (i.e. no probing attachment 
loss > 2mm over one year of observation), whereas P. 
gingivalis was not detected in any of these subjects (34). 
Therefore, the association of Prevotella intermedia with 
periodontitis as opposed to gingivitis is also equivocal.
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Since P. gingivalis and A. actinomycetemcomitans 
appear to be most strongly and unambiguously associated 
with periodontitis (35-38), the immune responses to these 
two organisms in particular were chosen for intensive 
study.
1.2.6. Current Concepts of Aetiology
In 1992 Socransky and Haffajee summarized current concepts 
of the aetiology of destructive periodontal disease in 
their review (39). Pathogenic species have been discussed 
above, and host susceptibility will be dealt with in the 
next section. However, the effect of beneficial species 
in the disease process is less clear, but it would seem 
reasonable to assume that non-pathogenic species could have 
a role in preventing disease initiation and progression by 
displacing pathogenic species.
Socransky and Haffajee conclude that the presence of 
a pathogenic species is necessary but not sufficient for 
disease to occur. In order that disease results from this 
pathogen 1) it must be of a virulent clonal type; 2) it 
must possess the chromosomal and extra-chromosomal genetic 
factors to initiate disease? 3) the host must be 
susceptible to this pathogen; 4) the pathogen must be in 
numbers sufficient to exceed the threshold for that host; 
5) it must be at the right site? 6) other bacterial species 
must foster, or at least not inhibit, the process and 7) 
the local environment must be one which is conducive to the
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expression of the species' virulence properties.
It may seem that the use of such extended requirements 
is an attempt to draw up a list of postulates which accord 
with what is already known about suspected 
periodontopathogens. However, their value can only be 
judged in truly prospective studies. In addition, the 
demonstration that virulence factors can be transmitted 
between different strains and even between different 
species, as evidenced by the transfer of antibiotic 
resistance between P. denticola and P. intermedia (40), 
may have enormous implications. The importance of bacteria 
in periodontal aetiology may in future be ascribed to genes 
coding for specific virulence factors rather than to 
particular microorganisms.
Socransky and Haffajee (39) conclude that diagnostic 
tests for bacteria should probably not exist in isolation 
but in combination with other diagnostic tests of host 
susceptibility. It is to this latter aspect in terms of 
humoral immune response that this study is applied.
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1.3. Epidemiology and pathogenesis of periodontal disease
and host responses
1.3.1. Introduction
Periodontal disease is a general term which can be used to 
refer to all diseases which could have an effect on the 
periodontium. Since the periodontium comprises tissues of 
different origin, both mesenchymal and ectodermal, a large 
range of systemic conditions with periodontal consequences 
could be included under this heading (41). However, in the 
present context, this term will only be used to denote 
gingivitis and periodontitis, i.e. dental plaque-induced 
inflammatory processes of the periodontium.
1.3.2. Gingivitis
In gingivitis, pathological changes are confined to the 
superficial gingival tissue, i.e. the gingiva. Clinical 
manifestations include redness and swelling, and an 
increased tendency to bleeding on probing, all associated 
with increased vascularity. The increased vascularity also 
leads to an increase in local temperature and increased 
gingival crevicular fluid flow. Gingival crevicular fluid 
(GCF) is an inflammatory exudate or preinflammatory 
transudate present in the gingival crevice. Its components 
are derived mainly from: 1) microbial products; 2)
interstitial fluid and locally-produced factors of host
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origin; 3) plasma; and 4) tissue degradation/turnover 
products (42). Production of GCF due to an inflammatory 
increase in the vascular permeability of the subendothelial 
vasculature was shown in early studies (43, 44).
1.3.3. Periodontitis
Periodontitis, however, also effects the deeper structures 
of the periodontium, i.e. cementum, periodontal ligament 
and bone attachment. This results in loss of periodontal 
support, bone loss as evidenced by radiographs and the 
development of the periodontal pocket. At least four 
different forms of periodontitis have been defined (45-47), 
and, as will be discussed later, it is thought that at 
least some of these have a basis in differences in host 
responsiveness.
Early studies in this field (48-50) contributed to the 
consensus that: 1) periodontitis is a virtually universal 
phenomenon affecting a very high percentage of the 
population; 2) the disease begins as gingivitis at an early 
age and if left untreated will develop into periodontitis; 
and 3) most of the perceived variance in periodontal 
disease is associated with age and deficient oral hygiene.
1.3.4. Recent Concepts in Epidemiology
However, recent studies have challenged these concepts and 
a different overall picture of the prevalence and
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progression of destructive periodontal disease has emerged.
Recent cross-sectional studies have demonstrated that, 
although a periodontium of reduced height becomes the norm 
with increasing age, relatively few subjects in each age 
group suffer from advanced periodontal destruction. These 
subjects account for most of the sites which are severely 
periodontally involved (51-53). Papapanou et al reported 
that 75% of the total sites with previous attachment loss 
of at least 6mm occurred in 23% of the individuals examined 
(52).
Loe et al (54) reported similar findings in a 15-year- 
long study of the natural history of periodontal disease 
in Sri Lanka. These investigations identified a group of 
subjects, comprising 8% of the total sample, who showed 
rapid progression of periodontal disease, as defined by 
tooth mortality rates and interproximal attachment levels. 
In the same study, however, 11% of the subjects did not 
show progression of periodontal disease beyond gingivitis.
In addition, longitudinal studies have shown that 
relatively few sites undergo extensive periodontal 
destruction within a given observation period (55-57). 
Lindhe et al (56) reported that during a six year follow-up 
of 64 Swedish subjects, showing signs of previous 
periodontal destruction but not receiving active 
periodontal treatment, only 3.9% and 11.6% of their sites 
demonstrated attachment loss of greater than 2mm from 
baseline at 3 and 6 years respectively. Similar 
percentages (3.2%) of sites exhibiting periodontal
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attachment loss were reported in the same study for a group 
of American subjects who were followed over a one year 
period. Moreover, it seems that relatively few individuals 
account for the sites which show active periodontal 
destruction over an observation period. Thus, Lindhe et 
al (57) in a recent study reported that 70% of the sites 
that deteriorated by 3mm or more during a two year 
monitoring period occurred in only 12% of the 265 Japanese 
subjects that were followed longitudinally.
1.3.5. Subject and Site Relatedness
Therefore, the current view is that periodontal disease is 
subject related, with a small subset of individuals within 
a given population suffering from advanced periodontal 
destruction, and with relatively few subjects and sites 
undergoing active periodontal destruction within a given 
period. In addition, in the absence of treatment, the mere 
presence of inflammatory periodontal lesions does not 
necessitate their progression (58). Thus, it has become 
apparent that any investigation of periodontal disease must 
take account of subject-specific and site-specific factors, 
and this will become clearer in the later discussion of 
subject and site susceptibility.
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1.3.6. The Classical Model
Page and Schroeder (59) proposed five distinct states in 
the pathogenesis of periodontitis, ranging from health to 
advanced disease. The stages within this classical picture 
are health, the initial lesion, the early lesion, the 
established lesion and the advanced lesion. The initial 
PMN infiltrate was postulated to be rapidly replaced within 
48 hours by a lymphocytic lesion. This lesion could then 
stabilise as the early lesion unless further challenged by 
plaque. With further plaque challenge, however, the 
cellular infiltrate was then thought to transform into a 
plasma cell dominated lesion. At this stage tissue 
destruction including bone resorption was thought to occur.
However, three factors have brought Page and 
Schroeder's model into serious question: l)the inability 
to test the validity of the model with true longitudinal 
studies; 2)recent changes in ideas on periodontal disease 
activity; and 3) the fact that not all postulated stages 
have been observed histologically (60-64).
1.3.7. Three Models of Pathogenesis
Three models have been described to explain destruction of 
the periodontal supporting tissues: the continuous
paradigm, the random burst theory and the asynchronous 
multiple burst hypothesis. The continuous paradigm 
postulates slow, constant and progressive destruction, and
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is supported by cross-sectional studies (65, 66), and
longitudinal monitoring of sites not responsive to 
treatment (67). However, as the study of Loe et al (66) 
shows, pooling data from groups, individuals and sites in 
cross-sectional studies can give the impression that 
destruction was slow and continuous.
The random burst theory proposes short periods of 
destruction punctuated by periods of resolution occurring 
randomly in time and at random sites within the subject 
(68). By contrast, the asynchronous multiple burst 
hypothesis proposes that destruction occurs within a 
defined time frame and then resolution or remission 
follows. This hypothesis suggests that many sites would 
show bursts of activity over a limited period of time and 
then these sites would become inactive indefinitely. None 
of these proposed mechanisms can be established or refuted 
by presently available data (69). However, a matter of 
some concern must be that methods of assessing parameters, 
such as attachment loss, generally yield such poor 
resolution. This means that such parameters will, almost 
by definition, lend themselves to the detection of "bursts" 
during longitudinal trials.
1.3.8. Stages in Pathogenesis
The Page and Schroeder model will be used as a framework 
for the following discussion of each stage in the
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pathogenesis of periodontal disease, but conflicting views 
will also be presented where appropriate.
Under experimental conditions, clinically "healthy” 
gingiva can be established. The tissues are characterized 
by gingival index (GI) scores of 0 and a mere trace of 
gingival exudate (70, 71), but this is not identical with 
histologically "normal" gingiva (72). This normal 
condition only exists in gingiva adjacent to plaque-free 
teeth and is, therefore, rarely encountered in humans. It 
has been described in animals whose gingivae have been kept 
meticulously clean (73) and also in germ-free animals (74). 
It must be stressed that even biopsies of clinically normal 
human gingiva demonstrate infiltration of inflammatory 
cells. This infiltrate comprises 3-5% of the connective 
tissue volume contiguous with the junctional epithelium, 
and contains PMNs, monocytes, macrophages and lymphocytes,
primarily T-cells with very few B-cells or plasma cells
(59, 63, 75). This infiltrated area suffers from collagen 
depletion and its vascularity is increased. Fluid and 
plasma proteins leak from the microvasculature, percolating 
through the connective tissue and junctional epithelium 
into the gingival sulcus, giving rise to the GCF (76).
This stage constitutes one of the main problems in
elucidating the pathogenesis of periodontitis. 
Investigators have been unable to make a clear distinction 
between normal and pathologically altered tissue. The 
crucial point at which disease commences has not been 
determined. Since definitive evidence on this point is
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lacking so far, two hypotheses have been adduced. The 
first states that the features of the initial lesion merely 
reflect enhanced levels of the host defences occurring 
within the gingiva as part of normal surveillance 
procedures (59, 61, 77, 78). The second states that the 
"initial" stage may be a quiescent phase following 
destructive disease. As such it may constitute a later or 
indefinitely recurring stage in disease progression (79).
The acute, exudative, inflammatory response to plaque 
accumulation is known as the initial lesion (61, 78),
according to the Page and Schroeder classification. The 
initial lesion usually manifests after 2-4 days, although 
vascular changes beneath the junctional epithelium can be 
seen within 24 hours of plaque accumulation; it is 
localized around the gingival sulcus. More blood is 
brought to the area by dilation of the arterioles, venules 
and capillaries of the dentogingival plexus. At the same 
time, intercellular spaces between capillary or venular 
endothelial cells appear because of the elevation of 
hydrostatic pressure. This causes increased permeability 
of the microvasculature resulting in leakage of fluids and 
proteins into the tissues. The result is the GCF flow. 
The fluid flow may act as a defence mechanism by flushing 
out bacterial products while, at the same time, delivering 
bactericidal host products, e.g. antibodies and complement.
Listgarten and Ellegaard (80) have shown that plasma 
cells predominate apically to the gingival sulcus in the 
initial lesion in animal models. However, in human models,
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the initial lesion contains no plasma cells in the 
connective tissue area subjacent to the junctional 
epithelium (61, 81). It has been suggested that host
defence mechanisms may not always have a beneficial role, 
and that they may also be destructive. Although 
neutrophils and macrophages are recruited to the area to 
defend the host against bacterial attack, their 
accumulation in the coronal part of the connective tissue 
and junctional epithelium probably accounts for much of the 
damage seen in this portion of the gingiva (82-85).
The initial lesion transforms into the early lesion 
within about one week of plaque accumulation (61, 86). The 
vessels of the coronal portion of the dentogingival plexus 
remain dilated (73, 76), and the additional plaque
accumulation results in more pronounced infiltration of the 
dentogingival epithelium by PMNs and macrophages. The 
inflammatory cell infiltrate now occupies 10-15% of the 
connective tissue volume of the free gingiva (86) and 
contains T-cells and some B-cells (63). Lymphocytes 
predominate in the early lesion but few plasma cells have 
been demonstrated (61, 63, 64, 80).
The basal cells of the junctional/sulcus epithelium 
proliferate at this stage, and rete pegs have been 
demonstrated invading the coronal portion of the infiltrate 
(87, 88). The character of the cellular infiltrate and the 
nature of the pathological alterations observed have led 
to the concept that cellular hypersensitivity may be an 
important aspect of the early lesion. Wilde, Cooper and
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Page (89) demonstrated that typical early lesions could be 
created in the gingival tissue of rats and monkeys 
sensitized to skin contact antigens followed by challenge 
at the gingival margin with the same antigen. They 
suggested a specific T-ce11-mediated mechanism, since 
sensitization can only be transferred to unsensitized 
animals by means of lymphocytes, but not serum.
The duration of the early lesion has not been 
determined. Recently, a six-month experimental gingivitis 
study by Brecx et al (81) has demonstrated that more than 
six months of oral hygiene abstention is required before 
plasma cells dominate the lesion. Therefore, the early 
lesion may continue for a much longer period than 
previously thought.
The established lesion, as defined by Page and 
Schroeder, is one dominated by plasma cells. Many 
investigators have stated that only 3-4 weeks of plaque 
accumulation are required for the formation of a plasma 
cell dominated lesion (61, 90). However, this assumption 
has been challenged by Brecx et al (81).
The established lesion continues to exhibit the 
features of the preceding stages, but in a more marked 
degree (88, 91). Large numbers of plasma cells are seen 
(88, 92), which are primarily located in the coronal
connective tissue and around vessels in more distal 
gingival connective tissue. Collagen loss continues in 
both apical and lateral directions as the inflammatory cell 
infiltrate expands, resulting in collagen-depleted areas
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radiating deeper into the tissues (83).
Two types of established lesion appear to exist, some 
remaining stable and not progressing for months or years 
(93-96), while others become more active and convert to 
progressive destructive lesions. Controversy surrounds the 
nature of this conversion. Seymour, Powell and Davis (97) 
hypothesized that a change from T-cell to B-cell dominance 
presages the conversion from stability to activity 
involving aggressive destruction. However, Page (98) has 
disagreed with this view; a recent study has shown B-cell 
infiltrate mainly associated with stable, non-progressive 
lesions in childhood gingivitis (99).
The final stage in this process is known as the 
advanced lesion. The advanced lesion has characteristic 
features including alveolar bone loss and fibrosis of the 
gingiva with widespread manifestations of inf lammatory and 
immunopathological tissue damage (100, 101). The lesion 
is no longer localized and the inf lammatory cell infiltrate 
extends laterally and apically into the connective tissue.
It is now generally accepted that plasma cells are the 
dominant cell type in the advanced lesion (100, 101).
1.3.9. Putative Immunological Mechanisms of Tissue Damage
Until fairly recently (102), discussions of the immunological 
mechanisms of tissue damage in periodontal diseases have 
referred to the four types of hypersensitivity reaction as 
classified by Coombs and Gell (103). However, the
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characteristics of these do not accord well with the 
clinical and histopathological signs.
Type I (anaphylactic), type II (cytotoxic) and type 
III (immune complex) reactions are all antibody-mediated 
whereas type IV (delayed hypersensitivity) is cell- 
mediated. However, since B-cells and plasma cells 
predominate in the later stages of periodontitis, this 
cannot represent a pure type IV reaction.
Type I hypersensitivity reactions rely on IgE antibody 
bound to the surface of mast cells. Upon reaction with 
specific antigen, these cells release histamine and other 
inflammatory mediators. Mast cells have been demonstrated 
in the gingiva (104, 105), as has IgE (106), but type I 
reactions are probably not important elements in the 
immunopathogenesis of periodontal disease, as reflected in 
the scarcity of mast cells and IgE antibody in the 
periodontal tissues.
Type II reactions rely on complement-fixing IgG and 
IgM antibody. Damaged and lysing cells have been 
demonstrated in periodontitis (107, 108). This type of
reaction is probably essentially protective. However, a 
recent study by Reinhardt et al (109) has shown a 
predominance of total IgGl and IgG4 in active as opposed 
to stable periodontitis sites. Since IgG4 is relatively 
inefficient in fixing complement, two mechanisms suggest 
themselves here: 1) IgG is basically protective and a
preponderance of I$G4 promotes disease progression by 
failure of antibody/complement mediated bacterial
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destruction; and 2) a shift to IgG4 production locally may 
constitute an attempt to limit the potentially damaging 
effects of complement-mediated activity. Care should be 
taken in this interpretation, however, since immunoglobulin 
synthesized by gingival plasma cells has been shown to have 
specificity for non-oral bacteria (110) or non-bacterial 
antigens (111).
Type III reactions involve complement fixation by 
antibody-antigen complexes. However, since studies of 
complement in periodontal disease have demonstrated that 
these components are easily washed out, suggesting soluble 
proteins rather than fixed immune complexes (112), and 
attempts to extract insoluble immune complexes from 
periodontal tissue have not been successful (113), this 
type of reaction is unlikely to be important in periodontal 
destruction.
Another possible mechanism in the immunopathogenesis 
of periodontal disease is that of autoimmunity. Serum 
antibodies against type I collagen have been found in 
higher levels in periodontitis than in control subjects 
(114). A model has been presented whereby polyclonal 
activators initiate clonal expansion of autoreactive B- 
cells, followed by a specific response to stimulation by 
autoantigens produced by the initial response (115). 
However, there is a general dearth of evidence implicating 
autoimmune mechanisms in the pathogenesis of periodontal 
disease.
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1.3.10. Role of Antibody-mediated Mechanisms
The role of antibody-mediated mechanisms will be discussed 
at greater length in a later section. At this stage, it 
seems reasonable to state that the role of antibody in 
periodontal disease is primarily protective, but that 
deficiencies or functional failure of local and/or systemic 
antibody may lead to subject and/or site susceptibility. 
The pathogenesis of periodontal destruction is probably 
determined to a large extent by the pro-inflammatory and 
tissue-degrading effects of cytokines released in response 
to bacterial products. Much evidence has been adduced 
demonstrating the ability of oral bacteria to directly 
stimulate cytokine production by macrophages (116-119). 
LPS from oral Gram-negative bacteria can markedly augment 
release of PGE2 from cells activated by IFN-a (120), and 
polyclonal activators when present in optimal proportion 
to antigen can considerably amplify the secondary response 
to antigen (121). When one comes to consider the effects 
of these cytokines on metalloproteinase synthesis, 
prostaglandin release and bone resorption for example, the 
potential for pro-inflammatory and tissue-destructive 
events mediated by cytokines becomes obvious. The humoral 
immune response, insofar as it can bring about a reduction 
in bacterial antigen load, can be seen as acting against 
the promotion of tissue-destructive events.
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1.3.11. Host Responses in Periodontal Diseases
To turn now specifically to host responses in periodontal 
diseases, it was demonstrated long ago that the gingiva 
adjacent to periodontal lesions is heavily infiltrated with 
mononuclear leucocytes. Models used in the earlier years 
of these studies suggested that the initial lesion is 
composed mainly of T-lymphocytes, with B-cells and plasma 
cells predominating at a later stage (63, 122, 123).
However, this concept has recently been contested (124, 
125). These studies found that both T-cells and B-cells 
may predominate in lesions, but that there was considerable 
variability in proportions of plasma cells. T4/T8 cell 
ratios are decreased in periodontal lesions compared with 
those seen in peripheral blood of periodontitis patients 
or in healthy gingiva (126, 127). A recent study has
demonstrated that many of the CD4+ cells in periodontal 
lesions are in fact memory cells, and that CD8+ cells 
suppress and macrophages promote immunoglobulin production 
by plasma cells in the gingiva (128). By these mechanisms, 
regulation of local immune responses by gingival cells is 
made possible.
Responsiveness of leucocytes to various stimuli has 
also been extensively studied in periodontal disease. 
Polyclonal B-cell activation, which involves hyper­
reactivity of B-cells to bacterial products as indicated 
by their blastogenesis leading to massive production of 
lymphokines and immunoglobulin, has been shown to be
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increased in most periodontitis patients (115, 129),
However, since this phenomenon cannot be demonstrated in 
about 30% of periodontitis patients, it may be that 
polyclonal B-cell activation offers another criterion by 
which these patients can be dichotomized into more 
susceptible and less susceptible groups. This concept will 
be dealt with further in the discussion of antibody 
avidity.
Elevated monocyte response to LPS has also been 
demonstrated (130, 131). These workers showed that
periodontitis patients exhibit hyper-reactivity to LPS, 
presenting as increased monocyte PGE2 and IL-ip production, 
and suggested that these patients may be susceptible to 
disease progression because of this state of hyper­
reactivity.
Degradation of soft tissue in periodontal disease can 
be effected by both bacterial and host enzymes, including 
the matrix metalloproteinases. These include collagenase 
which can be produced by both fibroblasts and PMNs. The 
fibroblast type degrades collagen type III, whereas the PMN 
type degrades collagen type I. The stromelysins have 
multiple specificity and can also superactivate the 
collagenases • Gelatinase can degrade collagen types IV and 
V and also breaks down denatured collagen. Birkedal-Hansen 
et al have shown that at least three suspected 
periodontopathogens, i.e. P. gingivalis, A . actinomycetem­
comitans and Fusobacterium nucleatum, produce factors that 
stimulate epithelial cells to degrade collagen fibrils
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(132). The most likely mediator, in the case of P. 
gingivalis, is a thiol-dependent proteinase which activates 
mammalian procollagenase. In addition, the cytokines, IL- 
ip, TGF-a and EGF, can stimulate keratinocytes to produce 
type I and type IV/V specific collagenase (133). The 
potent ability of certain bacteria to precipitate tissue 
degradation, not only indirectly via cytokines, but also 
directly, further emphasises the crucial role of the host 
response in eliminating or limiting these pathogens.
From the above discussion it is clear that there is 
a relationship between immune function and the pathogenesis 
of periodontal disease. It has also been shown that 
different forms of periodontal disease show differences in 
their immunopathogenesis.
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1.4. Specific Humoral Immune Response in Periodontal
Disease
1.4.1. Introduction
When we come to consider the specific humoral immune 
response in periodontal disease, i.e. antibodies directed 
against particular oral microorganisms, there are a number 
of issues which must be addressed. First, the organisms 
to which a response is being detected must be considered. 
At this point microbial aetiology and pathogenesis must be 
taken into account since, as has previously been discussed, 
organisms may provoke an immune response but not fulfil 
other aspects of the extended postulates (39). In 
addition, antibodies may be detected to non-oral bacteria 
and non-bacterial antigens (110, 111). Some investigators 
have used a battery of microorganisms, including many of 
doubtful relevance, and this has led to an apparent lack 
of focus. In this study P. gingivalis and A. actino­
mycetemcomitans were chosen for particular attention 
because of their strong association with periodontal 
disease using all of the criteria previously mentioned.
Secondly, there has been controversy over whether 
whole bacterial cells should be used in assays of specific 
antibody, or particular antigens isolated from these cells 
(134). However, in this study, it was decided to employ 
whole cells because of the importance attached to another 
aspect of the antibody response, that of antibody avidity.
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This can be seen as a global factor made up of the strength 
of interactions between numerous bacterial antigens and 
numerous host antibodies produced in response to these. 
Therefore, the overall response to a particular bacterium 
may yield information that would be lost by strict 
concentration on specific antigens, which may, in fact, not 
be virulence factors.
Thirdly, and related to the last point, there is the 
matter of antibody function. Clearly, demonstrations of 
an association between host antibody response and 
periodontal disease may be only academic unless it can be 
related to the biological function of this antibody. These 
functions, which include the ability to opsonize bacteria 
and the ability to bind strongly to fimbriae, which may 
prevent bacterial colonization, may relate to antibody 
avidity.
Fourthly, we must consider whether local antibody 
levels in the GCF or systemic levels or both are of 
importance; and whether local levels are merely a 
reflection of serum levels, or whether significant antibody 
production by gingival plasma cells is taking place. This 
is important in the consideration of subject and site 
susceptibility to disease onset and progression.
Fifthly, assessments of the titre and avidity of 
patient's antibody to suspected periodontopathogens may be 
useful in the differential diagnosis and classification of 
periodontal diseases.
Sixthly, the assay of these antibodies in longitudinal
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studies may provide information on the relationship between 
antibody titre and avidity and disease progression at both 
subject and site levels, which may prove to be a marker of 
disease activity.
Finally, there is evidence that the subclass of 
immunoglobulin produced has a bearing on aspects of its 
function such as complement fixation and opsonization.
1.4.2. Response to Gram-positive Organisms
Most studies concerned with the humoral immune response to 
oral microorganisms have tended to concentrate on Gram- 
negative organisms, but there have been some which have 
focused on Gram-positive organisms; however few of these 
have been in recent years.
An earlier study by Ebersole's group assayed IgG and 
IgM antibody directed against Actinomyces naeslundii, 
Actinomyces viscosus, Eubacterium brachy, Streptococcus 
mutans and Streptococcus sanguis in localized juvenile 
periodontitis (LJP), generalized juvenile periodontitis 
(GJP), adult periodontitis (AP), acute ulcerative 
gingivitis (AUG), and edentulous patients and normal 
subjects. For all of these bacteria and all of these 
disease states there was no difference from the normal 
subject population (135). Similarly, this group went on 
to examine antibody titres to some of these organisms in 
Papillon-Lefevre syndrome, a type of neutrophil dysfunction 
manifesting with severe periodontal disease (136). In this
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study no significant response to these organisms was 
detected. This does not suggest an important role for such 
organisms in this disease aetiology, since it might be 
expected that if Gram-positive antigens were penetrating 
the gingival tissues they would provoke a humoral immune 
response.
Page and Ebersole's groups also collaborated in a 
study which assayed levels of antibody to Actinomyces 
naeslundii in a family with a high prevalence of juvenile 
periodontitis (JP) (137). Elevated IgG levels to this 
organism were not detected although both patients and 
controls showed high levels of Actinomyces species in the 
subgingival microflora.
Ebersole's group have concluded that relatively 
abundant constituents of the Gram-positive flora in 
subgingival plaque, e.g. Actinomyces species, Streptococcus 
mutans and Streptococcus sanguis, do not provoke a 
significant humoral response even in patients whose 
microflora contain a large proportion of these organisms 
(138). They have also shown that these bacteria do not 
contain antigens that cross-react with Gram-negative 
constituents of the plaque (135, 139).
Studies of these organisms by other groups have also 
failed to demonstrate increased titres in periodontal 
disease (140-142). These have generally shown wide 
variation, lack of discrimination between diseased and 
healthy groups, and, in one study (140), higher levels of 
IgG and IgA antibody to Streptococcus sanguis in healthy
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controls than in periodontitis sera. The only exception 
seems to be a study in 1970 by Nisengard and Beutner (143) 
showing higher levels of IgG antibody to Actinomyces 
species with increasing periodontal inflammation. However, 
the antibody assays in this study were by 
immunofluorescence and, therefore, the facility for 
quantification was probably inferior to that achieved in 
later ELISA-based studies.
Generally, differences in the humoral immune response 
to Gram-positive bacteria do not appear to occur between 
periodontitis patients and healthy controls. However, a 
notable exception may be the study of Tew et al (144) which 
examined antibody levels to Eubacterium species, 
Lactobacillus minutus and Peptostreptococcus micros; this 
being based on their previous study (145) in which they 
showed these organisms to be predominant members of the 
cultivable subgingival microflora in a cohort of patients 
with severe periodontitis. Their findings were that IgG 
antibody to Eubacterium brachy and Peptostreptococcus 
micros was raised in those patients but not in JP patients 
or healthy controls. However, it must be borne in mind 
that this study employed radioimmunoassay (RIA), rather 
than ELISA, which is known to be more sensitive, and refers 
to dichotomous measures of seropositivity/seronegativity 
rather than quantitative differences.
Therefore, it seems fair to conclude that there are 
no abnormal changes in the humoral immune response to the 
Gram-positive flora in periodontal disease; but that
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constituents of this flora, e.g. Eubacterium species, 
although probably not aetiologic, may assume a more 
predominant role during the change to a pathogenic flora. 
There may concomitantly be an antibody response which could 
be a useful marker of this process. Accordingly, a section 
of the present study concerns the changes in antibody 
levels to certain Gram-positive organisms during an 
experimental gingivitis trial.
1.4.3. Response to Gram-negative Organisms
Studies of the humoral immune response to Gram-negative 
organisms have tended to target organisms such as P. 
gingivalis and A. actinomycetemcomitans because of their 
marked association with periodontal disease (27). An 
earlier study of particular relevance is that of Mouton et 
al in which serum IgG, IgM and IgA antibody to P. 
gingivalis was assayed in various patient groups, including 
AP, LJP and GJP (or RPP), and also in healthy controls 
(146). This report established that detectable levels of 
antibody to P. gingivalis are found in a significant 
proportion of healthy adults and also that there is a 
positive correlation between antibody levels and age. 80% 
of the healthy individuals studied had IgG antibody to this 
organism, 55% had IgM and 34% had IgA. Moreover, IgG and 
IgM serum antibodies were detectable in children as young 
as six months, and children aged 6-12 demonstrated 
significantly higher antibody levels than in younger
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children. The authors concluded that this organism 
probably has an aetiologic role in the disease process, and 
that the antibody response is essentially protective.
In addition, mean levels of IgG antibody were found 
to be five times higher in AP patients and eight times 
higher in RPP patients than in controls. Higher IgM levels 
were seen in JP patients and higher IgA levels in RPP. 
Therefore, this paper was important in establishing a 
number of points
1. Based upon the humoral immune response, P. gingivalis 
is probably aetiologic in periodontal disease.
2. This response is probably protective.
3. Diseased and healthy individuals can be distinguished 
in terms of their antibody response to this organism.
4. There are indications of differences in the response in 
different periodontal disease states.
These findings were confirmed and extended by this and 
other research groups. Ebersole et al (147) studied 85 AP 
patients, 67 JP patients, 62 RPP patients and 82 controls, 
and found that 95% of JP patients had elevated antibody 
levels to at least one organism, predominantly A . actino- 
mycetemcomitans. 48% of AP patients, and 37% of RPP
patients had elevated serum antibody levels to P. 
gingivalis, whereas 85% of control subjects showed no 
elevations in antibody to any of the organisms in their 
battery.
Naito et al (148) assayed IgG antibodies to P. 
gingivalis in 42 AP patients and 17 controls. They graded
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the AP patients according to disease severity and found a 
positive correlation of antibody level and disease 
severity. Although antibodies to A. actinomycetemcomitans 
were also elevated in this study, this was not significant, 
and, therefore, this was perhaps an indication of the 
differing relevance of these two organisms in AP.
1.4.4. Response to Porphvromonas gingivalis
Two studies by Ebersole et al (139) and Tew et al (144) 
examined antibody responses to various members of the 
Bacteroides genus as it was then classified. These 
included Bacteroides gingivalis, now Porphyromonas 
gingivalis, and Bacteroides intermedius, now Prevotella 
intermedia. Although elevated responses to other 
Bacteroides species were detected in some periodontitis 
patients, especially to Prevotella intermedia, P. 
gingivalis was found to be the most consistent example of 
a Bacteroides species eliciting an antibody response during 
periodontal disease; these responses being most frequent 
and of greatest magnitude.
Moreover, an investigation by Gmur et al (149) 
reported that IgG antibody levels to P. gingivalis were 
highly correlated with the extent of periodontal 
destruction, whereas anti-Prevotella intermedia
reactivities were not. Similarly, studies by other groups 
have confirmed that antibody levels to P. gingivalis are 
higher in AP patients than in controls (150, 151).
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Although these studies have tended to concur that an 
increased antibody response to P. gingivalis is associated 
with periodontal disease and may serve as an indicator, the 
protective nature of this antibody has been questioned. 
For example, Tollefsen et al (152) reported that 
immunoglobulin levels to P. gingivalis were lower in 
immunosuppressed transplant patients than in periodontitis 
patients, although the immunosuppressed patients also had 
a lower frequency of bleeding on probing and lower mean 
pocket depth than the periodontitis patients. They 
concluded that a reduced immune reactivity to plaque 
bacterial antigens leads to a milder and less destructive 
form of periodontitis. However, since both patient groups 
were not shown to be comparable in terms of previous 
periodontal disease experience, and the effects of 
immunosuppression on inflammation and vascularity could not 
be ruled out, it is difficult to see how such a conclusion 
can be drawn.
Generally, reports in this area have agreed that there 
is a positive relationship between serum antibody to P. 
gingivalis and other suspected periodontopathogens and 
periodontitis. However, there have been a significant 
number of studies reporting no difference between patients 
and controls or even lower antibody levels in patients 
(140, 144, 153-157). Although some of these studies are 
not particularly recent, and, therefore, may be seen as 
less accurate in their antibody assays, others, such as 
that of Chen et al (157) present a more significant
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counterpoint to this argument. These workers studied RPP 
in particular and found that some patients mounted a 
humoral immune response to P. gingivalis, whereas others 
did not. In addition, these antibodies were of low 
avidity, but periodontal therapy could induce the 
production of higher avidity, and presumably more 
biologically effective antibodies. Thus, Chen et al, in 
their discussion, crystallize many of the issues which will 
be dealt with in this study in relation to the humoral 
immune response to P. gingivalis, e.g. patient 
susceptibility, diagnostic categories, treatment effects, 
and the importance of antibody avidity.
1.4.5. Response to Actinobacillus actinomvcetemcomitans
An early study of the antibody response to A. actino- 
mycetemcomitans linked this response specifically to LJP 
by demonstrating the presence of these antibodies in these 
patients but not in normal subjects (158). Ebersole et al 
also showed an association between increased levels of, and 
increased frequency of, antibody to A. actinomycetem- 
comitans and LJP (159). These authors elaborated on this 
in a later study (160) in which they showed a significantly 
increased level of IgG antibody to A. actinomycetem- 
comitans serotype b in 90% of LJP patients, but only 40% 
of RPP and 25% of AP patients. Listgarten et al (161) had 
previously made similar findings by immunofluorescent 
techniques. Several other reports have shown a strong
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association between antibody to A. actinomycetemcomitans 
(especially serotype b) and LJP (155, 162, 163).
Zambon, in his review of 1985, stated that A. actino­
mycetemcomitans was an important organism in the aetiology 
of JP because of its increased prevalence in LJP patients 
and their families, and increased antibody responses to 
this organism (15).
Eisenmann et al (164) reported similar results with a 
Central African population and suggested that 
susceptibility to JP may have a genetic component related 
to a gene pool originally derived from Africa. This 
hypothesis was tested by a study examining the effect of 
race and periodontal status on antibody to A. actino­
mycetemcomitans (165). This showed a relationship between 
high levels of antibody to A. actinomycetemcomitans Y4 and 
both diagnosis of JP and black race.
Other studies in other ethnic groups have confirmed 
that A. actinomycetemcomitans is frequently associated 
with, and probably an aetiologic agent of JP, and may also 
be implicated in certain cases of RPP (166, 167). In
addition, an investigation of anti-A. actinomycetem­
comitans antibodies in individuals with AP showed no 
correlation between antibody levels and disease (149).
1.4.6. Response to other Gram-negative Organisms
Antibody responses to other Gram-negative organisms have 
generally failed to demonstrate any consistent and
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convincing association between these responses and the 
occurrence and extent of periodontal disease. For example, 
Ebersole et al could not demonstrate any association 
between antibody levels to the Capnocytophaga species, 
gingivalis, ochracea and sputigena, and particular disease 
classifications (168, 169). Levels of antibody to
Fusobacterium nucleatum have been shown to decrease after 
the age of twelve years in children with insulin-dependent 
diabetes (170), in contrast to the previously reported 
positively age-related antibody levels to P. gingivalis. 
Eikonella corrodens has been shown to provoke an antibody 
response during mono-infection induced periodontitis in 
gnotobiotic rats (171, 172). However, such studies are of 
doubtful relevance to human periodontal disease, not only 
because of the animal model employed but also because human 
periodontal disease involves mixed plaques rather than 
single organisms. It may be that some organisms, although 
capable of provoking periodontal destruction under 
artificial conditions, are normally limited in their 
effects by other plaque flora.
1.4.7. Response to Spirochaetes
There have also been some studies of antibodies directed 
against spirochaetes. Generally, these have not shown 
significant differences in antibody responses to organisms 
such as Treponema denticola between patients with 
periodontal disease and healthy controls (144, 173-175). 
Three explanations have been advanced to account for these
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findings s-
1. Spirochaetes lack antigenicity.
2. Immunosuppression by spirochaete products.
3. Spirochaetal colonization is limited to subgingival 
plaque. Organisms and their products do not pass into host 
tissues.
However, spirochaetes have been shown to be antigenic in 
animals, and variable responses in the above studies 
demonstrate their antigenicity in humans. Also,
immunosuppressive agents produced by spirochaetes have been 
shown to be generally suppressive in vitro. Therefore, the 
most probable explanation is that spirochaetes are limited 
to the subgingival plaque. The implication that 
spirochaete products cannot invade host tissues, although 
whole spirochaetes have been shown to invade the gingiva 
to a limited extent in AUG (33), does not suggest an 
aetiologic role. Spirochaetes have, however, been shown 
to be particularly associated with AUG. Even in this 
condition, however, no significant difference was seen in 
antibody levels to Borrelia vincentii between patients and 
controls (176).
1.4.8. Response to Particular Antigens
Some studies have investigated the humoral antibody 
response to particular antigens of bacteria rather than 
whole bacterial cells. However, intensive research into
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the fimbriae of Gram-positive organisms such as Actinomyces 
viscosus (177-181), on the premise that anti-fimbriae 
antibodies could block adherence and thus colonization, do 
not appear to have taken into account the extensive 
literature showing that no significant response to these 
organisms occurs in periodontal disease. Similarly, a 
study showing differences in the ability of antibodies of 
various inbred strains of mice to bind to fimbriae of 
Actinomyces viscosus (182) is of doubtful relevance for the 
same reason, and also because of the equivocal contribution 
of such animal models to our understanding of the aetiology 
and pathogenesis of periodontal disease in humans.
Increased levels of IgG antibody to LPS of P. 
gingivalis have been demonstrated in periodontitis patients 
(135, 183). Another study demonstrated increased antibody 
levels to trypsin-like protein produced by P. gingivalis 
in periodontitis patients compared with control subjects 
(184). However, the ability of this antibody to inhibit 
this enzyme has not been shown.
There have also been investigations of the antibody 
response directed against fimbriae of P. gingivalis. 
Mouse monoclonal IgGl antibody developed against P. 
gingivalis strain 381 inhibited adherence of P. gingivalis 
to buccal epithelial cells (185). Further work has shown 
that 67% of AP patients had antibody reactive with 
fimbriae, and that antibody activity could be detected to 
the 43kDa fimbrillin monomer and also to dimers, trimers 
and oligomers (186).
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Ebersole et al have demonstrated differences in the 
antibody responses to particular membrane antigens of P. 
gingivalis (187). However, it should be noted that these 
antigens have not been identified as virulence factors, and 
patients with strong responses to these antigens often 
tended to be those who had a strong response to whole 
cells. Although these studies will undoubtedly help to 
elucidate the immune response to P. gingivalis, their use 
in clinical studies can be criticised on three points
1. Until particular antigens are identified as virulence 
factors, the demonstration of antibodies against these may 
be of doubtful relevance.
2. The results of some of these studies, e.g. that of 
Watanabe et al (188), have suggested that antibody 
reactivity to particular groups of antigens may be no more 
useful than to whole cells.
3. Focusing too narrowly on particular antigens may result 
in other valuable information being lost.
A study of antibody directed against LPS of A. actino­
mycetemcomitans found no increase in AP or JP patients over 
controls (189). By contrast, an investigation of the 
ability of antibody to neutralise A. actinomycetemcomitans 
leucotoxin found that 95% of JP patients demonstrated these 
antibodies as compared with much lower frequencies in other 
patient groups and control subjects (190).
Other studies have also dealt with antibodies directed
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against leucotoxin (191, 192). However, the association 
between these antibodies and JP can also be shown in 
studies of antibodies to whole A. actinomycetemcomitans 
cells (166, 167), and the relevance of leucotoxin as a
virulence factor has not yet been demonstrated in vivo.
1.4.9. Antibody Avidity
Antibody avidity, that is a measure of the net binding 
strength between antibodies and antigens, has been 
extensively studied in a number of fields, both in relation 
to antibody titre and in isolation, in terms of disease 
susceptibility and progression. For example, Morikawa et 
al (193) found that the titre of IgA to soybean antigen in 
the breast milk of Indian mothers was significantly higher 
than in Japanese mothers, although the avidity was 
significantly lower. Udhayakumar et al (194) have shown 
that monoclonal antibodies of higher avidity have much 
greater effectiveness in activating B-cells and presumably 
enhancing an immune response. Interestingly, Charoenvit 
et al (195) found that a monoclonal antibody to Plasmodium 
yoelii, a malarial parasite, had lower avidity for the 
antigen than vaccine-induced polyclonal antibodies in mice.
Doi et al (196) suggested that low avidity may be a 
pathogenic characteristic of IgG circulating immune 
complexes in membraneous nephropathy. Significantly, 
Joynson et al (197) found that toxoplasmosis patients with
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acute infection had low avidity IgG to this organism 
whereas those with chronic infection had high avidity. 
This may have application in investigations of the phasic 
destructive episodes of chronic periodontitis, with the 
possibility that acute exacerbations and quiescent periods 
could be differentiated.
The secondary immune response classically generates 
antibodies of higher avidity. Francus et al (198) have 
demonstrated that a possible mechanism may be carrier 
primed T-cells which selectively activate virgin B-cells, 
which are then committed to the production of high avidity 
antibodies. A study with particular relevance to the 
suggested autoimmune aspects of periodontal disease is that 
of Panoskaltsis and Sinclair (199), who showed that 
autoimmune mice have lower avidity anti-single strand DNA 
than non-autoimmune mice.
There have, however, been very few reports dealing 
with antibody avidity in relation to periodontal disease. 
Ebersole et al (200) studied the increase in avidity in the 
non-human primate, Macaca fascicularis, following 
immunization with tetanus toxoid, which they used as a 
prototype bacterial exotoxin. They found that IgG avidity 
increased from 0.9M to 1.72M following primary 
immunization, and 2.56M after secondary immunization. 
Lopatin et al (201) demonstrated that avidity of antibody 
rose to a similarly high level in rabbits post-immunization 
with P. gingivalis, but that human antibodies to this 
organism appear to be of generally low avidity. They also
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discovered that IgG antibodies to P. gingivalis were of 
significantly higher avidity in periodontitis patients than 
in control subjects (0.96M compared with 0.71M). They 
suggested that the presence of low-avidity antibodies 
contributes to the pathology associated with periodontal 
disease.
Chen et al (157) demonstrated that IgG avidities to 
P. gingivalis were lower in RPP patients than in control 
subjects. However, after treatment, the avidities 
increased significantly to levels higher than in controls. 
They concluded that many RPP patients do not produce 
protective levels of biologically functional antibody as 
a result of natural infection, but that treatment may 
induce the production of such antibodies. Another recent 
study of titre and avidity of IgG antibodies to P. 
gingivalis in RPP patients by Whitney et al (202) also 
shows lower avidities in RPP patients than in controls. 
A very recent study by Sjostrom et al (203) showed that IgG 
antibodies in low-titre sera from control subjects were 
significantly more effective in opsonizing A. actino­
mycetemcomitans than IgG antibodies in low-titre sera from 
RPP patients. This study suggests a crucial link between 
antibody avidity and function. Further support for this 
is derived from two recent reports demonstrating that 
effective binding of IgG to virulent P. gingivalis has a 
crucial role in the opsonization and phagocytosis of this 
organism and also in complement activation (204, 205).
A recent study by Ebersole and Kornman (206)
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demonstrated that P. gingivalis emerges as an organism in 
the subgingival plaque during the conversion from 
gingivitis to progressing periodontitis in a non-human 
primate model, and that this elicits a systemic antibody 
response specific for this organism. Similarly, a study 
by Dahlen and Slots (18) in rabbits showed that animals co­
inoculated with P. gingivalis and A. actinomycetem­
comitans showed significantly more severe disease than 
animals which were monoinfected. They concluded that the 
immune system acting through systemic antibodies and/or 
cellular mechanisms may modulate the pathogenic potential 
of infecting periodontal pathogens. It may be that antibody 
avidity has a crucial role in this modulation.
1.4.10. The Local Response
Most studies investigating the humoral immune response have 
concentrated on systemic antibody levels. Much less work 
has been done on the relationship between local antibody 
levels and local disease status. Baranowska et al (207) 
found no significant difference in the level of specific 
IgG to P. gingivalis in GCF between healthy and diseased 
sites within the same individual. Tew et al (208) found 
no obvious differences in the clinical parameters of 
probeable depth and attachment level between sites with 
elevated antibody to P. gingivalis and/or A. actino­
mycetemcomitans, and those with normal or low levels, and 
concluded that elevated antibody in GCF may relate to
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changes in disease activity that are not detectable by 
normal clinical assessments.
However, Suzuki et al (151) demonstrated that local 
production of IgG to P. gingivalis was markedly increased 
in AP as compared with RPP patients, suggesting that 
disease progression is influenced by local antibody 
production. Challacombe et al (209) showed that levels of 
IgG antibody to P. gingivalis were lower in crevicular 
fluid washings (CFW) of patients with high periodontal 
disease index (PDI) as compared with those with low PDI, 
although this was not found to be statistically 
significant. Opsonic activity against P. gingivalis was, 
however, found to be significantly depressed in high PDI 
as compared with low PDI patients.
Lamster et al (210) reported a significant correlation 
between total IgG in GCF and specific serum antibody to 
Prevotella intermedia but not P. gingivalis. They 
concluded that the development of a serum immunoglobulin 
response to suspected periodontopathogens is consistent 
with a protective host response. A corollary of this view 
is that a local deficiency of IgG to these pathogens may 
lead to local disease progression. Alternatively, Killian 
(21) has demonstrated that P. gingivalis can degrade human 
IgG and IgA, suggesting that low GCF levels of IgG may be 
caused by degradation by this organism, or that locally 
available antibodies are adsorbed by the greater mass of 
subgingival plaque present.
An earlier study by Schenck (211) showed an inverse
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relationship between the number of deep pockets (>4iran) and 
serum antibody level to P. gingivalis LPS in chronic 
periodontitis patients. Similarly, Mouton et al (212) 
demonstrated a dichotomy in serological responses to P. 
gingivalis among chronic periodontitis patients, with one 
subgroup exhibiting high serum antibody levels and another 
having levels similar to those of healthy individuals.
1.4.11. The Host Response in Differentiation of Disease 
States
The humoral immune response has been suggested as a means 
of differentiating between distinct periodontal disease 
states. A strong local and systemic antibody response to 
A. actinomycetemcomitans has been adduced as an indicator 
of JP (213-215). An association between the most severe 
and extensive cases of RPP and relative lack of antibodies 
to P. gingivalis and/or A. actinomycetemcomitans has also 
been reported (155, 216). This, coupled with the previously 
quoted findings that humoral responsiveness in RPP in terms 
of antibody avidity is depressed compared with that found 
in AP patients and healthy individuals, suggests possible 
disease mechanisms. When localized and generalized early- 
onset periodontitis (EOP) cases (i.e. JP and RPP) are 
grouped together and the extent and severity of disease is 
related to age and plaque index, there is a positive 
correlation for the RPP group for both factors. This
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contrasts with the JP group for which the correlation is 
significant for plaque only (217). This would be consistent 
with an interdiction of disease progression in JP by an 
effective immune response, while those with an ineffective 
response would go on to develop generalized disease (RPP). 
Previous hypotheses have connected JP with PMN 
abnormalities (218-220), but these findings have been 
challenged recently (221-223). Thus this area would appear 
to be one in which fruitful progress may be made in 
enhanced differential diagnosis by objective tests of the 
humoral immune response.
1.4.12. Longitudinal Monitoring
In the most definitive study to date of longitudinal 
monitoring of humoral immunity in patients with destructive 
periodontal disease, Ebersole's group (224) studied 51 
subjects bi-monthly for a period of up to five years. 
These comprised four subject groups which they defined as 
AP, LJP, GJP and RPP. They found that, in general, most 
serum antibody levels to subgingival species remained 
relatively constant for periods of up to five years. 
However, major increases and decreases in antibody to 
specific species could be detected in certain subjects. 
They concluded that major changes occurring in serum 
antibody may reflect fluctuations in the nature of the 
infection. In addition, they stated that their data
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suggest that serum antibody levels to certain species over 
certain thresholds indicate an increased likelihood of 
disease activity taking place at some site in the oral 
cavity, and that it would be desirable to measure antibody 
to that species at the local sites in order to detect areas 
of active disease.
They further note differences between diagnostic 
categories and observe that the pattern of antibody 
fluctuation detected does not indicate a primary response, 
and that original antigen exposure probably occurred a long 
time in the past. This accords with the view of Lopatin 
et al (201) thatimmunological,tolerance may be induced by 
asymptomatic bacteraemia associated with often severe 
pregnancy gingivitis (225-227), resulting in in utero 
exposure, and leading to depletion of high-affinity 
antibody-producing clones, leaving only low-avidity 
capability (228).
1.4.13. Immunoglobulin Subclass
A small number of studies have focused on the subclass of 
IgG which is produced against suspected 
periodontopathogens. Reinhardt et al studied total IgG 
subclass levels without investigating the specificity of 
these antibodies (109). IgGl and IgG4 levels were found 
to be higher in active as compared with stable 
periodontitis sites with similar clinical characteristics. 
A more recent study investigated total IgG subclass levels
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in periodontitis patients and matched controls (229). This 
found that IgG2 levels were significantly higher in 
patients than in controls, and these data suggested that 
the predominant antibody response to periodontal pathogens 
is directed against carbohydrate or glycolipid antigens.
Whitney et al (202) investigated the titre, avidity 
and subclass distribution of serum IgG antibodies to P. 
gingivalis. They found the subclass order in both patients 
and controls to be IgG2>IgG3>IgGl>IgG4. They concluded 
that their findings were consistent with the hypothesis 
that both carbohydrate and protein antigens are important 
in the IgG response to P. gingivalis. However, the 
relative predominance of IgG2, a subclass which lacks 
strong complement fixation and opsonic properties, and the 
low avidity of patient anti-P. gingivalis antibodies 
suggested that the humoral response to infection may be 
ineffective in clearing this organism.
Lopatin and Blackburn (230) have recently reported 
that adult periodontitis patients produced IgG antibodies 
to streptokinase (SK) and tetanus toxoid (TT) with much 
higher avidity than to P. gingivalis. However, when the 
IgG subclasses were examined, the IgGl antibodies to this 
organism were found to be of similarly high avidity to 
those against SK and TT. Since IgG antibodies to P. 
gingivalis tended to be of the IgG2 subclass, which were 
of significantly lower avidity, the net effect of this 
predominating subclass was to lower the avidity of the 
overall IgG response to this organism.
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1.5. Aims of the study
The overall aim of this study was to relate the systemic 
and local humoral immune response to periodontal disease 
status and progression. Thus, there are essentially two 
elements in this study.
The first involves an investigation of the 
relationship between clinical events such as experimental 
gingivitis, loss of periodontal attachment and response to 
periodontal therapy, and the systemic response to 
periodontal pathogens. In addition, the ability of 
antibody avidity to discriminate different periodontal 
disease states is investigated.
The second focuses specifically on the antibody 
response in GCF and peri-implant sulcular fluid (PISF). 
The relationships between local disease state and antibody 
titres to periodontopathogens are investigated, and 
comparisons between natural teeth and implants are made. 
Additionally, an investigation of the relative coefficient 
of excretion (RCE) is conducted in order to establish 
whether or not this measure of local immunoglobulin 
production can be related to local disease state.
Other parameters are also measured locally, e.g. 
acute-phase proteins, iron-binding proteins, albumin, 
stromelysin (a matrix metalloproteinase) and TIMP-1 (an 
inhibitor of matrix metalloproteinases). These other data 
allow assessment of inflammation (acute-phase proteins), 
PMN infiltration (lactoferrin), serum exudation into
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2.1. Experimental gingivitis study
2.1.1. Subjects and clinical protocol
Six dental student volunteers (3 male, 3 female), with no 
evidence of periodontal disease and clear medical 
histories, were entered into the study. Their ages ranged 
between 20 and 21 years. All subjects had more than 26 
teeth, a high standard of oral hygiene and healthy gingival 
tissues. For two months prior to the study the subjects 
were regularly examined and their oral hygiene monitored 
to achieve maximal gingival health.
After determining baseline values the volunteers were 
instructed to stop all oral hygiene procedures for 14 days, 
after which they were given a thorough professional 
prophylaxis, instructed to recommence their normal oral 
hygiene procedures and were rechecked at 1 and 2 weeks post 
study. Clinical parameters and GCF samples were taken at 
Baseline and then at intervals 4, 7, 11, 14, 21 and 28 days 
from the same two sites in each patient, viz lower right 
lateral incisor, disto-buccal aspect, and the lower right 
central incisor, disto-buccal aspect. Clinical indices 
were recorded using the plaque index of Silness and Loe 
(231) (PI) and the modified gingival index (MGI). One 




The Plaque Index of Silness and Lde (PI) estimates plaque 
on the four tooth surfaces (interproximal, lingual and 
labial) with a scoring system from 0-3. The tooth's PI 
is assessed by adding the scores and dividing by four. By 
adding the scores of each tooth and dividing by the number 
of teeth examined, the PI of the individual is assessed. 
The Lobene index scores marginal and interproximal tissues 
separately on a scale of 0-4. Lobene et al. (232) modified 
the gingival index of Loe and Silness (233) to eliminate 
the bleeding-upon-probing component to permit a non- 
invasive evaluation of the early visible changes in 
severity and extent of gingivitis. This index is termed 
the Modified Gingival Index (MGI). The mean MGI for each 
individual was calculated in the same manner as described 
above for the PI.
2.1.3. Gingival crevicular fluid sampling and processing
Whatman grade 4 paper strips were used for the collection 
of GCF, and are described by the manufacturer as a thin 
pure cellulose paper with an average thickness of 0.21 mm. 
The paper was cut manually using a steel ruler and a 
scalpel, into 2x13 mm strips, as recommended by previous 
investigators (234). A line was drawn at each strip at the 
length of 8mm indicating the length of the paper to be 
inserted between the periotron jaws.
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The individual crevicular site was gently air-dried 
and any supragingival plaque was removed. The area was 
carefully isolated with cotton rolls so that no saliva 
contamination of the samples occurred. The paper strip was 
inserted into the crevice until mild resistance was felt, 
and was left there for 30s. Care was taken in order to 
avoid mechanical injury of the tissues. After the 
collection of the GCF, the paper strip was transferred to 
the chairside-located periotron (Periotron 6000, Harco 
Electronics, Winnipeg, Canada) for the quantification of 
the volume collected. The jaws of the periotron were wiped 
with pure methanol between sequential readings. The strips 
were then placed in individual sterile bijoux and stored 
at -30°C until further processing. Subsequently, the 
strips were eluted into 1 ml of phosphate-buffered saline 
with 0.05% Tween 20 (PBST) containing 0.1% bovine serum 
albumin for 1 hour using a rotating mixer, the strips were 
then discarded and the eluate was aliquoted and stored at 
the -70°C, until used. The 200 jil aliquots were analyzed 
for the quantification of a2-macroglobulin and transferrin.
2.1.4. Calibration of the Periotron 6000
Prior to commencement of this study a calibration graph was 
constructed for the Periotron in order to transform the 
digital indications for each filter strip into volumes and 
also to assess the accuracy of the instrument. Known 
volumes of serum dilution 1:1 in PBS were delivered to
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Whatman grade 4 paper strips with a Hamilton microsyringe 
in volumes ranging from 0.2 to lp.1, in 0.2pil increments. 
Each measurement was performed 6 times and the mean value 
for each volume was used in a regression analysis,
performed to construct the calibration graph, which was 
used for the determination of the volumes of gingival
crevicular fluid collected.
2.1.5. Anti-bacterial antibody ELISA
The method was based on that of Ebersole et al (159). 
Briefly, Streptococcus sanguis II, Actinomyces naeslundii 
and Fusobacterium nucleatum were harvested after twenty- 
four hours growth on blood agar, or 7 days growth in ABB 
in the case of F. nucleatum. After washing in phosphate- 
buffered saline, ImM Na2 EDTA, pH 7.4 (PBSE), fixation for 
1 hour in 10% formal saline and further washing and 
resuspension in a carbonate-bicarbonate coating buffer pH
9.6, 96-well ELISA plates were coated with the fixed
bacteria at an optimal OD600 determined for each species. 
Overnight coating at 4°C and washing with PBST was followed 
by incubation with normal human serum serially diluted 
(base 2) and test samples. Ten normal human serum
dilutions were used from the range 2-15 to yield the linear 
section of the curve. Test sera were diluted 1/100-1/4000 
depending on the dilution profile of normal serum. This 
incubation was for 90 minutes at 37°C. Further washing
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with PBST preceded the final incubation with HRP-anti-human 
IgG in the case of IgG estimation. IgA and IgM plates were 
incubated with anti-human-IgA (sheep) and anti-human-IgM 
(sheep) respectively, washed and then incubated with HRP- 
anti-sheep/goat IgG. These incubations were at 37°C for 90 
minutes. o-Phenylenediamine (oPD) was used as a substrate 
for 7-15 minutes at room temperature. The reaction was 
stopped with 1M H2S04 and the plates read at 490nm. All 
determinations were performed in triplicate and appropriate 
negative controls were employed throughout. Results were
converted to ELISA units (EU) using the method of Gmur et
'This involved relating the sample absorbance to the
al (149).
absorbance of the reference serum at the same dilution. This 
,latter value was arbitrarily set at 1,000 EU.
2.1.6. a2-Macroglobulin ELISA
The method was the indirect competitive ELISA of Altschuh 
and van Regenmortel (235). Briefly, 96-well ELISA plates 
were coated with a2-M at lp,g/ml in carbonate-bicarbonate 
coating buffer pH 9.6. Incubation was overnight at 4°C.
After washing, serial dilutions of a2-M or test samples 
were added. The test samples were prepared by eluting the 
GCF strips into 1ml of the incubation buffer used in the 
assay for 1 hour at room temperature. An equivalent volume 
of anti-a2-M(goat) at l^ ig/ml was also added. Incubation 
was for 2 hours at 37°C. HRP-anti-sheep/goat IgG was added 
after washing. Incubation was for 90 minutes at 37°C. 
Incubation with oPD for 15 minutes at room temperature
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after washing allowed visualisation. The reaction was 
stopped with 1M H2S04 and the plate read at 490nm. A 
standard curve was constructed allowing sample 
concentrations to be determined. These could then be 
related to GCF concentrations by employing the GCF volumes 
derived from fluid quantitation readings.
2.1.7. Transferrin ELISA
This was similar to the a2-M assay except for the 
substitution of transferrin and anti-transferrin antibody 
(sheep).
2.1.8. ELISA buffers
The buffers employed in ELISA assays throughout this entire 
study were as follows except where specifically mentioned 
in later sections:-
1. Coating buffer: 1.59g Na2C03, 2.93g NaHC03 in 800ml
distilled H20, dissolve, pH to 9.6 at just under 1L, add 
0.2g NaN3, make up to 1L in volumetric flask. Store in 
sterilized bottles at 4C for 1 week.
2. Wash buffer (xlO conc.): 80g NaCl, 14.4g Na2HP04.2H20, 2g 
KH2P04, 2g KC1, 5g Tween 20. Dissolve in 800 ml of 




3. Incubation buffer: 1/10 of the quantities added to above 
(2) made up to 1L with the addition of lg of BSA. This 
should be layered on the surface without mixing. Store at 
4C for maximum of 1 week.
4. Substrate buffer: 0.35g Na2HP04, 0.2375g citric acid. 
Dissolve, make up to 25ml in measuring cylinder and add 1 
tablet (lOmg) of oPD and 10pi hydrogen peroxide, mixing 
well, immediately before use.
2.1.9. In vitro analysis of ability of organisms to 
eliminate host proteins
Periodontopathogens have previously been reported to be 
able to digest human proteins (20, 21), and in order to 
elucidate this an experiment was undertaken in which 
bacteria were incubated anaerobically at 37C with human 
serum or pure protein solutions (at lmg/ml) for up to six 
days. Residual protein was assayed by ELISA, and related 
to 100% values, i.e. serum and protein similarly treated 
but without the presence of bacteria.
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2.1.10. Reagents
All antibodies were obtained from the Scottish Antibody 
Production Unit (SAPU) except for anti-a2-M which was 
purchased from Sigma. a2-M and transferrin were also
purchased from Sigma. ELISA plates were purchased from
Dynatech.
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2.2.Study of antibody avidity related to attachment loss
2.2.1. Bacteria
P. gingivalis NCTC 11834 was grown under anaerobic 
conditions (85% N2, 10% H2, 5% C02) and A. actinomycetem- 
comitans in C02 at 37C on Columbia blood agar. P. 
gingivalis was harvested after 5 days and A. actinomycetem- 
comitans after 24 hours into PBSE, washed by 
centrifugation, and fixed for 1 hour in 10% formal saline. 
The cells were then washed twice in PBSE and once in 0.1M 
Na carbonate-bicarbonate buffer containing 0.02% NaN3 at pH 
9.6 (coating buffer). Fixed cells were stored in coating 
buffer at 4C until use.
2.2.2. Subjects
Serum was collected from a total of 31 subjects. These 
included 11 periodontally healthy individuals and 20 
periodontitis patients on maintenance phase therapy. The 
periodontally healthy individuals did not demonstrate 
significant gingival inf lamination or attachment loss in any 
site. In addition, pocketing was £ 3mm in all sites. A 
serum sample was obtained for each healthy control subject.
The periodontitis patients were on a maintenance phase 
of therapy and had been diagnosed in the past as suffering 
from advanced periodontal disease (probing depth > 6mm in
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at least four sextants). These patients had received a 
full course of periodontal treatment in the Glasgow Dental 
Hospital, were on maintenance for at least 1 year and had 
not received any antibiotics for 3 months prior to the 
initiation of this study. The periodontitis patients were 
followed longitudinally, over a period of three months, and 
serum was obtained at baseline and 3 months of the 
observation period. A minimum of 6 and a maximum of 15 
sites were monitored in these patients and duplicate 
attachment level measurements were taken at the baseline 
and three month appointment. Attachment level change was 
determined using a prefabricated soft acrylic stent, the 
Florida probe stent handpiece (Florida Probe Corporation, 
Florida, USA) (236), and the tolerance method (237). The 
Florida Probe is a constant force (20g) electronic probe 
with a resolution of 0.2mm. The standard deviations of the 
difference of duplicate measurements, for subject, site and 
population were calculated (237). The attachment loss (AL) 
patients were those who demonstrated significant attachment 
loss surpassing the subject, site and population thresholds 
in at least one site during the three month observation 
period. Significant attachment loss at these sites ranged 
between 0.9 and 3.8mm (mean 1.91mm).
2.2.3. ELISA
Specific antibody titres were measured by ELISA based on 
the method of Ebersole et al (159), using formalinized
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whole cells at an absorbance (OD600 ) which had previously 
been determined as optimum to coat microtitre plates. 
Immulon 1 plates (Dynatech) were employed because of their 
low protein-binding characteristics. After coating, the 
plates were treated with PBS containing 0.1% bovine serum 
albumin (BSA), 0.05% Tween 20 and 5% skimmed milk to remove 
background binding. Serum serially diluted in this buffer, 
minus skimmed milk, was then added and the plates were 
subsequently incubated with biotin-conjugated anti-human 
IgG, IgA or IgM (Sigma) and thereafter with Extravidin- 
peroxidase (Sigma). Reaction was visualized using o- 
phenylenediamine dihydrochloride substrate and stopped with 
1M H2S04. Samples were assayed in duplicate and results 
were calculated using a regression line and derived 
equation from serial dilutions of a reference serum. 
Results were expressed as ELISA units (EU) (149).
2.2.4. Dissociation Assay
The dissociation assay to determine antibody avidity was 
performed as follows:- After incubation with serum as 
described above, the wells were treated with increasing 
concentrations of ammonium thiocyanate (0.2-8.0M). The 
concentration of thiocyanate required to dissociate 50% of 
bound antibody was determined by linear regression 
analysis. This was termed the ID50 and provides a measure 
of relative avidity as previously reported (238, 239).
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2.2.5. Statistical Analysis
Two-sample t-tests were used to determine differences in 
avidity between different clinical groups. Mann-Whitney 
tests were used in group comparisons of the non-normally 
distributed antibody titres. Student's paired t-tests were 
used to assess whether differences were significant between 
baseline and recall appointments and to compare relative 
avidities of antibodies to P. gingivalis and A. actino- 
mycetemcomitans in various sera.
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2.3.Comparison of antibody avidity in various forms of
periodontal disease
2.3.1. Subjects
Serum was collected from twenty-four adult periodontitis 
patients (AP), twelve rapidly progressive periodontitis 
patients (RPP) and twelve healthy control subjects who were 
age and sex matched to the RPP patients. Samples were 
collected from all patients before the commencement of 
therapy.
2.3.2. Statistical Analysis
Mann-Whitney tests were used in group comparisons of 
avidity where medians were employed and also in group 
comparisons of the non-normally distributed antibody 
titres. Student's paired t-tests employing the null 
hypothesis i.e. that difference = 0 were used to assess 
whether differences were significant between RPP data and 
that of age/sex matched controls. Regression analysis was 
used to correlate avidities and titres of antibodies to 




As for Section 2.2.
2.4. Investigation of treatment effect on systemic antibody
2.4.1. Subjects
Nineteen adult periodontitis patients were studied. Serum 
was collected before treatment was initiated and after the 
completion of oral hygiene-phase therapy.
2.4.2. Statistical Analysis
Student's paired t-tests employing the null hypothesis i.e. 
that difference=0 were used to assess whether differences 
were significant between baseline and post-treatment 
samples.
2.4.3. Other Methodology
As for Section 2.2.
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2.5. Comparison of local antibody titres in adult 
periodontitis patients (sites with differing clinical 
indices)
2.5.1. Subjects
The subjects were twenty patients with moderate 
periodontitis who were on recall maintenance therapy and 
had previously undergone active periodontal treatments All 
patients were over 18 years of age with no history of 
systemic disease or history of antibiotic therapy within 
the previous three months. Five non-adjacent periodontal 
sites, previously selected by radiograph as being the most 
severely affected (greatest loss of periodontal bone) were 
sampled. These sites varied in disease status as defined 
by probeable depth and modified gingival index.
2.5.2. Clinical sampling technique
Sites for analysis were chosen on the basis of radiographic 
evidence and the order of sampling and clinical assessment 
was as follows. The modified gingival index (non-invasive) 
was recorded followed by careful supragingival debridement. 
Gingival crevicular fluid was sampled next, and finally 
pocket depth was recorded.
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2.5.3. Microbiological culture technique
Each plaque sample was disaggregated by vortex mixing for 
10 seconds. Dilutions of 1:10, 1:100 and 1:1000 were made 
in 1ml volumes of sterile anaerobe blood broth (Gibco- 
Paisley, Scotland). The two latter dilutions were spiral 
plated (Don Whitley, Shipley, England) onto a Columbia agar 
plate supplemented with 7.5% defibrinated horse blood and 
1% v/v vitamin K/haemin solution. Actinobacillus selective 
agar plates (240) were inoculated with 50p,l of the neat and 
1:10 dilutions. The blood agar plates were incubated at 
37°C in an anaerobic incubator (Don Whitley, Shipley, 
England) and examined after 7 days incubation. The 
Actinobacillus agar plates were incubated in a C02 
incubator at 37°C within an atmosphere of 5% C02 in air for 
2-3 days.
Following incubation, the total viable count was 
determined using a spiral system counting grid (Don Whitley 
Scientific, Shipley, England) as were the number of black 
pigmented colonies and the number of suspected 
Actinobacillus actinomycetemcomitans colonies. Wherever 
possible the whole plate was counted but where this was 
impossible, a segment of the plate was used. In order to 
balance any irregularities in sample deposition a similar 
segment on another part of the plate was counted. The 
anaerobic blood agar plate was also examined under UV light 
(365 nm) for colonies which produced red fluorescence 
(241).
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A selection of pigmented colonies from the 
Actinobacillus agar, were subcultured to Colombia blood 
agar plates and incubated aerobically at 37°C in 5% C02. 
All Gram negative bacilli which were capnophilic and 
catalase positive were inoculated to an API 20A system (API 
lab products) to confirm identification of A, actino- 
mycetemcomitans (242, 243).
2.5.4. Statistical analysis
Correlations between serum and gingival crevicular fluid 
were assessed by Spearman rank order correlation analysis. 
Comparisons between groups of sites were performed using 
Mann-Whitney tests for non-parametric data. Antibody 
titres were generally expressed as EU/30 second sample in 
order to eliminate inaccuracies caused by calculations 
involving very low or high volumes of gingival crevicular 
fluid beyond the limits which can be accurately recorded 
by the Periotron (244). In some cases, where direct 
comparisons between serum and gingival crevicular fluid 
were made, antibody titres were expressed as EU/ml.
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2.5.5. Other Methodology
As for Section 2.2.
2.6. Comparison of humoral immunity in GCF and PISF
2.6.1. Subjects, sites and clinical indices
Thirty one partially edentulous subjects (18 males, 13 
females; age ranges 23 to 84 years), who had no history of 
systemic conditions which could influence the course of 
periodontal disease and had not been on antibiotics for the 
previous two months, were selected to participate in this 
study. The participants had at least two osseointegrated 
implants (ad modum Br&nemark), which had been in function 
for a minimum of one year (averages 3.5 years; ranges 1 to 
10 years). Peri-implant sulcular fluid (PISF) was sampled 
from one healthy and one inflamed non-adjacent peri-implant 
site. In addition, 17 of the 31 patients contributed with 
one healthy and one inflamed tooth site from which GCF was 
collected. Out of the remaining 14 subjects, 4 contributed 
with one healthy and 10 with one inflamed tooth site only. 
Hence, a total of 21 healthy and 27 inflamed tooth sites 
were sampled for intra-subject comparisons between implants 
and natural teeth.
The non-invasive modified gingival index (MGI) (232) 
was used to assess inf lamination and categorise the 
mucosa/gingiva at implants or teeth as healthy or inflamed. 
Sites with an MGI score of 0 or 1 were allocated to the 
clinically healthy group and sites with a score of 2 to 4, 
to the inflamed group. Presence of microbial deposits was 
assessed with the use of the Plaque Index system (PI)
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(231). Following GCF and PISF sampling, probing depth (PD) 
and bleeding on probing (BOP) was assessed at implants and 
teeth using a pressure-sensitive periodontal probe with 
Williams markings (0.25N; diameter: 0.45mm; Electronic
Periodontal Probe, Vine Valley Research, Middlesex, NY, 
USA). Dichotomous scoring was used for BOP.
2.6.2. GCF and PISF sampling
Sterile Whatman grade 4 (Whatman Labsales Ltd., Maidstone, 
Kent) paper strips (2x13mm) were cut using a steel ruler 
and a scalpel and a line was drawn at 5mm indicating the 
length of the strip to be inserted between the Periotron 
jaws. The individual crevicular site was gently air-dried 
in an apico-coronal direction and any visible supragingival 
plaque was removed. The area was carefully isolated with 
cotton wool rolls and a saliva ejector, to avoid salivary 
contamination of the samples. The paper strip was 
introduced into the crevice or peri-implant sulcus until 
mild resistance was felt or to a maximum of 1mm in deeper 
pockets. The strip was left in situ for 30s and then 
transferred, for volume determination, to the chairside 
located Periotron 6000 (Harco Electronics, Winnipeg, 
Canada), which was calibrated at each session using known 
volumes of phosphate-buffered saline in a 1:1 dilution with 
serum. The strip was then stored in a labelled sterile 1ml 
microcentrifuge tube, and placed on ice until all sampling 
was completed. The strips were subsequently transported
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to the laboratory and stored frozen at -70°C until further 
processing. Prior to assaying, samples were eluted into 
lml of phosphate buffered saline containing 0.05% Tween 20 
for lh at room temperature.
2.6.3. Quantitation of GCF and PISF constituents
a2-M, al-AT, TF, LF, albumin (Alb) and IgG against P. 
gingivalis in GCF and PISF eluates were assessed in the 
same sample using enzyme linked immunosorbent assays 
(ELISA).
The five sandwich ELISAs for a2-M, al-AT, TF, LF and 
Alb are based on the technique described by Hetherington 
et al. (245) and modified by Adonogianaki et al. (246). 
In brief, the 96-well polystyrene microplate (Immulon 4, 
Dynatech Laboratories, Billinghurst, Sussex) was coated 
with the first antibody, a goat antiserum specific to the 
antigen to be quantified (1:6000 dilution in carbonate/bi­
carbonate buffer for a2-M, TF, LF and Alb; 1:3000 for al- 
AT). The eluate of the sample was then added and any 
antigen present was captured by the immobilized antibody. 
This was followed by incubation with the second specific 
antiserum, developed in rabbit at 1:4000 dilution in 
incubation buffer, containing either 0.1% bovine serum 
albumin for the a2-M, al-AT, TF and LF ELISAs (IB) or 5% 
skimmed milk for alb (IBM). Finally, the horseradish
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peroxidase (HRP) conjugated anti-rabbit IgG (goat) was 
added (1:4000 dilution in the respective incubation buffer, 
IB or IBM). Visualisation was achieved by incubation with 
the substrate and stopping the reaction with H2S04. The 
plate was read at 490nm. Plates included serial two-fold 
dilutions of purified antigen for the construction of a 
standard curve. Only the central wells were used when 
running standards or samples (in triplicate). The 
peripheral wells were used for assaying the controls. 
Prior to assaying with these sandwich ELISAs, GCF sample 
eluates were diluted further either in IB (or IBM when 
assaying for albumin), in order to achieve an optimal final 
dilution for each assay. The optimal dilution ranges for 
the samples, the working range for the standard for the a2- 
M, al-AT, TF and LF ELISAs as well as the recovery rate for 
each of the acute-phase proteins from paper strips have 
been given elsewhere (247). The working range for the 
albumin ELISA was 125-1.95 ng/ml. Results were expressed 
either as ng/30s sample or ng/jig albumin.
2.6.4. Other Methodology
The method for determining specific antibody levels was as 
given in section 2.2. Results were expressed as absolute 
amounts in ELISA units (149) per 30s sample (EU/30s) sample 
or as specific amounts in EU/^ig Alb.
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2.6.5. Reagents
Purified a2-M ,TF and Alb were obtained from Sigma (Sigma 
Chemical Company Ltd., Poole, Dorset) whereas LF and al-AT 
were purchased from Calbiochem (Novabiochem Ltd., 
Nottingham). Goat and rabbit anti-a2-M and anti-Alb, goat 
anti-TF, biotin-anti-human IgG and extravidin-peroxidase 
were also obtained from Sigma. Goat anti-LF as well as 
rabbit anti-LF and anti-TF were obtained from Nordic 
Immunological Laboratories (Maidenhead, Berkshire) whereas 
goat and rabbit anti-al-AT were purchased from Calbiochem. 
The horseradish peroxidase (HRP) conjugated anti-rabbit IgG 
(goat) was purchased from ICN Immunobiologicals (Lisle, IL, 
USA). Of the above antisera the rabbit antisera to a2-M, 
al-AT, the goat anti-TF and the HRP conjugates were 
fractionated.
2.6.6. Statistical analysis
In order to control for inter-patient variability only 
within patient comparisons were made. GCF or PISF results 
were logarithmically transformed in order to satisfy their 
distributional requirements (log10 (1+x) where x= original 
data value). Four separate multivariate repeated measures 
analysis of variance (MANOVA) procedures were applied to 
the logarithmically transformed data to test for all 
proteins simultaneously for differences between: a) healthy 
and inflamed peri-implant mucosa (n=31 pairs), b) healthy
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and inflamed gingiva (n=17 pairs), c) healthy gingiva and 
peri-implant mucosa (n=21 pairs) and finally d) between 
infleaned gingiva and peri-implant mucosa (n=27 pairs). 
When a significant difference was detected by the analysis 
of variance, univariate paired t-tests were applied to the 
log transformed data to identify the location and direction 
of the statistically significant differences.
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2.7. Cross-sectional study of local antibody levels
2.7.1. Subjects
A further cross-sectional study was performed on 
thirty adult periodontitis patients. One healthy site, one 
gingivitis site, and one periodontitis site were sampled 
for GCF as detailed in section 2.5.
2.7.2. Assay for stromelvsin
This was based on the method of Cooksley et al (248). 
Extensive modification was carried out in order to increase 
sensitivity for use with GCF. Briefly, Immulon 4 plates 
were coated with a monoclonal antibody against human 
stromelysin. After overnight incubation at 4C, these were 
washed, blocked and incubated with serial dilutions of 
recombinant human stromelysin and eluted GCF samples in an 
incubation buffer containing 0.1% protease-free BSA 
(Calbiochem), for one hour at 25C with constant mixing. 
The plates were then washed and incubated with rabbit-anti- 
human stromelysin in the same buffer for one hour at 25C 
with constant mixing. The plates were then washed and 
incubated with HRP-anti-rabbit IgG (Jackson) in the same 
buffer for one hour at 25C with constant mixing. Finally, 
the plates were developed with 3,3',5,5'- 
tetramethylbenzidine (TMB) (KPL) for 15 minutes at 25C with 
constant mixing and reaction was stopped with 2.5% sodium
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fluoride. The plates were read at 630nm. Sensitivity of 
25pg/ml was achieved.
2.7.3. Assay for TIMP
This was based on the method of Cooksley et al (248). 
Extensive modification was carried out in order to increase 
sensitivity for use with GCF. Briefly, Immulon 4 plates 
were coated with a monoclonal antibody against human TIMP-
1. After overnight incubation at 4C, these were washed, 
blocked and incubated with serial dilutions of recombinant 
human TIMP-1 and eluted GCF samples in an incubation buffer 
containing 0.1% protease-free BSA (Calbiochem), for one 
hour at 25C with constant mixing. The plates were then 
washed and incubated with another monoclonal antibody 
against human TIMP-1 which had been conjugated to biotin 
in the same buffer for one hour at 25C with constant 
mixing. The plates were then washed and incubated with 
Extravidin-peroxidase (Sigma) in the same buffer for one 
hour at 25C with constant mixing. Finally, the plates were 
developed with 3,3',5,5'-tetramethylbenzidine (TMB) (KPL) 
for 15 minutes at 25C with constant mixing and reaction was 
stopped with 2.5% sodium fluoride. The plates were read 
at 630nm. Sensitivity of 25pg/ml was achieved.
2.7.4. Reagents
All antibodies and proteins for the above two assays,
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except where otherwise mentioned, were kindly supplied by 
Dr AJP Docherty, Department of Immunochemistry, Celltech 
Ltd., Slough, U.K. Protease-free BSA was obtained from 
Calbiochem-Novabiochem, La Jolla, CA, USA. HRP-anti-rabbit 
IgG was obtained from Jackson Immunoresearch Laboratories, 
West Grove, PA, USA. TMB was obtained from KPL
Laboratories, Gaithersburg, MD, USA.
2.7.5. Other Methodology
As given in Section 2.5.
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2.8. Cross-sectional comparison of natural teeth and
implants
2.8.1. Subjects
Twenty partly edentulous patients with osseointegrated 
implants were studied. All of these patients had 
previously suffered from moderate to severe periodontitis, 
which was treated before placement of implants. The 
following inclusion criteria operateds-
1. No bleeding on probing.
2. Probing depths less than 4mm.
3. Absence of visible plaque (PI=0).
4. Clinical and radiographic signs of osseointegration 
present at implant sites.
5. Implants placed at least six months previously.
Implant and tooth sites were selected and matched according 
to probing pocket depth and modified gingival index.
2.8.2. Other Methodology
As for Section 2.5.
2.8.3. Statistical Analysis
Paired t-tests were performed on the log transformed data
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using the null-hypothesis (i.e. that there is no difference 
between implant and natural tooth).
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2.9. Potential of RCE to distinguish healthy and
periodontitis sites
2.9.1. Introduction
This was a small study of ten healthy subjects and five 
periodontitis subjects in which GCF was sampled from two 
sites in each subject. Total IgG, IgM, IgA and albumin was 
assayed in both GCF and serum and the RCE value as used by 
Giannopoulou et al (249) and Out et al (250) was 






This ratio gives a value directly proportional to the 
extent of local immunoglobulin production.
2.9.2. Total Immunoglobulin Assays
The three sandwich ELISAs for total IgG, IgM and IgA 
concentration in serum and GCF are based on the technique 
described by Hetherington et al. (245) and modified by 
Adonogianaki et al (246). Briefly, Immulon 4 plates were 
coated with anti-human IgG or IgM or IgA (sheep). Plates 
were then washed and blocked with incubation buffer (IB) 
containing 5% Marvel (IBM). The plates were then incubated
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with serial dilutions (1/2) of normal serum of known 
concentration beginning at lOOOng Ig/ml, together with 
diluted test sera and GCF samples diluted as given below. 
There then followed an incubation with biotin-anti-human 
IgG or IgM or IgA. Finally, plates were incubated with 
Extravidin-peroxidase. Reaction was visualised using oPD 
substrate. Reaction was stopped with 1M H2S04 and plates 
read at 490nm.
2.9.3. GCF sample dilutions
1. GCF strips were eluted into 500ul of IB without BSA for 
lhr at RT on rotary mixer.
2. A 20ul aliquot was removed for albumin assay and 500ul 
of IB with 0.2% BSA was added (total volume 980ul).
3. The sample was mixed well and aliquoted in 120ul 
volumes. Aliquots stored at -30C.
4. The dilutions of eluted GCF samples for assay were as 
follows:-
Volume IgG IgM and IgA
v < O.lul 1/10 1/4
0.1 < v < 0.2 1/25 1/10
0.2 < v < 0.4 1/50 1/20
0.4 < v < 0.8 1/100 1/40
v > 0.8 1/200 1/80
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2.9.4. Albumin Assay
This was performed as detailed in Section 2.6.
2.9.5. Data Analysis
The reliability of the RCE was assessed using 
parameters adapted by Lang et al (251). These weres-
1. Sensitivity = true positives
true positives + false negatives
I
2. Specificity = true negatives
true negatives + false positives
3. Accuracy = true positives + true negatives
all results
2.9.6. Other Methodology




The results of the investigation into the humoral 
immune response will be presented as studies of the 
systemic antibody response and of the local antibody 
response.
3.1. Systemic Response
3.1.1. Experimental gingivitis study
A study was performed on six subjects undergoing a 14-day 
experimental gingivitis trial. The systemic antibody 
response to the three organisms most commonly isolated 
during this study (data not shown) is detailed in Table 1. 
No significant changes were observed during the 28-day 
monitoring period. Another element of this investigation 
was to establish whether or not GCF levels of the protease- 
inhibitor, a2-macroglobulin (a2-M) and the iron-binding 
protein, transferrin (TF) change with regard to clinical 
indices. These data are shown in Figure 1. a2-M levels 
peak after 4 days and then fall off, showing a similar 
pattern to that previously reported for interleukin 1 (IL- 
1) (252). In contrast, TF levels fall off constantly
during the trial and do not begin to recover until day 28. 
The results of the in vitro analysis of the ability of 
organisms to eliminate these host proteins are shown in 
































































































PM inin r» PM
o vo CO








































































































































gingivalis, which may be attributed to degradation and/or 
adsorption.
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3.1.2. Study of antibody avidity related to attachment loss
ELISA was used to determine both the avidity and titre of 
IgG, IgA and IgM antibodies to the Gram-negative anaerobe, 
P. gingivalis, in twenty periodontitis patients enroled 
in a longitudinal study of attachment loss and eleven non­
periodontitis affected subjects. A cross-sectional 
analysis of the longitudinal patients at baseline and non- 
periodontally affected controls confirmed earlier findings 
that IgG and IgA antibody titres to this organism were 
higher in periodontitis patients than in individuals who 
were not periodontally affected. In this cross-sectional 
analysis, IgG antibody avidities were not found to be 
significantly higher in periodontitis patients than in 
control subjects (p=0.065). However, indications of the 
potential prognostic value of antibody avidity were 
demonstrated by the higher IgM avidities in patients who 
did not experience attachment loss during the three-month 
monitoring period than in those who did (p=0.0005).
The periodontally healthy (n=ll) and maintenance 
periodontitis groups were compared in terms of titre and 
avidity of IgG, IgM and IgA class antibodies to P. 
gingivalis. The periodontitis group was also sub-divided 
into a sub-group of 14 patients who experienced attachment 
loss in at least one site during the three month monitoring 
period (AL) and another sub-group of 6 patients who 
exhibited no attachment loss (NAL). Table 3 shows the 
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antibodies in controls and periodontitis patients at 
baseline. Comparisons between patients and controls for 
titre and avidity to P. gingivalis in all three 
immunoglobulin classes were made and significant 
differences (p<0.01) were only noted between IgG median 
titres and IgA median titres (Mann-Whitney or two-sample 
t-test). The comparison between periodontitis patients at 
baseline grouped in terms of attachment loss and lack of 
attachment loss after three months is also shown in this 
table. A significant difference was noted between the mean 
avidity of IgM antibodies between subjects with attachment 
loss and those without attachment loss (p<0.001). These 
data are further illustrated in Figures 2 and 3.
Table 4 and Figures 4 and 5 show the changes in 
antibody titre and avidity between baseline and three 
months for all periodontitis subjects but indicates no 
significant differences. Interestingly, sub-grouping the 
periodontitis patients into AL and NAL gave divergent 
results for IgG avidity to P. gingivalis in that over the 
three month period, the AL group had IgG avidities which 
tended to increase whereas the NAL avidities tended to 
decrease (Table 5 and Figure 6). Similarly, although also 
not statistically significant, IgM and IgA avidities tended 
to decrease more in NAL than in AL patients.
Control and periodontitis groups were compared for 
differences in IgG titre and avidity to the two organisms 
(P. gingivalis and A. actinomycetemcomitans) and the 
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to P. gingivalis were significantly higher than to A. 
actinomycetemcomitans in both groups but only in the 
periodontitis group was this difference significant.
Table 7 presents the correlations between titre and 
avidity. These correlations are shown for IgG, IgM and IgA 
specific for P. gingivalis and IgG specific for A • actino­
mycetemcomitans (Aa). The subject groups for which these 
are shown are all subjects, control subjects, all 
periodontitis subjects, attachment loss periodontitis 
subjects (AL) and non-attachment loss periodontitis 
subjects (NAL). The results are shown as R2 (%) and p- 
value.
The data presented in Table 7 show that there was a 
significant correlation between titre and avidity of IgG 
against P. gingivalis for NAL patients and between titre 
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3.1.3. Comparison of antibody avidity in various forms of
periodontal disease
The relationships between various forms of periodontal 
disease and the avidities of serum antibodies of all three 
immunoglobulin classes (IgG, IgM and IgA) to P. gingivalis 
and A. actinomycetemcomitans were investigated. Twenty- 
four patients with untreated adult periodontitis (AP) and 
twelve patients diagnosed as suffering from the early-onset 
form of periodontitis, rapidly progressive periodontitis 
(RPP) were studied. The latter group were age and sex 
matched to healthy controls (C).
The differences between median avidity and median 
titre of antibody to both organisms for AP and RPP groups 
are given in Tables 8 and 9 and also in Figures 7-10. 
These show that avidity of IgG tended to be higher and IgM 
avidity to P. gingivalis was significantly higher in AP 
than in RPP patients, and that IgA titre was significantly 
lower in RPP patients. In contrast, IgA avidity to A. 
actinomycetemcomitans tended to be higher in RPP than in 
AP and IgG and IgA titres were significantly higher in RPP 
than in AP. Statistically significant differences between 
groups were assessed using the Mann-Whitney U-test and p- 
values are given. Similarly, the differences between 
median avidity of antibody to both organisms for AP and 
seronegative RPP groups are given in Table 10. 
Statistically significant differences between groups were 











































0 > 0 0 3
G cd 0 >
T) v 
0  4-> 





















































































A  H-> 
•H *rH 






T3 rHG 0 0 >
0 * 0 A 
•H G 
A 0 











































































































§ & o E
E 10 <2 oi
*■> A0) o 
u £
E
































£ > -rH .. -p
o <d












































































































































































































given. Seronegativity here is as defined by Chen et al 
(157), and it should be noted that the seronegative groups 
for P. gingivalis and A • actinomycetemcomitans were not 
identical, i.e. two patients were seropositive for P. 
gingivalis and another two for A. actinomycetemcomitans.
A comparison between seronegative RPP patients and 
their age/sex matched controls in terms of IgG avidity to 
P. gingivalis is shown in Table 11 and a paired t-test was 
used.
The percentage of patients in both patient groups who 
were seropositive in terms of titre and avidity to P. 
gingivalis and A. actinomycetemcomitans are shown in 
Tables 12 and 13. The seropositivity definition is 
extended here to include avidity, i.e. avidity > 2x median 
control avidity.
The results of a discriminant analysis of AP and RPP 
groups are given in Table 14. This was performed with 
cross-validation thereby mimicking a prospective analysis. 
Cross-validation operates by removing each point in turn 
and treating it as an unknown value, comparing its 
resultant predicted value with its true value. Data are 
shown for the analyses of the whole RPP group and also the 
seronegative RPP group.
Correlations between titre and avidity of antibody to 
P. gingivalis and A. actinomycetemcomitans are given in 
Table 15 for AP, RPP and control (C) groups. Results are 
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3.1.4. Investigation of treatment effect on systemic 
antibody
This longitudinal study of nineteen adult periodontitis 
patients investigated IgG, IgM and IgA antibody titres and 
avidities to P. gingivalis and A. actinomycetemcomitans 
before and after periodontal therapy. These data are given 
in Tables 16-19. A significant increase in avidity of IgG 
antibody against P. gingivalis was observed between 
baseline and post-treatment (Table 16 and Figure 11), 
whereas the titre of IgA antibody to this organism 
increased significantly (Table 17 and Figure 12). There 
were no significant differences in the avidities of any 
class to A. actinomycetemcomitans during the monitoring 
period (Table 18 and Figure 13). However, the titre of all 
three classes to A. actinomycetemcomitans increased 
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3.2.1. Comparison of local antibody titres in adult 
periodontitis patients (sites with differing clinical 
indices)
Specific IgG, IgA and IgM antibody titres to P. gingivalis 
and A. actinomycetemcomitans were measured by ELISA in 
serum and gingival crevicular fluid (GCF) at five sites in 
each of twenty chronic periodontitis patients. Specific 
serum antibody titres correlated with mean gingival 
crevicular fluid titres (p<0.001). The three
immunoglobulin subclass responses (IgA, IgG and IgM) to P. 
gingivalis correlated (R2 ranged from 24.4% to 70.9% and in 
all cases p<0.03). A comparison of sites with PD<4mm and 
PD^4mm showed that the latter group had significantly lower 
gingival crevicular fluid IgG titres to P. gingivalis 
(p<0.01). Sites with GI=3 had significantly lower gingival 
crevicular fluid IgG titres to this organism than those 
with GI<3 (p<0.001).
The Mann-Whitney tests relating the sites grouped on 
pocket depth and gingival index with local IgG antibody 
levels to P. gingivalis and A. actinomycetemcomitans are 
presented in Table 20. P. gingivalis IgG levels were 
found to be significantly lower in the sites with pocket 
depth greater than or equal to 4mm as compared with PD<4 
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(p<0.001). Further tests relating the sites grouped on 
pocket depth and gingival index with IgG antibody to A. 
actinomycetemcomitans (Table 20) or IgA antibodies to P. 
gingivalis gave no statistically significant differences 
for these comparisons. The data are further illustrated 
in Figure 15. Table 21 shows the correlations between 
serum and mean GCF levels for IgG and IgA against P. 
gingivalis and IgG directed against A. actinomycetem­
comitans. Both P. gingivalis and A. actinomycetem­
comitans IgG serum and GCF levels correlated well (R2 = 
66.6% and 96.4% respectively; pcO.OOl). Reanalysis of the 
data categorised on clinical indices revealed slightly 
higher R2 values for the sites with more disease (i.e. GI 
= 3 and PD ^ 4mm) but did not show a significant trend. 
Due to the restrictions imposed by the limited sample 
volume (mean = 0.31p,l) obtained using the standardised 30s 
gingival crevicular fluid sampling technique, insufficient 
sample was available to compare, via ELISA, specific 
gingival crevicular fluid IgM with IgA and IgG. Previous 
work within this laboratory has indicated that levels of 
total and specific IgM in gingival crevicular fluid were 
much lower than both IgA and IgG.
Table 22 shows the Spearman rank correlations between 
PD, GI and IgG antibody to P. gingivalis. All of these 
correlations are statistically significant but the 
relatively low R2 values suggest that other factors have 
influence.
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Table 23 shows the mean GCF volumes collected from sites 
with differing clinical indices. These data are presented 
to establish that GCF volumes were not lower in more 
diseased sites; if this were so it would be a possible 
explanation for the finding that titres are lower in more 
diseased sites when expressed as EU/30s sample. In fact, 
there is a trend towards higher GCF yields from more 
diseased sites.
Table 24 shows the percentage of sites and patients 
from which suspected periodontopathogens were isolated.
i
No further data are presented from the microbiological 
aspect of this study, since no correlation could be 
demonstrated between the isolation of an organism and the 





























































3.2.2. Comparison of humoral immunity in GCF and PISF
There were two main aims of this investigation; firstly, 
to determine the levels of acute-phase proteins and IgG 
against P. gingivalis in peri-implant sulcus fluid (PISF) 
and their association with the clinical condition of the 
peri-implant mucosa; and secondly, to compare the 
inflammatory and immunological responses at implants and 
teeth as reflected by the gingival crevicular fluid (GCF) 
and PISF levels of acute-phase proteins and 
immunoglobulins.
The clinical data are depicted in Table 25. By 
definition, inflamed implant and tooth sites had higher MGI 
scores than healthy implant and tooth sites respectively. 
PI was also higher at both categories of inflamed sites 
when compared to their healthy counterparts. Average 
probing depths were deeper at implants when compared to 
teeth, particularly at healthy sites, and in addition, 
average GCF volumes were higher. 67% of the healthy 
implant sites bled on probing compared to 14% of healthy 
tooth sites. The percentage of bleeding implant and tooth 
sites, allocated to the inflamed category was 93% and 85% 
respectively.
Multivariate repeated measures analysis of variance 
(MANOVA) demonstrated a significant effect when healthy and 
inflamed tooth sites (p=0.021) were compared for their GCF 
absolute amounts of a2-M, al-AT, TF, LF, Alb (ng/30s 
sample) and IgG against P.gingivalis (EU/30s). Follow-up
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Table 25: Clinical indices at teeth and implants. The 
average (SD) are given as well as the frequency 
distribution and percentages for MGI, PI, PD, BOP and GCF.
Implant sites Tooth sites
Healthy Inflamed Healthy Inflamed
n®31 n«31 n®21 n-21
Score n (%) n (%) n (%) n (%)
MGI 0 25 (81) — 17 (81) _
1 6 (19) - 4 (19) -
2 - 18 (58) - 10 (37)
3 - 12 (39) - 16 (59)
4 — 1 (3) — 1 (4)
mean (SD) mean (SD) mean (SD) mean (SD)
0.193 (0.4) 2.452 (0.6) 0.190 (0.4) 2.667 (0.6)
Score n (%) n (%) n (%) n (%)
PI 0 20 (65) 8 (26) 14 (67) 5 (19)
1 10 (32) 4 (13) 6 (29) 9 (33)
2 1 (3) 19 (61) 1 (4) 11 (41)
3 — — — 2 (7)
mean (SD) mean (SD) mean (SD) mean (SD)
0.387 (0.6) 1.355 (0.9) 0.381 (0.6) 1.385 (0.9)
mm n (%) n*(%) n (%) n (%)
PD 1 — — 4 (19) —
2 3 (10) 5 (17) 13 (62) 9 (33.3)
3 21 (68) 13 (43) 4 (19) 9 (33.3)
4 5 (16) 11 (37) - 9 (33.3)
5 2 (6) 1 (3) — -
mean (SD) mean (SD) mean (SD) mean (SD)
3.193 (0.7) 3.27 (0.8) 2.00 (0.6) 3 (0.8)
n (%) n (%) n (%) n (%)
BOP 21 (67) 29 (94) 3 (14) 23 (85)
GCF mean (SD) mean (SD) mean (SD) mean (SD)
*il 0.156 (0.1) 0.335 (0.3) 0.111 (0.1) 0.276 (0.2)
* one PD value missing
analysis, using univariate paired t-tests, demonstrated 
significantly higher levels for all six proteins (a2-M, al- 
AT, TF, Albs p<0.001; IgG: p=0.036; LFs p=0.021) in GCF 
from inflamed compared to healthy tooth sites (Table 26). 
Similarly, repeated measures MANOVA demonstrated a 
significant effect when the absolute amounts of the six 
proteins in PISF from healthy and inflamed sites were 
compared (p=0.004). Univariate paired t-tests, comparing 
the levels of these proteins between healthy and inflamed 
implant sites, demonstrated that the levels of a2-M, al-AT, 
TF, Alb (ng/30s) and IgG (EU/30s) were significantly higher 
(p<0.01) in PISF from inflamed sites (Table 26). However, 
although LF levels showed a tendency towards increased 
levels in PISF from inflamed sites, this increase failed 
to reach statistical significance (p=0.097) (Table 26). 
When the absolute amounts of each protein in fluid from 
around healthy implant and tooth sites were compared, no 
significant differences were noted (MANOVA, p=0.299). 
Similarly, when absolute amounts from inflamed tooth and 
implant sites were compared, the MANOVA did not demonstrate 
a significant effect (p=0.06) (Table 26).
When results were expressed as ng/^ig Alb (a2-M, al-AT, 
TF and LF) or EU/pig Alb (IgG) the picture was divergent 
(Table 27). Repeated measures MANOVA demonstrated a 
significant effect when inflamed and healthy tooth sites 
(p=0.011) were compared. However, univariate analysis 
demonstrated that the only significant differences were the 
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(p=0.001 and p=0.024 respectively, Table 27). GCF a2-M, 
al-AT and LF levels did not demonstrate a significant 
difference between healthy and inflamed tooth sites when 
expressed as ng/^ig Alb. Similarly, MANOVA demonstrated a 
significant effect when PISF levels of these proteins from 
healthy and diseased implant sites were compared (p=0.007), 
but univariate analysis demonstrated a significant 
difference only in the reduction of the levels of IgG in 
PISF from inflamed compared to healthy implant sites 
(p=0.03). Finally, MANOVA did not demonstrate a 
significant effect when healthy or inflamed tooth and 






























































































































































3.2.3. Cross-sectional study of local antibody levels
The median titre of IgG antibodies against P. gingivalis 
and median concentrations of stromelysin and TIMP are given 
in Table 28. A MANOVA was performed on these results as 
for section 3.2.2. and the p-value is given for the within- 
subjects or treatment effect. Table 29 shows the resultant 
paired t-tests for this analysis comparing the three 
disease states. Stromelysin and TIMP show a similar 
pattern to the acute-phase proteins in being unable to 
distinguish gingivitis and periodontitis. Specific antibody 
levels, however, show a tendency towards a distinction 
between these two states, which is echoed in the greater 
difference between health and gingivitis than between 
health and periodontitis. A parallel can also be seen 
between these findings and those of section 3.2.1. in which 
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3.2.4. Cross-sectional comparison of natural teeth and 
implants
Table 30 shows the median titres of antibodies to P. 
gingivalis in GCF around natural teeth as compared with 
PISF around implants. There is a tendency towards higher 
IgG levels in natural teeth. This is also observed for IgG
t











































































































































































































3.2.5. Potential of RCE to distinguish healthy and 
periodontitis sites
Table 32 shows the RCE values for each antibody class for 
both periodontitis and healthy sites. The reliability of 
the RCE ratio in the evaluation of the disease status of 
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4.1.1. Experimental gingivitis study
The results presented here on changes in systemic antibody 
titres to three microorganisms which were found to be 
predominant in the subjects studied, do not show any 
significant differences over a 28-day period. This is in 
accord with previous findings that serum antibody responses 
to Gram-positive organisms do not yield useful data in 
relation to periodontal disease (135-138). It would also 
perhaps have been surprising if any such systemic effects 
had been detectable after such a short period of 
experimentally-induced gingivitis.
In this early study, the ELISA technology had not yet 
been modified sufficiently to have the sensitivity to 
quantify local antibody levels. However, the acute-phase 
protein, a2-macroglobulin (a2-M) and the iron-binding 
protein, transferrin (TF) were assayed in GCF to monitor 
the progression of inflammation.
a2-macroglobulin (a2-M) is a plasma protease inhibitor 
(MW 725kd) (253). Other work in this laboratory indicates 
that a2-M is normally present in gingival crevicular fluid 
(GCF) at about 10% of the serum level (2.2-3.8 mg/ml). It 
is important in the inhibition and ultimate removal of 
potentially harmful endoproteases, either exogenous or 
endogenous (254). The protective function of a2-M is not
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confined to the blood circulation as it is also found in 
other body fluids including gingival crevicular fluid 
(GCF). In a recent study it was found that the total GCF 
concentration of a2-M correlates inversely with the 
proportion of alveolar bone loss in patients with severe 
periodontitis (255). These authors also reported that a2-M 
total concentration was lower in GCF collected from sites 
with more inflamed gingiva in patients with gingivitis.
Transferrin is a serum-derived glycoprotein with a 
molecular weight of 81kd (256). It functions in serum as 
an iron transport protein between sites of absorption, 
utilisation, storage and excretion (257). Its serum level 
is normally around 3mg/ml (258), although this can be 
raised in various inflammatory conditions. In GCF it could 
function as an antibacterial agent, in conjunction with 
lactoferrin and other iron-binding proteins, to produce an 
iron-limiting micro-environment (259). Further,
transferrin has a role in the cell-mediated immune response 
and is required for T-cell transformation and macrophage 
activation (260). Transferrin was first identified in GCF 
by Schenkein and Genco (261) in levels similar to those of 
a2-M.
Figure 1 shows the changes in a2-M and TF 
concentration in GCF during the study. a2-M increases 
sharply at an early stage in inflammation and then falls 
off, recovering at the end of the study period. This 
suggests that a2-M levels increase as a response to 
inflamination (probably augmented by local production) but
124
decrease as a2-M is consumed by greatly increased levels 
of host and bacterial proteases. By contrast, TF levels 
fall off consistently throughout the study period, 
reflecting the purely serum-derived nature of this protein.
In addition, Table 2 demonstrates the ability of P. 
gingivalis to degrade both of these proteins to a much 
greater extent than that evidenced by the three Gram- 
positive organisms studied. In the light of these 
preliminary findings, it was decided to concentrate further 
studies of the humoral immune response on P. gingivalis.
4.1.2. Study of antibody avidity related to attachment loss
The relationship between antibodies to various suspected 
periodontopathogens and periodontal status has been 
extensively investigated although many of the findings have 
been contradictory and this remains a highly controversial 
field. Ebersole and Holt (262) have dealt with the 
application of antibody titres to diagnostics in great 
detail. However, Wilton et al (134), in their review, 
stated that the data currently available do not allow these 
responses to be diagnostic. Generally, reports in this 
field are agreed that an elevation in the humoral immune 
response to certain plaque-associated microorganisms is 
detected in the presence of and/or increasing extent of 
periodontitis (134, 146). However, a few studies have
suggested the opposite tendency (140, 154).
Antibody avidity, that is the measure of the net
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binding strength of antibody to antigen, has been 
extensively studied in a number of fields, both in relation 
to antibody titre and in isolation, in terms of disease 
susceptibility and progression. There have, however, been 
very few reports dealing with antibody avidity in relation 
to periodontal disease, as reviewed in the introduction. 
The investigation of Ebersole et al (200) studying the 
increase in avidity in the non-human primate, Macaca 
fascicularis, following immunization with tetanus toxoid, 
previously discussed, found that IgG avidity increased from 
0.9M to 1.72M following primary immunization and 2.56M 
after secondary immunization. Lopatin et al (201) 
demonstrated that avidity of antibody rose to a similarly 
high level in rabbits post-immunization with P. 
gingivalis, but that human antibodies to this organism 
appear to be of generally low avidity. This latter finding 
was confirmed by the present study. The present report 
also confirms the finding of Lopatin et al, and others 
(148, 214, 263), that IgG serum antibody titres to P.
gingivalis are significantly higher in periodontitis 
patients on maintenance than in controls (p<0.01) (Table 
3 and Figure 2). Additionally it is shown that this is 
also the case for IgA antibodies, but not IgM. However, 
it was not possible to demonstrate a statistically 
significant difference in antibody avidity for any 
immunoglobulin class in the above subject groups. The 
observation that IgM avidity to P. gingivalis is higher 
in NAL than in AL patients is difficult to explain,
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although perhaps the metabolic block referred to by 
Panoskaltsis and Sinclair (199) preventing IgM-IgG 
switching and leading to increased IgM avidity is operating 
here. Nevertheless, the finding may have prognostic 
significance if confirmed by further studies.
Chen et al (157) concluded that after periodontal 
treatment of rapidly progressive periodontitis patients, 
their IgG antibody avidity increased. The data from the 
present study presented in Table 5 may reflect the 
treatment effect reported by these authors. In this case 
the treatment effect would generate a strong and 
statistically significant positive correlation between 
titres and avidities of IgG antibodies to P. gingivalis 
in NAL patients as seen in Table 7. This would result from 
increased avidities and decreased titres stimulated by 
treatment, or in other words, a shift to more biologically 
effective antibodies. However, the present study dealt 
with adult periodontitis patients in maintenance phase, and 
Chen et al examined rapidly progressive periodontitis 
patients prior to, and after initial treatment, therefore 
the two studies are not strictly comparable.
Another recent study of titre and avidity of IgG 
antibodies to P. gingivalis in rapidly progressive 
periodontitis by Whitney et al (202) also shows lower 
avidities in RPP patients than in controls. This contrasts 
with the present study which demonstrated a trend towards 
higher IgG avidities in adult periodontitis patients than 
in controls (p=0.065). Moreover, if seropositive control
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subjects are excluded using the criterion of Chen et al 
(157), i.e. titre > 2x median control titre, then this 
yields a significant difference between seronegative 
control subjects and adult periodontitis patients (p=0 .02). 
These contrasting findings for these different 
periodontitis patient groups may reflect a differing 
aetiology in terms of immunological susceptibility.
The longitudinal aspect of this study failed to show 
any significant changes in titre or avidity of antibodies 
to P. gingivalis during the three month monitoring period 
(Table 5). The non-statistically significant increase of 
0.46M in AL patients compared with a decrease of 0.10M for 
NAL patients (p=0.14) raises speculation about long-term 
changes in antibody avidity which can only be answered by 
a further longitudinal study over a longer time period.
The comparison of the responses to P. gingivalis and 
A. actinomycetemcomitans is interesting in that the 
avidity of IgG antibodies to the latter was found to be 
significantly lower than to the former (Table 6 ). However, 
only the periodontitis group were seen to have a 
significant divergence in response; i.e. equivalent to 6-7 
times the binding strength, using the scale of Ebersole et 
al (200). The relevance of this is unclear but there is 
a suggestion that not only do IgG avidities to P. 
gingivalis tend to be higher in periodontitis, but IgG 
avidities to A. actinomycetemcomitans tend to be lower 
than normal as shown in Table 6 . This may indicate the 
differing relevance of these two organisms in adult
128
periodontitis.
A very recent study by Sjostrom et al (203) showed 
that IgG antibodies in low-titre sera from controls 
subjects were significantly more effective in opsonizing 
A, actinomycetemcomitans than IgG antibodies in low-titre 
sera from RPP patients. The finding of the present study 
that avidities of IgG antibodies to A. actinomycetem­
comitans tend to be lower in adult periodontitis patients 
than in control subjects, although not statistically 
significant, may indicate a failure of biological function 
of antibody directed against A. actinomycetemcomitans in 
these patients also.
Unlike Lopatin et al (201), the present study has 
demonstrated a significant correlation between titre and 
avidity of the IgG response to both organisms studied. In 
addition, these data show that there are differences 
between patient groups in relation to these correlations. 
This indicates the potential prognostic value of antibody 
avidity in determining patients susceptibility to further 
attachment loss.
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4.1.3. Comparison of antibody avidity in various forms of
periodontal disease
The present study shows that IgG and IgM antibody avidities 
to P. gingivalis were lower in RPP patients than AP 
patients, with IgA titres being significantly lower than 
in AP, and tended to be lower than in age/sex matched 
controls. However, a contrasting pattern could be 
discerned for A. actinomycetemcomitans, with IgA avidity 
tending to be higher in RPP than in AP and IgG and IgA 
titres also being significantly higher. As such this study 
supports the hypothesis that there are differences in the 
humoral immune response to these two organisms in RPP and 
AP, and is consistent with previous studies demonstrating 
that avidities to P. gingivalis are lower than normal in 
RPP (157, 202) and higher than normal in AP (201) (Tables 
8-11, Figures 7-10). In relation to AP avidities, this 
also confirms the findings of the previous Section 
(4.1.2.).
RPP has been recognized as a distinct clinical 
condition (264, 265). In addition, an association has been 
demonstrated between the occurrence of RPP and the HLA 
system (266, 267). A correlation has been demonstrated 
between HLA A9 and RPP. A number of studies have been 
published showing that RPP patients differ in their humoral 
immune response expressed as antibody titre to suspected 
periodontopathogens (268-271).
A recent study by Ebersole and Kornman (206)
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demonstrated that P. gingivalis emerges as an organism in 
the subgingival plaque during the conversion from 
gingivitis to progressing periodontitis in a non-human 
primate model, and that this elicits a systemic antibody 
response specific for this microorganism. Similarly, a 
study by Dahlen and Slots (18) in rabbits showed that 
animals co-inoculated with P. gingivalis and A. actino­
mycetemcomitans showed significantly more severe disease 
than animals which were monoinfected. They conclude that 
the immune system acting through systemic antibodies and/or 
cellular mechanisms may modulate the pathogenic potential 
of infecting periodontal pathogens. It may be that antibody 
avidity has a crucial role in this modulation.
In the light of these findings and evidence of the 
importance of avidity as an aspect of the biological 
function of antibody (204, 205, 272), it may be that RPP 
patients constitute a sub-group which is predisposed to 
early and rapidly progressive disease as a result of a 
mechanism blocking the production and/or deployment of 
strongly-binding antibody to suspected periodontopathogens.
The findings presented here of overall low-avidity 
antibodies in RPP patients, and generally in humans, are 
in agreement with previous reports (157, 201, 202). They 
are also in accord with the results of the previous Section 
(4.1.2.). However, they contrast with higher avidities of 
antibody to P. gingivalis and A. actinomycetemcomitans 
found in an early study in this field (168). It must be 
borne in mind, however, that these data were based on
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samples of five and four patients respectively in a mixed 
periodontitis group, and that these samples may have 
contained an unrepresentatively high proportion of 
seropositive AP patients. As the present study shows, 
these, and a small percentage of seropositive RPP patients 
can skew analyses unless measures are taken such as 
dichotomization into seropositive and seronegative groups 
or non-parametric testing based on medians rather than 
means.
The data presented in Table 15 on the relationship 
between titre and avidity are in general agreement with the 
findings of the previous Section (4.1.2.). A clear 
difference can be discerned between periodontitis patients 
and control subjects, and there is also an indication that 
these relationships in terms of the responses to P. 
gingivalis and A. actinomycetemcomitans may also yield a 
useful distinction between AP and RPP patients. It is 
interesting to note that all of the correlations here were 
positive compared with the negative correlations between 
titre and avidity of antibody to Candida albicans found in 
a recent study (273).
The data presented here demonstrating the ability of 
a discriminant analysis to successfully classify RPP 
patients based on antibody avidity also shows that 
misclassification of AP patients also occurs. This 
requires a prospective study employing other parameters, 
e.g. radiographic evidence, to establish the value of 
antibody avidity to P. gingivalis as an aid in the
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differential diagnosis of AP and RPP.
4.1.4. Investigation of treatment effect on systemic 
antibody
An early study by Ebersole's group (135) investigated the 
ability of serum antibody titres to distinguish 
periodontitis from healthy subjects and suggested that 
these responses could provide an appraisal of treatment 
effects in the management of periodontitis patients. Naito 
et al (148) demonstrated that the serum titre to P. 
gingivalis was reduced in periodontitis patients post­
therapy. This has been confirmed by Aukhil et al (173). 
The treatment regime employed here included scaling, root 
planing and oral hygiene instruction, followed by surgery 
or scaling and root planing under anaesthesia.
However, Mouton et al (212) reported that a reduction 
of 50% in antibody titres to P. gingivalis occurred within 
one year post-treatment in most patients, after an initial 
increase. A sub-group of patients, however, did not 
respond to the challenge of the mechanical treatment 
regimen by producing an increased antibody titre to P. 
gingivalis.
An investigation of antibody titres to A . actino­
mycetemcomitans in LJP (274) has shown that these decreased 
post-treatment. It has been shown that untreated AP 
patients have significantly elevated antibody titres to P. 
gingivalis compared with treated AP patients (275).
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Additionally, an investigation of serum titres to P. 
gingivalis LPS in relation to treatment effects 
demonstrated levels reduced by 15-30% long-term post­
treatment (276). Ebersole et al have reported that the 
homologous organism can be detected in subgingival plaque 
when antibody titre elevations are found post-scaling
(277), and also that multiple foci of infection must be 
successfully treated to have an effect on serum IgG levels
(278). They have also demonstrated that the long-term 
reductions in antibody titres occur most frequently 8-10 
months post-therapy, within a range of 2 months- 2 years 
(262).
A recent report by Ebersole et al (279) quotes data 
showing that 60% of periodontitis patients exhibited 
increased titres to a battery of suspected 
periodontopathogens post-treatment, and that these patients 
had fewer episodes of active disease during the monitoring 
interval (two years) than those who did not demonstrate 
increased titres.
The available literature on this subject concurs that 
increases in antibody titre to P. gingivalis occur post­
therapy in most periodontitis patients and thus could have 
a bearing on treatment outcome. In addition, long-term 
reductions in antibody level are associated with the 
resolution of infection.
However, these studies have focused on antibody titre 
and have not considered antibody avidity in relation to 
treatment effects. Chen et al (157) studied both titre and
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avidity of IgG antibodies to P. gingivalis before and 
after treatment in RPP patients. They found that, although 
avidities are significantly lower in RPP patients pre­
treatment than in controls, these avidities increased 
significantly post-treatment to levels higher than in 
controls. They concluded that many RPP patients do not 
produce protective levels of biologically functional 
antibody during the course of natural infection, but that 
they may be stimulated to do so by treatment.
These conclusions are borne out by the findings of the 
present study (extended to the investigation of IgG, IgM 
and IgA avidity and titre against P. gingivalis and A. 
actinomycetemcomitans) in relation to IgG avidity to P. 
gingivalis (Table 16 and Fig.11), IgA titre to P. 
gingivalis (Table 17 and Fig.12), and IgG,IgM and IgA titre 
to A. actinomycetemcomitans (Table 19 and Fig.14).
The effect of treatment on antibody responsiveness may 
result from an inoculation effect during scaling and root 
planing, or from the reduction in antigen load resulting 
from these procedures and improved oral hygiene, or from 
a combination of these two mechanisms. Reduction in 
antigen load is known to result in selection of B-cell 
clones producing higher avidity antibodies (2). Treatment 
may also permit the development of a normal maturation of 
the immune response, perhaps mediated by an inoculation 
effect, leading to antibodies of increasingly higher 
avidity.
Both the present study and that of Chen et al (157)
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demonstrate that IgG avidities to P. gingivalis are 
subject to a general increase in all patients post­
treatment, the present study dealing with AP patients and 
Chen et al's study with RPP patients. However, when 
patients are dichotomized into seropositive and 
seronegative groups, using Chen et al's criterion of titre 
> 2x control median titre, then both studies show 
convincing increases in IgG titre to P. gingivalis only 
in the seronegative group. The present study found that 
IgG titre increased in 10/11 (91%) of seronegative
patients, but only 3/8 (38%) of seropositive patients.
Chen et al suggest that some patients (seropositive) are 
producing large amounts of low-avidity, biologically 
ineffective antibody until therapy induces production of 
higher-avidity antibodies required at lower concentration; 
whereas others (seronegative) are producing very little 
specific antibody until therapy induces production of 
higher-avidity antibodies at much higher concentration.
4.2. Local Response
4.2.1. Comparison of local antibody titres in adult 
periodontitis patients (sites with differing clinical 
indices)
In the present study specific IgG levels against P. 
gingivalis were found to be significantly lower in more
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severe chronic periodontitis sites as defined by PD and GI. 
However, no significant differences in IgA levels were 
found between chronic periodontitis sites of varying 
disease levels. Baranowska et al (207) found no difference 
between levels of specific IgG to P. gingivalis in healthy 
and diseased sites within the same individual. However, 
fixed volume samples of 0.5pl were taken. This means that 
strips from sites which did not yield 0.5(il were discarded 
and that samples were taken over variable time periods 
resulting in variable rates of serum contamination (280). 
Since healthy sites tend to yield lower volumes than 
diseased sites, this method treats healthy and diseased 
sites in different ways. Therefore, these results are not 
strictly comparable with the present study. An earlier 
study by Schenck (211) showed an inverse relationship 
between the number of deep pockets (>4mm) and serum 
antibody level to P. gingivalis lipopolysaccharide in 
chronic periodontitis patients. Mouton et al (212) 
demonstrated a dichotomy in serological responses to P. 
gingivalis among chronic periodontitis patients with one 
sub-group exhibiting high serum antibody levels and another 
having levels similar to those of healthy individuals. The 
patients with high serum antibody levels appeared to 
respond better to therapy as evidenced by reduction in the 
number of deep pockets within one month post-treatment. 
Their findings are consistent with the data reported here 
that lower P. gingivalis IgG titres are found in more 
severely affected sites.
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A fairly strong correlation between IgG, but not IgA, 
to P. gingivalis in serum and gingival crevicular fluid 
was found in this study (Table 21) and similar results have 
been reported previously (207). However, other studies 
have reported lower mean gingival crevicular fluid than 
serum IgG levels to P. gingivalis (281) as well as lower 
total IgG in gingival crevicular fluid than in serum (282). 
In addition, Lamster et al (210) reported a significant 
correlation between total IgG in gingival crevicular fluid 
and specific serum antibody to Bacteroides intezmedius (now 
Prevotella intermedia) but not P. gingivalis. They 
conclude that the development of a serum immunoglobulin 
response to suspected periodontopathogens is consistent 
with a protective host response. A corollary of this view 
is that a local deficiency of IgG to P. gingivalis may 
lead to local disease progression. Alternatively, Kilian 
(21) has demonstrated that P. gingivalis can degrade human 
IgG and IgA, suggesting that low gingival crevicular fluid 
levels of IgG may be caused by degradation by P. 
gingivalis, or that locally available antibodies are 
adsorbed by the greater mass of subgingival plaque present.
Levels of serum and gingival crevicular fluid IgG 
against A. actinomycetemcomitans were found to be highly 
correlated in this study. In contrast to the results 
presented on P. gingivalis IgG, there were no differences 
in gingival crevicular fluid IgG levels to A, actino­
mycetemcomitans in chronic periodontitis sites of varying 
disease levels (Table 20 and Fig.15). Gunsolley et al
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(216) found that serum antibody levels to A. actinomycete­
mcomitans and P. gingivalis are inversely related to the 
degree of periodontal destruction in young adults with 
juvenile periodontitis or generalized severe periodontitis 
and concluded that this is consistent with a hypothesis 
that failure to mount a substantial antibody response to 
these organisms leads to more widespread periodontal 
destruction. The present study of adult periodontitis 
patients would support this view at both local and systemic 
levels, but only for P. gingivalis.
Genco et al (283) showed that adsorption of serum from 
localized juvenile periodontitis patients with A, actino­
mycetemcomitans and H. aphrophilus resulted in the 
elimination of most of the reactivity to the homologous 
strain but not to the heterologous strain. In the present 
study most of the reactivity to A. actinomycetemcomitans 
could be removed by adsorption with both organisms (data 
not shown) suggesting that there is cross-reaction between 
antibodies to these two species. Similarly, strong 
correlations were found between serum IgG and IgM levels 
to these two organisms. The indications are that 
antibodies detected to A. actinomycetemcomitans in adult 
periodontitis patients could be confounded with cross­
reacting antibodies directed against H. aphrophilus, which 
is, with other Haemophili, commonly isolated from dental 
plaque (284).
Ebersole et al (169) demonstrated in patients with 
various types of periodontal disease, that the same
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organism to which the individual exhibited elevated serum 
antibody was detected in 55% of disease-active sites but 
only 18% of disease-inactive sites. However, Williams et 
al (285) in a study of patients with early-onset 
periodontitis, found that many patients had serum 
antibodies to organisms not found in the pocket flora and 
that some organisms which made up a large proportion of the 
pocket flora did not seem to provoke a corresponding 
antibody response. These authors suggested that seguential 
infection occurs in these forms of periodontitis leading 
to induction of protective immunity against reinfection by 
the same organism.
In conclusion, there appears to be general agreement 
that antibody levels to P. gingivalis are raised in 
periodontitis patients as compared with healthy individuals 
but there are also indications, supported by the present 
study, that lower antibody levels may be present in the 
more disease affected sites within the periodontitis group. 
In addition, this study failed to demonstrate any 
significant differences between gingival crevicular fluid 
IgG levels against A. actinomycetemcomitans between sites 
with different pocket depths and gingival indices. Care 
must be taken, however, in interpreting these results as 
although these patients exhibited sites with pocketing and 
gingivitis (Table 20 and Fig.15), they were maintenance 
regime patients who have received extensive periodontal 
treatment. Thus they may not be strictly comparable with
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non-treated adult periodontitis patients. This study, 
however, addresses the cross-sectional comparison of 
healthy and diseased sites and the correlation between 
local and systemic antibody titres. Further work is 
required to elucidate the inverse relationship between the 
clinical indices and gingival crevicular fluid and serum 
IgG antibody to P. gingivalis found in the periodontitis 
patients of the present study.
4.2.2. Comparison of humoral immunity in GCF and PISF
The long-term success of osseointegrated dental implants 
relies on the maintenance of the (biological seal and the 
integrity of the peri-implant tissues (286). The peri- 
implant supracrestal tissues are in many ways comparable 
to their periodontal counterparts (287). Like the gingival 
crevice at a tooth, the peri-implant sulcus provides a 
niche for the establishment and growth of oral 
microorganisms. The microflora around natural teeth and 
implants have been compared in partially edentulous 
patients, and were found to be analogous (288-290). In 
addition, an animal study has shown that microbial 
colonization and establishment on titanium osseointegrated 
implants, from healthy mucosa to experimental mucositis and 
peri-implantitis, follow a very similar pattern to that of 
natural teeth (291).
One issue which has recently attracted attention, is 
whether periodontal (gingiva) and peri-implant mucosa share
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the same inflammatory and immunological responses. The 
inflammatory infiltrate in peri-implant healthy and 
inflamed mucosal biopsies from humans has been 
immunohistochemically characterised and resembles that 
found in the gingival tissue. It comprises mainly 
lymphocytes, macrophages and only very few plasma cells
(292). Moreover, histological studies on animals have 
demonstrated that the reaction of the soft tissues to early 
plaque formation is similar around teeth and implants
(293). Long term animal studies, however, have shown that 
prolonged plaque accumulation and inflammation may result 
in a greater apical extension of the inflammatory 
infiltrate around implants than teeth (294) and that in 
experimental peri-implantitis, inflammatory cells may be 
found even in the adjacent bone marrow (295). Thus, a more 
intense inflammatory response may develop around implants 
when compared to teeth in response to prolonged plaque 
accumulation, although further human studies are needed to 
confirm this.
Gingival crevicular fluid (GCF) or peri-implant sulcus 
fluid (PISF) provide a non-invasive means of comparing the 
inflammatory and immunological responses around natural 
teeth and implants. However, in contrast to GCF which has 
been widely examined (259), very few studies exist on PISF 
components and their relation to peri-implant status (289, 
296).
The protease inhibitors, a2-M and al-AT play an 
important role in the neutralisation of the proteases
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released in the gingival crevice (297), whereas the iron- 
binding proteins TF and LF may act as antimicrobial agents 
in the area (259). These acute-phase proteins have been 
previously identified in GCF (255, 298-302). In addition, 
it has recently been demonstrated that their absolute 
amounts are elevated in GCF from 'diseased' compared to 
'healthy' sites (246, 247), and also that LF reflects PMN 
numbers in the crevice (247). Thus, these acute-phase 
proteins may also serve as markers of peri-implant 
inflammatory status.
Local GCF immunoglobulin levels against putative 
periodontal pathogens, including P. gingivalis, may 
provide a measure of the humoral immune response at a 
specific site. The results of Section 3.2.1. showed that 
GCF antibody titres against P.gingivalis were lower in deep 
pockets and inflamed sites than in shallow pockets or less 
inflamed sites. As P. gingivalis has been isolated also 
from the subgingival microflora around implants in 
partially edentulous patients (288-290), PISF IgG levels 
against this periodontal pathogen may provide useful 
information on the immunological status of peri-implant 
sites.
The clinical data displayed some interesting features. 
Very few inflamed implant and tooth sites had an MGI score 
of 4, demonstrating that implants and teeth were relatively 
well maintained. As expected, inflamed implant and tooth 
sites demonstrated higher amounts of plaque than healthy 
sites depicting, within the limits of this cross-sectional
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investigation, the well-known association of plaque 
accumulation with inf lamination of the gingival tissues but 
also of the peri-implant tissues. The allocation of 
implant and tooth sites to the clinically healthy or 
inflamed group was done on the basis of the MGI, which 
assesses only visual changes of the soft tissues and thus, 
does not interfere with GCF or PISF sampling. When the 
clinically healthy sites were probed after all sampling was 
completed, 3 tooth sites (14%) compared to 21 implant sites 
(67%) bled following the probing. This difference in 
bleeding frequency is most likely to be due to the reduced 
resistance to probing offered by the peri-implant mucosa 
in comparison to that offered by the gingiva, as a 
consequence of differences in terms of tissue composition, 
organisation and attachment to the root/implant surface 
(303). In fact, in a recent beagle dog study (304), in 
which probing with standardised pressure (0.5N; probe 
diameter 0.5mm) at implants and teeth with non-inflamed 
mucosa was histologically evaluated, it was reported that 
the probe penetrated on the average 1. 3mm (SD 0.3) into the 
supracrestal connective tissue at implants, while at teeth 
the tip of the probe was consistently located within the 
zone of the junctional epithelium. The high frequency of 
bleeding found in the present study following probing of 
the 'clinically healthy' implant sites, despite the use of 
a probing pressure of only 0.25N, indicates that a pressure 
less than 0.25N may be needed in order not to traverse the 
apical termination of the peri-implant junctional
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epithelium, and hence caution must be exercised when 
comparing the probing data for teeth and implants in the 
present investigation.
The assessment of the four acute-phase proteins, Alb 
and also IgG against P.gingivalis provides a profile for 
GCF and PISF components of different sources and with 
different functions. Such a profile, especially when 
components are assessed in GCF or PISF from the same site, 
gives a picture of the inflammatory and immunological 
responses at a specific site. None of the constituents 
reported in this study have been previously determined in 
PISF. Similarly to GCF, PISF demonstrates protease- 
inhibitory capacity due to the presence of the potent 
protease-inhibitors a2-M and al-AT, as well as general 
antimicrobial properties via the iron-binding proteins TF 
and LF. The presence in PISF of specific immunoglobulin 
against P.gingivalis, a putative periodontopathogen that 
has been isolated from peri-implant sulci (288-290), could 
be due to localised induction of plasma cells of the peri- 
implant mucosa to IgG production and/or leakage from serum. 
Specific immunoglobulin in the peri-implant sulcus could 
be involved in the opsonisation of micro-organisms and also 
complement activation rendering further specific 
antimicrobial properties to PISF.
In this investigation, it was decided to express 
results of GCF and PISF constituents in two ways, as ng/30s 
sample and as ng/p,g Alb. The rationale for expressing 
results as ng/30s sample has been discussed previously
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(244). Reporting results per unit Alb provides information 
on constituent levels relative to the serum derived 
component of GCF or PISF and may thus supply an indication 
of proteins derived from the systemic circulation.
It has been shown in previous investigations that the 
levels of the acute-phase proteins are higher in GCF from 
inflamed tooth sites compared to healthy sites (246, 299, 
302). Thus, when the results were expressed as ng/30s, the 
increase at inflamed sites was anticipated, for the 
protease inhibitors a2-M and al-AT and the iron-binding 
proteins TF and LF (Table 26). For a2-M, al-AT and TF, 
which have high serum concentrations (2mg/ml) (256), 
increased vascularity and vascular permeability is probably 
the major factor contributing to higher GCF or PISF levels 
at inflamed sites. This is supported by the simultaneous 
rise in GCF or PISF volume as well as Alb at inflamed sites 
around both implants and natural teeth. Further support 
for the predominantly serum origin of a2-M and al-AT is 
provided by the inability to demonstrate a significant 
difference between healthy and inflamed sites for both 
implants and teeth when the results were expressed relative 
to Alb (Table 27).
When results were expressed as ng/30s LF demonstrated 
a statistically significant increase in GCF from inflamed 
compared to healthy tooth sites. As LF may be considered 
a crevicular PMN marker (247) its increase in GCF at 
inflamed sites may be accounted for by increased PMN 
emigration. Although a significant difference was not
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shown when inflamed implant and tooth sites were compared, 
there was a tendency for inf leaned implant sites to have 
lower levels of LF than inflamed tooth sites. This 
tendency is in line with findings reported from a recent 
animal study showing that lower PMN numbers may be found 
in inf leaned peri-implant tissue compared to inflamed tooth 
sites (294) .
The finding that inflamed tooth sites demonstrated 
higher antibody titres (EU/30s) of IgG against P.gingivalis 
than healthy tooth sites appears to contradict the findings 
of Section 3.2.1. However, one has to consider that the 
present study refers to non-periodontally involved sites 
from well-maintained patients, whereas the previous study 
was on a periodontitis affected population. In addition, 
Table 27 demonstrates that specific IgG titres to 
P.gingivalis were significantly lower in both GCF and PISF 
from inf leaned sites when expressed as EU/ng albumin. This 
suggests that in inflamed sites proportionately less 
specific antibody is derived from serum and proportionately 
more from the local plasma cell infiltrate. There also 
appears to be a trend towards IgG titres in PISF from 
healthy implant sites being lower than in GCF from healthy 
tooth sites measured on this basis, suggesting the 
possibility of a difference in the plasma cell infiltrate 
around implants and natural teeth. This will be explored 
further in the later discussion of the second implant 
study.
An interesting observation was the drop in TF and IgG
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levels and the tendency for lower LF levels at inflamed 
tooth sites compared to healthy sites when results were 
expressed as ng/|xg Alb (Table 27). The drop in specific 
IgG levels in inflamed tooth sites may be related to the 
opsonisation and/or degradation by P.gingivalis resulting 
in consumption of the immunoglobulin (21). Furthermore, 
both TF and LF may bind to oral isolates, which may 
contribute to decreased levels of the iron-binding proteins 
at diseased sites (305). These events would result in a 
relative dilution of TF, LF and IgG compared to Alb. At 
diseased implant sites, however, only IgG showed a trend 
for lower levels when the results were expressed as ng/p,g 
Alb, which may be related to the tendency for higher Alb 
levels (ng/30s) at healthy implants sites compared to 
healthy tooth sites. The tendency for higher albumin 
levels may suggest that structural and anatomical 
differences in implant sites result in greater leakiness 
in healthy implant compared to healthy tooth sites. 
However, the fact that overall no significant differences 
were observed between implants and teeth (ng/30s or ng/\ig 
Alb; Tables 26 and 27) suggests that production of PISF is 
probably governed by similar mechanisms to that of GCF and 
that inflammatory events are similar in the peri-implant 
mucosa and the gingiva.
In conclusion, this investigation suggests that great 
similarities exist in the profile of GCF and PISF 
constituents and analogous mechanisms seem to control
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inflammatory and immunological responses around both 
implants and natural teeth. However, there is also a 
suggestion that implants and natural teeth may differ in 
the local plasma cell infiltrate, and this will be 
discussed further later.
4.2.3. Cross-sectional study of local antibody levels
A further cross-sectional study of specific IgG titres to 
P.gingivalis was conducted. This differed from the 
previous study in that three sites were sampled in each 
patient; one healthy, one gingivitis and one periodontitis 
site. In addition, an assessment of the levels of the 
tissue metalloproteinase, stromelysin, and the tissue 
inhibitor of metalloproteinases (TIMP) was made.
Members of the metalloproteinase family, such as 
collagenase, stromelysin and gelatinase, are thought to 
play a role in the natural processes occurring during 
tissue remodelling and repair. The precise role of these 
enzymes in the pathological destruction of tissue observed 
in disease processes such as the arthritides (306, 307), 
periodontal disease (308) and tumour metastasis (309) is 
the subject of much current research. It is thought likely 
that these enzymes are controlled in vivo by the rate of 
activation (310, 311) and through the action of TIMP, which 
forms tight non-covalent complexes with active forms (312- 
314) .
Most connective tissue cells, including fibroblasts,
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chondrocytes and endothelial cells, produce low or 
undetectable levels of metalloproteinases in monolayer 
culture. They can, however, be stimulated to synthesise 
relatively high levels of these enzymes in the presence of 
mononuclear cell cytokines, e.g. IL-1 (315) and TNF (316). 
In human gingival or synovial fibroblasts three separate 
metalloproteinases, collagenase, stromelysin and 
gelatinase, can be shown to be coordinately induced after 
stimulation with a variety of cytokines and growth factors 
(317). These cell types also produce TIMP (318) and 
several, but not all, of the factors which stimulate enzyme 
production also stimulate synthesis of the inhibitor (319, 
320). These enzymes and TIMP are not present in 
appreciable concentration in serum in systemic health (313) 
and, therefore, their presence in GCF can be used as an 
indicator of local activation and inhibition of tissue 
destruction.
Table 28 shows that all three parameters, i.e. IgG 
against P.gingivalis, stromelysin and TIMP show significant 
p-values for the within-subjects effect (i.e. that the 
presence of disease within a subject has an effect on the 
measured level of the parameter).
However, as Table 29 demonstrates, a significant 
difference between health and gingivitis, as opposed to 
health and periodontitis, is observed for IgG against 
P.gingivalis only. In addition, there is a definite trend 
towards specific IgG levels being lower in periodontitis 
sites than in gingivitis sites. This bears out the
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findings of the previous cross-sectional study and suggests 
that measurement of specific IgG levels in GCF may provide 
a more sensitive indicator of local disease progression 
than metalloproteinase or TIMP levels.
4.2.4. Cross-sectional comparison of natural teeth and 
implants
The further comparative study of GCF from natural teeth and 
PISF from matched implants was extended in its scope to 
include all three main immunoglobulin classes, IgG,IgM and 
IgA, directed against both P.gingivalis and A. actino- 
mycetemcomitans. The findings are presented in Tables 30 
and 31. These accord generally with the findings of the 
earlier implant study presented in Tables 26 and 27.
This later study demonstrates that there is a tendency 
towards IgG titres to P. gingivalis being higher in natural 
teeth than in matched implants. This also applies for IgG 
to A . actinomycetemcomitansr although there is an opposite 
tendency for IgA against A. actinomycetemcomitans. This 
agrees with the data presented for the earlier study in 
Table 27, which show that IgG titres to P.gingivalis are 
significantly higher in GCF from natural teeth than in PISF 
from implants when expressed as EU/ug albumin. Statistical 
significance may also have been achieved in this later 
study if albumin data had been available.
The other striking point when one comes to compare 
these two implant studies is the fact that IgG titres were
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found to be markedly higher in the earlier than in the 
later study. Possible explanations for this are the 
differing periods post-implantation (1-10 years and 6 
months-1 year respectively), and the more stringent 
inclusion criteria in the later study (probing depths < 
4mm, absence of visible plaque i.e. PI = 0).
4.2.5. Potential of RCE to distinguish healthy and 
periodontitis sites
A pilot study was conducted in which total IgG, IgM and IgA 
levels and albumin levels were assayed in serum and GCF 
from periodontitis patients and healthy controls. The aim 
was to apply the RCE ratio, using the method of 
Giannopoulou et al (249) and Out et al (250), to assess the 
extent of local immunoglobulin production.
The data presented in Tables 32 and 33 show that, 
although there are definite tendencies toward increased 
local IgG and IgA production and decreased IgM production 
in periodontitis, the small sample numbers probably had a 
large influence on the low accuracies achieved.
Immunocytochemical techniques have demonstrated that 
B-cells and plasma cells are the predominant cell types in 
periodontitis, producing IgG,IgA and, more rarely, IgM 
(321). The present study suggests that local production 
of IgM occurs in healthy sites, but that infiltration of
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IgG- and IgA-producing clones may occur in periodontitis. 
It has recently been suggested that the numbers and 
proportions of plasma cells producing IgG subclasses might 
be associated with the stage of periodontitis (322).
These preliminary findings require to be thoroughly 
investigated using both ELISA technology and 
immunolocalization techniques. Since conventional
immunocytochemistry techniques have been known to produce 
background-staining problems in this field (323), in situ 
hybridization techniques would appear to provide a better 
option (324).
These techniques would be especially useful in 
distinguishing IgG subclass secreting cells, distinguishing 
secreting plasma cells from memory B-cells on the basis of 
mRNA copy number (325, 326), and distinguishing IgAl and 
IgA2 secreting cells (322, 327).
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4.3. Conclusions
The work presented in this thesis has demonstrated that 
systemic levels of antibody directed against particular 
suspected periodontopathogens are influenced by periodontal 
disease type, disease status and the effect of treatment. 
The differences in avidity of antibody to P.gingivalis 
between AP and RPP patients perhaps point to differences 
in host related disease susceptibility. Similarly, the 
differences in antibody avidity between AP patients with 
different attachment loss experience suggest that the 
efficacy of the humoral immune response has a bearing on 
disease progression. The treatment effects seen would 
suggest that periodontal treatment, such as root planing, 
provokes an immune response leading to the selection of B- 
cell clones producing higher affinity antibody.
In terms of site susceptibility, the data presented 
here suggest that a local deficiency of specific antibody, 
caused by reduced production or increased absorption and 
consumption, may lead to local disease progression. There 
are also indications, based on the findings of two cross- 
sectional studies, that IgG titres to P.gingivalis may 
allow discrimination between gingivitis and periodontitis 
sites. This cannot be achieved by markers of inflammation, 
e.g. acute-phase proteins, or markers of tissue 
degradation, e.g. matrix metalloproteinases and TIMP.
The comparative studies of implants and natural teeth 
have suggested that there may be differences in the plasma
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cell infiltrate around these fixtures.
All of these areas require much further research. For 
example, if the rate of immunoglobulin production in the 
gingival tissue could be determined in periodontitis, 
gingivitis and health, then an answer may be found to the 
question of whether lower GCF antibody levels observed in 
periodontitis sites are attributable to greater local 
consumption or by a repression of synthesis.
Use of further advanced technologies, e.g. in situ 
hybridization (ISH) and polymerase chain reaction (PCR), 
will probably be required to elucidate changes in disease 
stage, different periodontal disease types, and site- 
specific differences, especially in relation to oral 
implants. However, the use of antibody avidity assessments 
also has the potential to further elucidate the 
immunological basis of periodontal disease susceptibility.
Further studies of the humoral immune response in 
periodontal disease will require to approach the problem 
from the various perspectives that these technologies, 
developed and developing, provide.
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Kinane DF, Mooney J, MacFarlane TW. McDonald M. Local and systemic antibody 
response to putative periodontopathogens in patients with chronic periodontitis: corre­
lation with clinical indices.
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i
Specific immunoglobulin G (IgG), IgA and IgM antibody titres to Porphyromonas 
gingivalis and Actinobacillus actinomvcetemcomitans were measured by enzyme- 
linked immunosorbent assay in serum and gingival crevicular fluid at 5 sites in 
each of 20 chronic periodontitis patients. Specific serum antibody titres correlated 
with mean gingival crevicular fluid titres. The 3 immunoglobulin subclass re­
sponses (IgA, IgG and IgM) to P. gingivalis correlated. A comparison of sites 
with probing depth < 4  mm and > 4  mm showed that the latter group had 
significantly lower gingival crevicular fluid IgG titres to P. gingivalis. Sites with 
a gingival index of 3 had significantly lower gingival crevicular fluid IgG titres 
to this organism than those with a gingival index of less than 3. These findings 
support the concept that the humoral immune response is protective, as chronic perio­
dontitis patients with greater pocket depths and more gingival inflammation had 
paradoxically lower antibody titres to suspected periodontopathogens.
Porphyromonas gingivalis and Actino­
bacillus actinomvcetemcomitans are con­
sidered important periodontopathogens 
in different types of periodontal disease 
(21,22). Studies of the systemic humoral 
immune response to these organisms 
have related specific serum antibody tit­
res to disease progression. For example, 
Gunsolley et al. (12) found that the level 
of serum antibody to P. gingivalis and A. 
actinomvcetemcomitans in periodontitis 
subjects was inversely related to disease 
level. Ebersole et al. (7, 8), however, 
reported a positive correlation between 
serum immunoglobulin G (IgG) to A. 
actinomvcetemcomitans and the severity 
of the disease. Also when patients with 
similar P. gingivalis antibody levels were 
compared, greater disease severity was 
evident in rapidly progressive perio­
dontitis patients than in adult perio­
dontitis and localized juvenile perio­
dontitis patients (7).
The relationship between local anti­
body levels and local disease status has 
not been investigated to the same extent. 
Baranowska et al. (1) found no signifi­
cant difference in the level of specific 
IgG to P. gingivalis in gingival crevicular 
fluid (GCF) between healthy and dis­
eased sites within the same individual. 
Tew et al. (24) found no obvious differ­
ences in the clinical parameters of prob­
ing depth and attachment level between 
sites with elevated antibody to P. gingi­
valis and/or A. actinomycetemcomitans 
and those with normal or low levels. 
They concluded that elevated antibody 
in GCF may relate to changes in disease 
activity that are not detectable by con­
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ventional clinical assessment tech­
niques. Suzuki et al. (23) demonstrated 
that local production of IgG to P. gingi­
valis was markedly increased in adult 
periodontitis as compared with rapidly 
progressive periodontitis, suggesting 
that disease progression is influenced by 
local antibody production. Challacom- 
be et al. (2) showed that levels of IgG 
antibody to P. gingivalis were lower in 
crevicular fluid washings of patients 
with a high periodontal disease index 
than in those with low scores (not statis­
tically significant). In addition, the op­
sonic activity against P. gingivalis was 
significantly depressed in high peri­
odontal disease index patients as com­
pared with low-scoring patients.
Microbial challenge generally induces 
antibody production and high titres indi­
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cate current or previous infection. How­
ever, in periodontal disease the corre­
lation between high antibody titres and 
disease status is equivocal. The aims of 
this study were to measure the local 
(GCF) and systemic (serum) levels of 
IgG, IgA and IgM antibody to type 
strains of P. gingivalis and A. actino- 
mycetemcomitans within a group of 20 
periodontitis patients and to correlate 
these with pocket depth and gingival 
index.
Material and methods 
Patients
The subjects were 20 patients with mod­
erate periodontitis who were recall main­
tenance therapy and had previously 
undergone active periodontal treatment. 
All patients were over 18 years of age 
with no history of systemic disease or his- 
| tory of antibiotic therapy within the pre- 
| vious 3 months. Five non-adjacent peri- 
I odontal sites, previously selected by 
j radiograph as being the most severely af- 
; fected (greatest loss of periodontal 
| bone), were sampled. These sites varied 
t  in disease status as defined by probing 
j depth (PD) (18) and modified gingival 
i index (GI) (18). Gingival crevicular fluid 
; was collected on Whatman grade 4 filter 
| paper strips (11) over a period of 30 s.
| Strips contaminated by blood were dis- 
i carded. Fluid volume was quantified by 
a Periotron 6000 (Harco Electronics, 
Winnipeg, Manitoba, Canada). The 
strips were placed in vials containing 1 ml 
of phosphate-buffered saline (PBS) with 
0.1% bovine serum albumin and 0.05% 
[ Tween 20 and antibody was eluted for I 
j h with mixing at 25°C. The eluates were 
aliquotted and stored at — 20°C until 
used. Serum was also collected from each 
'patient and stored at — 20°C.
Clinical sam pling technique
Sites for analysis were chosen on the 
basis of radiographic evidence and the 
order of sampling and clinical assess­
ment was as follows. The modified GI 
(non-invasive) was recorded followed 
by careful supragingival debridement. 
GCF was sampled next, and finally 
pocket depth was recorded.
Enzyme-linked im m unosorbent assay  
(ELISA)
Specific antibody titres were measured 
| by ELISA based on the method of Eber-
sole et al. (4, 5), using formalinized 
whole cells at an absorbance (OD 600) 
that had previously been determined as 
optimum to coat microtitre plates. The 
bacterial strains used were P. gingivalis 
NCTC 11834, A. actinomycetemcomi- 
tans ATCC 29523 and Haemophilus 
aphrophilus NCTC 5886. P. gingivalis 
was grown under anaerobic conditions 
(85% N;, 10% H-, 5% CO-) and A. acti- 
nomycetemcomiians in CO- at 37°C on 
Columbia blood agar. P. gingivalis was 
harvested after 5 days and A. actino- 
mycetemcomitans after 24 h into PBS 
(pH 7.4), with 1 mM disodium EDTA, 
washed by centrifugation, and fixed for 
1 h in 10% formal saline. The cells were 
then washed twice in PBS and once in 
0.1 M sodium carbonate-bicarbonate 
buffer containing 0.02% NaN3 at pH 
9.6 (coating buffer). Fixed cells were 
stored in coating buffer at 4°C until use.
Immulon 1 plates (Dynatech Indus­
tries. McLean, VA) were used because 
of their low protein-binding character­
istics. After coating, the plates were 
treated with PBS containing 0.1% bo­
vine serum albumin, 0.05% Tween 20 
and 5% skimmed milk to remove back­
ground binding. Serum or GCF diluted 
in this buffer to a concentration within 
the range of the calibration graph was 
then added for 2 h at 37° C, and the 
plates were subsequently incubated with 
biotin-anti-human IgG (150 ng/ml), 
IgA (220 ng/ml) or IgM (170 ng/ml) 
(Sigma Chemical Co., Detroit, MI) and 
thereafter with 1 /tg/ml extravidin-per- 
oxidase (Sigma Chemical Co.).
The reaction was visualized using 
o-phenylenediamine substrate and 
stopped with 1 M H2S 04. The optical 
densities were read at 490 nm. The 
samples were assayed in triplicate, cor­
rection was made for non-specific bind­
ing and the results were read from a 
reference line derived from serial di­
lutions of a reference positive control 
serum. The results were expressed as 
ELISA units (10).
Adsorption studies
Sera were prediluted 1 / 200 in PBS and 
were added to an equal volume of bac­
terial suspension at an OD«oo related to 
the optimum coating concentration for 
that organism (for A. actinomycetemco- 
mitans the OD^o was 0.5 and for H. 
aphrophilus the O D ^  was 0.8). These 
were mixed at 3TC  for 6 h and then 
incubated at 4°C overnight. The sera 
were centrifuged and the supernatant 
collected for subsequent analysis.
Statistical analysis
The correlations between serum and 
GCF were assessed by Spearman rank- 
order correlation analysis. The com­
parisons between groups of sites were 
performed using Mann-Whitney tests 
for nonparametric data. Antibody titres 
were generally expressed as ELISA 
units per 30-s sample to eliminate inac­
curacies caused by calculations involv­
ing very low or high volumes of GCF 
beyond the limits that can be accurately 
recorded by the Periotron (17). In some 
cases, where direct comparisons be­
tween serum and GCF were made, anti­
body titres were expressed as ELISA 
units/ml.
Results
The Mann-Whitney tests relating the 
sites grouped on PD and GI with local 
IgG antibody levels to P. gingivalis and 
A. actinomvcetemcomitans are presented 
in Table 1. P. gingivalis IgG levels were 
found to be lower in the sites with PD 
greater than or equal to 4 mm as com­
pared with PD < 4 groups (P<0.01) and 
GI > 3 as compared with GI < 3 groups 
(P< 0.001). Further tests relating the 
sites grouped on PD and GI with IgG 
antibody to A. actinomvcetemcomitans 
(Table 1) or IgA antibodies to P. gingi­
valis gave no statistically significant dif­
ferences for these comparisons.
Table J. Comparisons between different degrees of PD and GI and IgG antibodies in GCF 
to P. gingivalis and A. actinomvcetemcomitans at these sites (Mann-Whitney test)
P. gingivalis IgG (EU /30 s) A. actinomvcetemcomitans IgG (EU /30 s)
n mean (SD) n mean (SD)
P D < 4 45 891 (2304) /><0.01 17 25 (46) NSPD 2t4 49 518 (1775) 32 21 (46)
G I< 3 61 1602 (2465) P < 0  001 36 21 (43) NSG I> 3 28 24 (67) 8 41 (64)
NS =  not significant. Comparisons for all sites were not performed due to the limited volume 
of GCF available in site samples. IgA response to P. gingivalis was also tested but gave no 
significant differences between clinical index groupings. EU =  ELISA units.
Humoral response in periodontitis 67
Table 2. Correlations between serum and mean G C F antibodies
n r
Mean (EU/m l) 
Serum GCF R1 P
P. gingivalis IgG 16 0.82 2987 512 66.7% <0.001
P. gingivalis IgA 13 0.22 265 157 6.8% NS
A. actinomvcetemcomitans IgG 10 0.98 2738 121 96.3% <0.001
NS = not significant. Correlations of P. gingivalis IgM and A. actinomvcetemcomitans IgM 
and IgA were not performed due to the limited volume of gingival crevicular fluid available 
in site samples. EU =  ELISA units.
Table 2 shows the correlations be­
tween serum and mean GCF levels for 
IgG and IgA against P. gingivalis and 
IgG directed against A. actinomvcetem- 
' comitans. Both P. gingivalis and A. acti- 
nomycetemcomitans IgG serum and 
| GCF levels correlated well (/?2 = 66.7% 
and 96.3% respectively; P<  0.001). Re­
analysis of the data categorized on clin- 
: ical indices revealed slightly higher R2 
| values for the sites with more disease 
| (i.e. GI = 3 and PD > 4 mm) but did not 
[ show a significant trend. Due to the 
\ restrictions imposed by the limited 
\ sample volume (mean =  0.31 pi) ob- 
I tained using the standardized 30-s GCF 
! sampling technique, insufficient sample 
[ was available to compare via ELISA,
; specific GCF IgM with IgA and IgG. 
j  Previous work within our laboratory 
' has indicated that levels o f total and 
j specific IgM in GCF were much lower 
than both IgA and IgG.
The correlations between serum IgG, 
IgA and IgM levels to P. gingivalis were 
examined. The 3 serum immunoglo­
bulin class responses to P. gingivalis cor­
related well. Similar correlations for A. 
actinomvcetemcomitans and H. aphro­
philus did not occur within the main 
antibody classes, although correlations 
between H. aphrophilus and A. actino- 
pivctemcomitans IgG and IgM were 
highly significant (F<0.001), which in­
dicates that these species may share 
cross-reacting antigens. Adsorption 
studies were carried out in which the 20 
patients’ sera were adsorbed with either 
A. actinomycetemcomitans or H. aphro­
philus. The adsorbed sera were then as­
sessed for specific antibody to A. acti­
nomycetemcomitans. A. actinomycete­
mcomitans adsorption resulted in a 
mean reduction in anti-/L actinomycet­
emcomitans IgG of 68% (SD =  21%), 
, and a similar reduction of 63% (SD =
| 22%) was achieved following adsorption 
with H. aphrophilus. These results give 
additional evidence for cross-reactivity 
between antibodies to these 2 bacterial 
species in chronic periodontitis patients.
Discussion
Specific IgG levels against P. gingivalis 
were found to be significantly lower in 
more severe chronic periodontitis sites 
as defined by PD and GI. However, no 
significant differences in IgA levels were 
found between chronic periodontitis 
sites of varying disease levels (Table 1). 
Baranowska et al. (1) found no differ­
ence between levels of specific IgG to P. 
gingivalis in healthy and diseased sites 
within the same individual. However, 
fixed volume samples of 0.5 pi were 
taken. This means that strips from sites 
that did not yield 0.5 p\ were discarded 
and that samples were taken over vari­
able time periods, resulting in variable 
rates of serum contamination (3). Since 
healthy sites tend to yield lower volumes 
than diseased sites, this method treats 
healthy and diseased sites in different 
ways. Therefore, these results are not 
strictly comparable with the present 
study. An earlier study by Schenck (20) 
showed an inverse relationship between 
the number of deep pockets (>  4 mm) 
and serum antibody level to P. gingi­
valis lipopolysaccharide in chronic 
periodontitis patients. Mouton et al. 
(19) demonstrated a dichotomy in 
serological responses to P. gingivalis 
among chronic periodontitis patients, 
with one subgroup exhibiting high 
serum antibody levels and another 
having levels similar to those of 
healthy individuals. The patients with 
high serum antibody levels appeared 
to respond better to therapy, as evi­
denced by reduction in the number of 
deep pockets within one month post- 
treatment. Their findings are consist­
ent with the data reported here than 
lower P. gingivalis IgG titres are found 
in more severely affected sites.
A fairly strong correlation between 
IgG, but not IgA, to P. gingivalis in serum 
and GCF was found in this study (Table 
2), and similar results have been reported 
previously (1). However, other studies 
have reported lower mean GCF than
serum IgG levels to P. gingivalis (5) as 
well as lower total IgG in GCF than in 
serum (13). In addition, Lamster et al. 
(16) reported a significant correlation be­
tween total IgG in GCF and specific 
serum antibody to Bacteroides intermed- 
ius but not P. gingivalis. They conclude 
that the development of a serum im­
munoglobulin response to suspected 
periodontopathogens is consistent with 
a protective host response. A corollary 
of this view is that a local deficiency of 
IgG to P. gingivalis may lead to local dis­
ease progression. Alternatively, Kilian 
(15) has demonstrated that P. gingivalis 
can degrade human IgG and IgA. sug­
gesting that low GCF levels of IgG may 
be caused by degradation by P. gingivalis. 
or that locally available antibodies are 
adsorbed by the greater mass of subgin­
gival plaque present.
Levels of serum and GCF IgG against 
A. actinomycetemcomitans were found to 
be highly correlated in this study. In con­
trast to the results presented on P. gingi­
valis IgG, there were no differences in 
GCF IgG levels to A. actinomycetemco­
mitans in chronic periodontitis sites of 
varying disease levels (Table 1). Gunsol- 
ley et al. (12) found that serum antibody 
levels to A. actinomycetemcomitans and 
P. gingivalis are inversely related to the 
degree of periodontal destruction in 
young adults with juvenile periodontitis 
or generalized severe periodontitis and 
concluded that this is consistent with a 
hypothesis that failure to mount a sub­
stantial antibody response to these or­
ganisms leads to more widespread peri­
odontal destruction. The present study 
of adult periodontitis patients would 
support this view at both local and sys­
temic levels, but only for P. gingivalis.
Genco et al. (9) showed that ad­
sorption of serum from localized juvenile 
periodontitis patients with A. actinom­
ycetemcomitans and H. aphrophilus re­
sulted in the elimination of most of the 
reactivity to the homologous strain but 
not to the heterologous strain. In the 
present study, most of the reactivity to A. 
actinomycetemcomitans could be re­
moved by adsorption with both organ­
isms, suggesting that there is cross-reac­
tion between antibodies to these 2 spe­
cies. Similarly, strong correlations were 
found between serum IgG and IgM 
levels to these 2 organisms. The indi­
cations are that antibodies detected to A. 
actinomycetemcomitans in adult perio­
dontitis patients could be confounded 
with cross-reacting antibodies directed 
against H. aphrophilus. which is, with
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other haemophili, commonly isolated 
from dental plaque (14).
Ebersole et al. (6) demonstrated in pa­
tients with various types of periodontal
■ disease that the same organism to which 
jthe individual exhibited elevated serum 
,antibody was detected in 55% of disease- 
i active sites but only 18% of disease-inac-
■ tive sites. However, in a study of patients 
with early-onset periodontitis, Williams 
jet al. (25) found that many patients had 
, serum antibodies to organisms not found 
fin the pocket flora and that some organ­
isms that made up a large proportion of 
I the pocket flora did not seem to provoke 
a corresponding antibody response. 
.These authors suggested that sequential
■ infection occurs in these forms of perio­
dontitis, leading to induction of protec­
tive immunity against reinfection by the 
same organism.
| In conclusion, there appears to be gen­
eral agreement that antibody levels to P. 
gingivalis are elevated in periodontitis 
patients as compared with healthy indi­
viduals, but there are also indications, 
supported by the present study, that 
lower antibody levels may be present in 
the more affected sites within the perio­
dontitis group. In addition, this study 
failed to demonstrate any significant dif­
ferences between GCF IgG levels against 
A. actinomvcetemcomitans between sites 
with different PD and GI. Care must be 
taken, however, in interpreting these re­
sults, as although these patients ex­
hibited sites with pocketing and gingi- 
.vitis (Table 1), they were maintenance 
| regimen patients who have received ex­
tensive periodontal treatment. Thus, al­
though they may not be strictly compar­
able with nion-treated adult periodontitis 
patients, this study addresses the cross- 
sectional comparison of healthy and dis­
eased sites and the correlation between 
local and systemic antibody titres. 
Further work is required to elucidate the 
inverse relationship between the clinical 
indices and GCF and serum IgG anti­
body to P. gingivalis found in the perio­
dontitis patients of the present study.
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ELISA was used to determine both the avidity and titre o f IgG. IgA and IgM 
antibodies to the gram-negative anaerobe. Porphyromonas gingivaiis, in twenty 
periodontitis patients enrolled in a longitudinal study of attachment loss and 
eleven non-periodontitis affected subjects. The avidity and titre of IgG anti­
bodies to Actinobacillus Actinomycetemcomitans were also examined. A cross- 
sectional analysis of the longitudinal patients at baseline and non-perio- 
dontally affected controls confirmed earlier findings that IgG and IgA antibody 
titres to P. gingivalis were higher in periodontitis patients than in individuals who 
were not periodontally affected. In this cross-sectional analysis. IgG antibody 
avidities to P. gingivalis were not found to be significantly higher in periodontitis 
than in control subjects (p =*0.065). However, indications of the potential prog­
nostic value of antibody avidity was demonstrated by the higher IgM avidities 
to P. gingivalis in patients who did not experience attachment loss during the 
three-month monitoring period than in those who did (p =  0.0005).
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Previous studies have reported antibodies directed 
against putative periodontopathogens, e.g. Porphy­
romonas gingivalis and Actinobacillus actinomycet- 
emcomitans, in the sera of patients with periodontal 
disease and also in healthy subjects (1,2). Contro­
versy surrounds the exact relationship between 
antibody titres to these organisms and disease pro­
gression. For example, Gunsolley et al. (3) found 
that the level of serum antibody to these two organ­
isms in periodontitis subjects was inversely related 
to disease level. Ebersole et al. (4, 5), in contrast, 
reported a positive correlation between serum IgG 
to .4. actinomycetemcomitans and the severity of 
the disease.
These studies have tended to examine titres of 
antibodies and there has been little work on anti­
body avidity in relation to periodontal disease. 
Avidity is a measure of the net binding strength
Abbreviations: Ig -  Immunoglobulin; ELISA -  Enzyme linked 
immunosorbent assay; EDTA -  ethylene diamine tetracetic add: 
PBS -  phosphate buttered saline: BSA -  bovine serum albumin: 
ssdna -  single strand DNA.
between antibodies and antigens. Bacteria nor­
mally have numerous antigens on their surface and 
each of these may have several epitopes capable of 
provoking an antibody response. The antibodies 
produced in response to each epitope will be of 
differing affinities. The innate intrinsic strength of 
the interaction between a single epitope on the 
antigen and an antigen-binding site on the anti­
body is defined as the affinity of that interaction. 
The avidity of serum antibodies to microorganisms 
involves many antigenic and epitopic interactions. 
Therefore, avidity in this context is an overall 
measure of the mean affinity or overall stability of 
potentially extensive interactions.
Lopatin et al. (6) showed that the avidity of IgG- 
class antibodies to P. gingivalis was significantly 
increased in periodontitis patients compared with 
healthy controls. No such elevation was detected in 
IgM-class antibodies. The authors suggested that 
since human antibodies to P. gingivalis appeared 
to be of generally low avidity, compared with those 
in rabbits immunized with this organism, the pres­
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ence of low avidity antibodies may contribute to 
the pathology associated with periodontal disease.
Chen et al. (7) demonstrated that IgG avidities 
to P. gingivalis were lower in rapidly progressive 
periodontitis (RPP) patients than in control sub­
jects. However, after treatment the avidities in­
creased significantly to levels higher than in con­
trols. They concluded that many RPP padents do 
not produce protecrive levels of biologically func­
tional anubody as a result o f natural infecuon. 
but treatment may induce the production of such 
antibodies.
This study examined the relationship between 
antibody avidity and periodontal status. Titres and 
avidity of three immunoglobulin classes (IgG, IgM 
and IgA) against P. gingivalis and of IgG to A. 
actinomycetemcomitans were assayed in a cross- 
sectional comparison of adult periodontitis pa­
tients on maintenance and healthy controls. The 
association of avidity with probing attachment loss 
in the course of a three month duration longitudi- 
| nal study and the relationship between avidities 
| and titres of antibodies to P. gingivalis and A. acti- 
: nomycetemcomitans was also examined.
I
t Material and methods
, B acteria
P. gingivalis NCTC 11834 was grown under anaer­
obic conditions (85% N ;, 10% H:, 5% CO-J and A. 
actinomycetemcomitans in CO: at 37°C on Colum­
bia blood agar. P. gingivalis was harvested after 5 
days and A. actinomycetemcomitans after 24 h into 
phosphate-buffered saline, 1 mM Na: EDTA, pH 
7.4 (PBSE), washed by centrifugation, and fixed 
for I h in 10% formal saline. The cells were than 
washed twice in PBSE and once in 0 .1 M Na car­
bonate-bicarbonate buffer containing 0.02% NaN3 
at pH 9.6 (coating buffer). Fixed cells were stored 
in coating buffer at 4°C until use.
Subjects
Serum was collected from a total of 31 subjects. 
These included 20 adult periodontitis patients (age 
range: 28-68 years; 11 men, 9 women) and 11 
periodontally healthy individuals (age range: 22-35 
years; 6 men, 5 women).
The 20 periodontitis patients of the present study 
participated in a 3-month duration longitudinal 
study of periodontal disease activity which actually 
followed 38 patients in total who had been diag­
nosed in the past as suffering from advanced peri- 
[odontal disease (at least one site demonstrating 
probing depth > 6  mm in at least four sextants). 
These patients had received a full course of peri­
odontal treatment in the Glasgow Dental Hospital.
were on maintenance for at least I year and demon­
strated pocketing of greater or equal to 4 mm in 
at least four non-adjacent sites, as assessed during 
conventional periodontal charting using the PC 12 
periodontal probe with a tip diameter of 0.4 nun 
(Prisme. U.K.). In addition, these patients had not 
received any antibiotics for 3 months prior to the 
initiation of this study. All non-adjacent sites, dem­
onstrating probing depth above or equal to 4 mm. 
were monitored in these 38 patients over a 3-month 
period. A minimum of 6 and a maximum of 15 
non-adjacent sites were thus followed per subject, 
and a full clinical data set including duplicate 
attachment level measurements and gingival crevic- 
uiar fluid samples was taken. In addition, serum 
samples were taken at the baseline and three month 
appointments. Attachment level change was deter­
mined using a custom-made soft acrylic stent, 
the Florida probe stent handpiece (Florida Probe 
Corporation. Florida, USA) (8), and the tolerance 
method (9). The full clinical data set of the 38 
patients and the analysis of gingival crevicular fluid 
will be presented elsewhere.
Fourteen of these 38 periodontitis patients, who 
constituted the attachment loss group (AL) of sub­
jects in the present study, demonstrated significant 
attachment loss in at least one site during the 3- 
month observation period.
A subgroup of the remaining 24 periodontitis 
patients, who did not demonstrate significant 
attachment loss at the studied sites, was made by 
retrospective examination of previous periodontal 
pocket chartings. This subgroup of 6 ‘stable’ sub­
jects was selected to form the non-attachment loss 
group (NAL) in the present investigation. These 6 
patients did not demonstrate attachment loss 
greater or equal to 2 mm at any site, as assessed 
by manual periodontal probing using the PC 12 
periodontal probe (Prisma, U.K.) over the whole 
period of their periodontal maintenance (a mini­
mum of I year) during the normal recall system of 
the Periodontal Department of the Glasgow Den­
tal Hospital. In contrast, the remaining 18 subjects 
had demonstrated progressive attachment loss of 
greater than 2 mm according to conventional peri­
odontal pocket chartings in at least one site within 
the last year of periodontal maintenance. These 18 
patients were therefore not considered ‘stable’ and 
were excluded from the NAL group in the present 
immunological study on relative antibody avidity.
The periodontally healthy individuals did not 
demonstrate significant gingival inflammation or 
attachment loss at any site. In addition, pocketing 
was below 3 mm at all sites. A serum sample was 
obtained from each healthy control subject at one 
time-point in a cross-sectional manner. When 
cross-sectional comparisons involving the 20 perio­
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dontitis subjects were made, data from baseline 
sera (0 months) were used.
ELISA
Specific antibody titres were measured by ELISA 
based on the method of Ebersole et al. (10), using 
formalinized whole cells at an absorbance which 
had previously been determined as optimum to 
coat microtitre plates. Immulon -I plates (Dvna- 
tech) were employed because of their low protein- 
binding characteristics. After coating, the plates 
were treated with PBS containing 0.1% bovine 
serum albumin (BSA), 0.05% Tween 20 and 5% 
skimmed milk to reduce non-specific antibody 
binding to the plates. Serum serially diluted in 
this buffer was then added and the plates were 
subsequendy incubated with biotin-conjugated 
anti-human IgG, IgA or IgM (Sigma) and there­
after with ExtrAvidin-perioxidase (Sigma). Reac­
tion was visualized using o-phenylenediamine dihy­
drochloride substrate and stopped with 1 M H;S 0 4. 
Samples were assayed in duplicate and results were 
calculated using a regression line and derived equa­
tion from serial dilutions of a reference serum. 
Results were expressed as ELISA units (EU) (11).
Dissociation assay
The dissociation assay to determine antibody avid­
ity was performed as follows: after incubation with 
serum as described above, the wells were treated
with increasing concentrations of ammonium thio- 
cyanate (0.2-8.0 M). The concentration of thio- 
cyanate required to dissociate 50% of bound anti­
body was determined by linear regression analysis. 
This was termed the ID;o and provides a measure 
of relative avidity as previously reported (12. 13).
S ta tistica l an a ly sis
Two-sample t-tests were used to determine differ­
ences in avidity between different clinical groups. 
Mann-Whitney tests were used in group compari­
sons of the non-normally distributed antibody tit­
res. Student’s paired t-tests were used to assess 
whether differences were significant between base­
line and recall appointments and to compare rela­
tive avidities of antibodies to P. gingivalis and A. 
actinomycetemcomitans in various sera.
Results
The periodontally healthy (n = ll)  and mainten­
ance periodontitis groups (n =  20) were compared 
in terms of titre and avidity of IgG, IgM and IgA 
class antibodies to P. gingivalis. The periodontitis 
group was also sub-divided into a sub-group of 14 
patients who experienced attachment loss in at 
least one site during the 3-month monitoring 
period (AL) and another sub-group of 6 patients 
who exhibited no attachment loss (NAL). Table 1 
shows the median titres and mean avidities of the 
three classes of antibodies in controls and perio­
Tabie I. Titres and avidities of antibodies to P. gingivalis in control subjects and total periodontitis patients and periodontitis 
patients grouped according to attachment loss and no attachment loss___________________________________ _____________
Controls
( n - l l ) Periodontitis patients
Total(n = 20) Attachment loss (n= 14) No attachment loss (n = 6)
Median titre Mean Median titre Mean Median titre Mean Median titre Mean
(EU) avidity (M) (EU) avidity (M) (EU) avidity (M) (EU) avidity (M)
IgG 320 1.21 2390 1.74 2390 1.66 2149 1.93
(107-884)1 (0.85-1.70) (1017-5595)' (1.12-2.14) (841-4806) (1.21-2.04) (1017-7835) (0.95-3.34)
IgM 537 0.81 206 0.78 280 0.70* 153 0.97-*
(188-2170) (0.69-0.94) (105-603) (0.64-0.93) (105-761) (0.60-0.84) (72-722) (0.86-1.07)
IgA 28 1.35 586 1.66 631 1.66 268 1.66
(19-60)* (0.60-1.74) (151-1478)* (1.34-1.99) (44-2261) (1.16-2.01) (187-14154) (1.37-2.04)
‘•*J Significant differences between compared groups are shown by paired symbols (p<0.0l). Interquartile ranges (Qt-Q3) given in 
parentheses.
Table 2. Titres and avidities of antibodies to P. gingivalis for all periodontitis subjects I n = 20) at baseline and after three months
Median titre IEU) Mean avidity (M)
______ Baseline 3 months Mean difference Interquartile range Baseline 3 months Mean difference Interquartile range
IgG 2390 1824 -  566 -  603/-1400 1.74 2.02 ^0.28 -0 .16 /-0 .73
IgM 206 150 -56  - 1 15/-328 0.78 0.70 -0.08 -0 .29/-0 .11
IgA 386 410  -1 7 6 _________ -194 /-441  1.66 1.49 -0.17 -0.51/ -0.32
No significant differences were detected between baseline and  3 m onths for ail com parisons: S tu d en t's  paired t-test.
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dontitis patients" at baseline. Comparisons between 
patients and controls for titre and avidity to P. 
gingivalis in all three immunoglobulin classes were 
made and significant differences (p<0.0l) were 
only noted between IgG median titres and IgA 
median titres (Mann-Whitney or two-sample t- 
test). The comparison between periodontitis pa­
tients at baseline grouped in terms of attachment 
loss and lack of attachment loss after three months 
is also shown in this table. A significant difference 
was noted between the mean avidity of IgM anti­
bodies between subjects with attachment loss and 
those without attachment loss (p< 0.001).
Table 2 shows the changes in antibody titre and 
avidity to P. gingivalis between baseline and three 
months for ail periodontitis subjects but indicates 
no significant differences. Interestingly, sub-group­
ing the periodontitis patients into AL and NAL 
gave divergent results for IgG avidity to P..gingi­
valis, in that over the 3-month period, the AL 
group had avidities which tended to increase 
whereas the NAL avidities tended to decrease 
(Table 3). Similarly, although also not statistically 
significant, IgM and IgA avidities tended to de­
crease more in NAL than in AL patients.
Healthy control and periodontitis groups at 
baseline were compared for differences in IgG titre 
and avidity to the two organisms {P. gingivalis and 
A. actinomycetemcomitans) and the results are 
shown in Table 4. These show that avidities to 
I P. gingivalis were significantly higher than to A.
: actinomycetemcomitans in both groups but only in 
the periodontitis group was this difference signifi­
cant.
Table 5 presents the correlations between titre 
and avidity. These correlations (titre to avidity) are 
shown for IgG, IgM and IgA specific for P. gingi-
Table 3. Longitudinal changes in avidities of IgG antibodies to 
P. gingivalis for AL and NAL periodontitis subjects________






IgG AL -*-0.46 0.14
(n *  14) (—0.13/ t - 1.12)
NAL -0.10 0.74
(n*6) ( -0 .4 7 / ^-0.42)
IgM AL -0 .0 1 0.30
(n= 14) (—0.14/ —0.11)
NAL
fio1 0.22
(n = 6) (-0 .6 0 / -0.09)
TeA AL -0.07 0.71
(n=l4) (-0 .54 /^0 .35)
NAL -0.15 0.74
(n = 6) (_0.74/ -0.61)
In terquartile  ranges i Q . - Q j  given in parentheses. 
AL: A ttachm ent loss periodontitis group.
N A L: N on-a ttachm en t loss periodontitis group.
valis and IgG specific for A. actinomycetemcomit­
ans. The subject groups for which these are shown 
are: all subjects (n =  3l); control subjects (n = ll);  
all periodontitis subjects (n = 20); attachment loss 
periodontitis subjects (AL) (n=l4); and non­
attachment loss periodontitis subjects (NAL) (n =  
6). Baseline data were used for the periodontitis 
patients. The results of the correlation analyses are 
shown as R2 (%) and p-value. The data presented 
in Table 5 show that there was a significant corre­
lation between titre and avidity of IgG against P. 
gingivalis for NAL patients and between titre and 
avidity of IgM against P. gingivalis for AL patients.
Discussion
The relationship between antibody titres to various 
suspected periodontopathogens and periodontal 
status has been extensively investigated although 
many of the findings have been contradictory and 
this remains a highly controversial field. Eberso­
le & Holt (5) have dealt with the application of 
antibody titres to diagnostics in great detail. How­
ever, Wilton et aL (2), in their review, stated that 
the data currently available does not allow these 
responses to be diagnostic. Generally, reports in 
this field are agreed that an elevation in the hu­
moral immune response to certain plaque-associ­
ated microorganisms is detected in the presence of 
and/or increasing extent of periodontitis (14, 15). 
However, a few studies have suggested the opposite 
tendency (16, 17).
Antibody avidity, that is the measure of the net 
binding strength of antibody to antigen, has been 
extensively studied in a number of fields, both in 
relation to antibody titre and in isolation, in terms 
of disease susceptibility and progression. For ex­
ample, Morikawa et al. (18) found that the titre of 
IgA to soybean antigen in the breast milk of Indian 
mothers was significantly higher than in Japanese 
mothers, although the avidity was significantly 
lower. Udhayakumar et al. (19) have shown that 
monoclonal antibodies of higher avidity have much 
greater effectiveness in activating B-cells and pre­
sumably enhancing an immune response. Interest­
ingly, Charoenvit et al. (20) found that a mono­
clonal antibody to Plasmodium yoelii, a malarial 
parasite, has lower avidity for the antigen than 
vaccine-induced polyclonal antibodies in mice. Doi 
et al. (21) suggested that low avidity may be a 
pathogenic characteristic of IgG circulating im­
mune complexes in membraneous nephropathy. 
Significantly, Jovnson et al. (22) found that tox­
oplasmosis patients with acute infection had low 
avidity IgG whereas those with chronic infection 
had high avidity. This may have application in 
investigations of the phasic destructive episodes of
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Table 4. Titres and avidities of IgG antibodies to P. gingivalis and A. actinomycetemcomitans (A.a.) tor control and periodontitis 
subjects at baseline___________________________________________________________________________________________
Control (n» 11) Periodontitis (n =* 20)
P. gingivalis Aa R gingivalis Aa
IgG 320 173 2390 1189
Median titre (107-884) (141-214) (1017-5595) (109-12239)
IgG 1.21 0.93 1.74- 0.83*
Mean avidity (0.85-1.70) (0.73-1.03) (1.12-2.14) (0.50-0.94)
* Significant difference: p<0.0L for comparison (Student's paired c-testl.
Interquartile ranges (Qi-Qj) given in parentheses.
Table 5. Correlations between titres and avidities. R: (%) and associated p-vaiues are given for all immunoglobulin classes for P.
gingivalis and IgG antibodies for A. actinomycetemcomitans M.o.) in each subject group
P. gingivalis A.a.
IgG IgM IgA IgG
All subjects n —31 42.0%. 10.2%. 7.5%. 24.3%.
<0.001* 0.079 0.257 0.009*
Control subjects n=  11 24.3%, 16.5%. 0.1%, — 1.2%.t 0.123 0.215 0.939 0.762
All periodontitis subjects n *  20 39.2%. 12.2%. 1.4%. 32.2%.
0.003* 0.131 0.689 0.018*
AL n -  14 13.7%. 54.9%, 14.1%. 90.1%.
0.193 0.002* 0.234 <0.001*
NAL n = 6 69.3%, 12.6%, 18.2%, 0.3%,
0.04* 0.491 0.474 0.932
Results given as R* (%), p-value. * denotes significant conelauons (significance level of p<0.05). 
AL at Attachment loss periodontitis group.
NAL =■ Non-attachment loss periodondtis group.
chronic periodontitis, with the possibility that 
acute exacerbations and quiescent periods could 
be differentiated. The secondary immune response 
classically generates antibodies of higher avidity. 
Francus et aL (23) have demonstrated that a poss­
ible mechanism may be carrier primed T-cells 
which selectively activate virgin B-cells, which are 
then committed to the production of high avidity 
antibodies. A study with particular relevance to 
the present report is that of Panoskaltsis and Sin­
clair (24) who showed that autoimmune mice have 
lower avidity anti-ssDNA (single-strand DNA) 
IgM antibodies than non-autoimmune mice.
There have, however, been very few reports deal­
ing with antibody avidity in relation to periodontal 
disease. Ebersole et a l (25) studied the increase in 
avidity in the non-human primate, Macaca fascicu- 
laris, following immunization with tetanus toxoid, 
which they used as a prototype bacterial exotoxin. 
They found that IgG avidity increased from 0.9 M 
to 1.72 M following primary immunization and 
2.56 M after secondary immunization. Lopatin et 
al. (6) demonstrated that avidity of antibody rose 
to a similarly high level in rabbits post-immuniz­
ation with P. gingivalis. but that human antibodies 
to this organism appear to be of generally low 
avidity. This latter finding was confirmed by the
present study. The present report also confirms the 
finding of Lopatin et a l , and others (26, 27, 28), 
that IgG serum antibody titres to P. gingivalis are 
significantly higher in periodontitis patients on 
maintenance than in controls (p< 0 .0 1) (Table I). 
Additionally we show that this is also the case for 
IgA antibodies, but not IgM. However, we were 
not able to demonstrate a statistically significant 
difference in antibody avidity for any immunoglob­
ulin class in the above subject groups. The obser­
vation that IgM avidity to P. gingivalis is higher in 
NAL than in AL patients is difficult to explain, 
although perhaps the metabolic block referred to 
by Panoskaltsis and Sinclair (24) preventing IgM- 
IgG switching and leading to increased IgM avidity 
is operating here. Nevertheless, the finding may 
have prognostic significance if confirmed by 
further studies.
Chen et al. (7) concluded that after periodontal 
treatment of rapidly progressive periodontitis pa­
tients, their IgG antibody avidity increased. The 
data from the present study presented in Table 5 
may reflect the treatment effect reported by these 
authors. In this case the treatment effect would 
generate a strong and statistically significant posi­
tive correlation between titres and avidities of anti­
bodies to P. gingivalis in NAL patients as seen in
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Table 5. This would result from increased avidities 
and decreased titres stimulated by treatment, or in 
other words, a shift to more biologically effective 
antibodies. This patient sub-group may in fact cor­
respond to the “seropositive” subgroup of Chen et 
al.’s study. However, the present study dealt with 
adult periodontitis patients in maintenance phase 
and Chen et al. examined rapidly progressive perio­
dontitis pauencs prior to, and after initial treat­
ment, therefore the two studies are not strictly 
comparable.
Another recent study o f titre and avidity of IgG 
antibodies to P. gingivalis in rapidly progressive 
periodontitis (RPP) by Whitney et al. (29) also 
shows lower avidities in RPP patients than in con­
trols. This contrasts with our study of adult perio­
dontitis patients which demonstrated a trend 
towards higher IgG avidities in patients than in 
healthy controls (p =  0.065). Moreover, if seroposi­
tive healthy control subjects are excluded using the 
criterion of Chen et al. (7), i.e. titre > 2 x median 
control titre, then this yields a significant difference 
between seronegative control subjects and adult 
periodontitis patients (p=0.02). These differences 
between the periodontitis patient groups may re­
flect a differing immunological susceptibility.
The longitudinal aspect of the study failed to 
show any significant changes in titre or avidity 
of antibodies to P. gingivalis during the 3-month 
monitoring period (Table 3). Although not statisti- 
! caily significant, the increase in avidity of 0.46 M 
I in AL patients compared with a decrease of 0.10 
M for NAL patients (p =  0.14) may suggest long­
term changes in antibody avidity which should be 
examined further by longitudinal studies.
The comparison of the responses to P. gingivalis 
and A. actinomycetemcomitans is interesting in that 
the avidity of IgG antibodies to the latter was 
found to be significantly lower than to the former 
' (Table 4). However, only the periodontitis group 
were seen to have a significant divergence in re­
sponse (i.e. equivalent to 6-7 times the binding 
strength) (Table 4). The relevance of this is unclear 
but there is a suggestion that not only do IgG 
avidities to P. gingivalis tend to be higher in perio­
dontitis, but IgG avidities to A. actinomycetemcom­
itans tend to be lower than normal as shown in 
Table 4. This may indicate the differing relevance 
of these two organisms in adult periodontitis.
A very recent study by Sjostrom et al. (30) 
showed that IgG antibodies in low-titre sera from 
control subjects were significantly more etfective 
in opsonizing A. actinomycetemcomitans than IgG 
antibodies in low-titre sera from RPP patients. The 
finding of the present study that avidities of IgG 
antibodies to A. actinomycetemcomitans tend to be 
lower in adult periodontitis patients than in healthy
control subjects, although this failed to reach stat­
istical significance, may indicate a failure of bio­
logical function of antibody directed against A. 
actinomycetemcomitans in these patients also.
Unlike Lopatin et al. (6) we have found a signifi­
cant correlation between titre and avidity of the 
IgG response to both organisms studied. In ad­
dition. our data show that there are differences 
between patients groups in relation to these corre­
lations. The data presented in Table 5 suggest that 
switching to higher avidity IgG antibodies may 
be occurring in those patients who tend not to 
experience further attachment loss, but not in those 
who do. This indicates the potential prognostic 
value of antibody avidity in determining patients 
susceptibility to further attachment loss.
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Introduction
During the initiation of inflammation, vascular en­
dothelium is activated by a vanetv of molecules 
which increase the permeability of vessels and regu­
late the passage of leukocytes from the blood­
stream into the inflamed tissues. Of the molecules 
capable of acting on the endothelial ceils, interleu- 
kin-1 (IL-I). an inflammatory cytokine, has been 
detected in inflamed gingiva (1). IL-i upregulates 
expression of endotheiial leucocyte adhesion mol­
ecules-1 (ELAM-1) and intercellular adhesion mol­
ecule-1 (1CAM-1). which are ligands for adhesion 
molecules on leukocytes untegnnsi. and thus influ­
ence gingival leukocyte infiltration.
x2-macrogiobuiin (x2-M) and a I -antitrypsin 
(xl-AT) together comprise 90% of the serum pro- 
tease inhibitors (2) and have been identified in 
gingival crevicular fluid (GCF) from diseased sites 
at about 75% of their serum leveis (31. Transferrin 
(TF) is a serum-denved iron-binding giycorprotem 
(4) which in GCF might function as an antibac­
terial agent by producing an iron-limiting environ­
ment (5). TF has been reported in GCF at leveis 
similar to those of x2-M and al-AT (3). Recent 
evidence suggests that, in addition to their classical 
roles, these proteins can modulate the immune re­
sponses via several pathways: x2-M binds import­
ant effector molecules such as cytokines and cell 
receptors which inhibit immunological reactions 
(6): xl-AT has been implicated in the inhibition oi 
lymphocyte responses, complement activation and 
neutrophil migration (7): and TF is involved in 7-
cell transformation and macrophage activation (8).
The dynamics of these acute-phase proteins, and 
the cytokine IL-1 in GCF. were compared with 
leukocyte infiltration and expression of the endo­
theiial ceil adhesion molecules ICAM-1 and 
ELAM-1, during 21-day experimental gingivitis 
episode (9).
Material and Methods
Tweive healthy students stopped tootnbrushing for 
21 d. At baseiine (d 0). and after 4. 7. 11. 14. 17 
and 21 d of undisturbed plaque accumulation and 
following the reinstirution of oral hygiene pro­
cedures (d 28 and 35). clinical changes were re­
corded using a Plaque Index (10) and a modified 
Gingival Index (II). and GCF was sampled using 
Whatman grade-4 paper strips (2x13 mmi (12) for 
30 seconds. Quantification of GCF voiume was 
penormea using the Penotron 6000 (Harcoi. The 
stnps were eiuted into 1 mi of phosphate-buffered 
saline and 200 ix\ aiiquots were analyzed for the 
z2-M. xl-AT and TF. For the IL-1 bioassav. GCF 
was eluted from the paper stnps by incubation for 
30 minutes at 4'-C in 150 /xi of RPMI 1640 medium 
with supplements. Indirect competitive immunoas­
says were developed for the quantification of x2- 
M and TF. xl-AT was assayed using a double- 
antibody sandwich assay. For each individual, a 
mean values was obtained for each sampling inci­
dence for x2-M. xl-AT and TF ieveis tin ng per 
30-s sampiei.
IL-i activity was determined by bioassav using
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the IL-i-sensitive cell iine DlO(N-i)M il3) except 
that cell proliferation was determined by a colorim­
etric method < I A). The potency of the stimulatory 
activity in the eiuate was determined from dose- 
response curves obtained with a recombinant hu­
man DNA-denved IL-1 beta irnlL-ltf) standard, 
using the computer program ALLFIT i 15). Gin­
gival biODsies ( 2 x 2  mmi were taken from the first 
moiar buccal gingiva on u 0. id and 21 and 
embedded in Tissue Tek, snap frozen in liquid ni­
trogen after which senai 3 urn thick sections were 
cut. Frozen sections were immunoperoxidase- 
stained using a panel of monocionai antibodies for 
Langerhans cells. T-heiper. T-suppressor. primed 
|T iCOdSRO). pan-T and B cells, monocyte:macro­
phages. neutrophils. HLA-DR. ICAM-l and 
.ELAM-1. Leukocytes in the sections were counted 
;at xdOO magnification in defined areas. Lang- 
,erhans cells and other infiltrating ceils withm the 
j epithelium were counted and the area of sectioned 
; oral epithelium (AOE) determined, using computer 
‘ assisted image analysis. Three adjacent areas 
| within each section were counted and the mean 
i number of positive cells per biopsy was calculated 
j and expressed as either cells per 0.1 mm: of connec­
tive  tissue or of AOE. HLA-DR. ICAM-l and 
j ELAM-i were scored using a grading system for 





Following withdrawal of oral hygiene procedures 
the piaaue index rose rapidly and was followed by 
the gingivai inflammatory index. GCF IL-l peaked 
within 7 d of the inflammatory episode tp < 0.05'). 
x2-M. xl-AT. TF and GCF voiume increases 
matched the gingivai inflammation index. x2-M 
leveis throughout the study were markedly higher 
than the leveis of xl-AT (p<0.05).
' The term suicular epitheiium (Sc) was used to 
include both the JE and oral sulcuiar epitheiium. 
Langerhans cell (LC) numbers increased from 
baseline and peaked at d U ip =  0.03: Mann-Whit­
neys HLA-DR staining increased from baseiine 
and peaked at d 7. after which the HLA-DR~ 
celluiar infiltrate started to fall, reaching baseiine 
levels by d 21. Pan-T cells and PMN aiso peaked 
at d in the SE. then reduced as inflammation 
progressed. Expression of vascuiar ICAM-l and 
EL.AM-l increased at or before d ". which co­
incided wuh the peak in IL-1 leveis and T-cell 
infiltration. ICAM-l expression in junctional epi­
thelial keratmocytes peaked at a 7 and exhibited a 
gradient effect in the density of ICAM-l from the 
! crevicuiar towards the basai region of the epithe­
lium.
Discussion
During the initiation of gingival inflammation 
many immune and inflammatory events take piace 
at ditferent time points. IL-i aDoears to peak at d 
7. as does uoregulation of ELAM-1. [CAM-1. 
HLA-DR and leukocyte infiltration. The changes 
in acute-phase proteins appear to follow cnanges 
in the inflammatory index and probabiv reflect 
the changes in vascular permeability. x2-M leveis 
throughout the study were markedly higher than 
the levels of xl-AT and may reflect the fact that 
x2-M can be locally produced by resident ceils or 
infiltrating macrophages (16).
Suicular neutrophil numbers decreased as gingi­
vitis progressed and only recovered to baseline 
leveis at d 21. suggesting PMN movement into the 
gingival crevice, presumably by cnemotaxis. The 
spatial and temporal changes in PMN numbers 
illustrate the difficulty in interpretation using 
sequential biopsies. The flux of ceils into the crev­
ice. or back into the connective tissue, or arriving 
from the blood vessels, cannot easily be determined 
without time-lapse video analysis. However, immu- 
nocytochemistrv and GCF ELISA techniques are 
valuable tools in the investigation of immune and 
inflammatory processes in expenmental gingivitis 
and may elucidate the role of specific ceils and 
solubie factors in the initiation and pathogenesis 
of penodontai disease.
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The ability of gingival crevicular 
fluid acute phase proteins to 
distinguish healthy, gingivitis and 
periodontitis sites
Adonogianaki E. Mooney J and Kinane DF: The ability o f gingival crevicular fluid 
acute phase proteins to distinguish healthy, gingivitis and periodontitis sites. J Clin 
Periodontol 1992: 19: 98-102.
Abstract. 3 acute phase proteins, from the local gingival inflammatory response, 
were examined for their ability to distinguish healthy, gingivitis and periodontitis 
sites. Indirect competitive immunoassays were developed for the quantification 
of a2-macroglobulin (a2-M) and transferrin (TF), and for a 1-antitrypsin (al- 
AT), a double antibody sandwich assay was produced. Healthy (25), gingivitis 
(31) and periodontitis (28) sites were sampled with filter paper strips (2x13 
mm) and the volume assessed with the Periotron 6000. The samples were eluted 
in phosphate-buffered saline and analyzed for a2-M. al-AT and TF. The results 
were expressed as absolute amounts per sample (ng/30 s) and on a concentration 
basis (ng/Jal of GCF). Higher GCF absolute amounts of a2-M. al-AT and TF 
were consistently obtained from diseased (gingivitis and periodontitis) sites than 
healthy sites (p< 0.005). Absolute amounts of GCF u2-M. al-AT and TF were 
increased in periodontitis sites over gingivitis sites, although these differences 
were not statistically significant (/?>0.1). When the results were expressed on a 
concentration basis. a2-M levels from diseased sites were significantly higher than 
healthy sites {/? < 0.01). In addition. GCF TF concentration was increased in 
periodontitis compared to healthy sites (/? = 0.03).
Host proteases released into the gingival 
crevice are considered potentially harm­
ful to the surrounding tissues (Wilton 
1986). These proteolytic enzymes are 
mainly of lysosomal origin and are de­
rived from phagocytic cells that migrate 
into the gingival crevice region during 
inflammation (Attstrom & Egelberg 
1970). The activity of these enzymes is 
modulated by specific inhibitors either 
locally produced or circulating in plas­
ma (Condacci et al. 1982, Condacci et 
al. 1988. Giannopoulou et al. 1990). a2- 
macroglobulin (a2-M) and a I-antitryp­
sin (al-AT) are the main serum protease 
inhibitors and they account for approxi­
mately 90% of its inhibitory capacity. 
Together they neutralise the majority of 
harmful proteases from each of the four 
catalytic classes (Ohlsson et al. 1973. 
Van Leuven 1982. Sandholm 1986). u2- 
M is a high molecular weight plasma 
protein (MWt: “20 kd) and its concen­
tration in plasma is approximately 2—i 
mg ml. a 1 -AT is of much lower molecu­
lar weight (MWt: 55 kd) but has a simi­
lar or higher plasma concentration to 
a2-M (Cimasoni 1983, Sandholm 1986). 
Both serum protease inhibitors have 
been identified in material from the gin­
gival crevice by Schenkein & Genco 
(1977) who reported gingival crevicular 
fluid (GCF) concentrations of a2- 
macroglobulin and a I-antitrypsin from 
diseased sites at about 70% of those 
found in serum. Condacci et al. (1982) 
and most recently Sengupta et al. (1988) 
reported decreasing absolute values of 
a2-M in GCF samples with the resol­
ution of inflammation. Skaleric et al. 
(1986) reported that the concentration 
of a2-M in GCF decreased with increas­
ing gingival inflammation and alveolar 
bone loss. The al-AT to transferrin (TF) 
ratio in GCF and blood samples has 
been compared and higher mean ratios 
were found in GCF. although these did 
not correlate with the severity of perio­
dontal disease <Asman et al. 19811.
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glycoprotein (MWt: 81 kd) whose main 
function in man is the transport of iron 
between sites of absorption, storage, 
utilisation and excretion (Aisen 1980). 
In GCF. it might function as an antibac­
terial agent by producing an iron limit­
ing environment (Curtis et al. 1989). TF 
has been reported in GCF at levels simi­
lar to those of a2-M and al-AT (Schen­
kein & Genco 1977). Other workers 
found that the dilution of TF in GCF 
is higher than that of al-AT (Asman et 
al. 1981). a2-M in GCF differs from TF 
and al-AT as it is considered to be both 
serum derived and locally produced by 
fibroblasts and macrophages (Condacci 
et al. 1988. Giannopoulou et al. 1990. 
White et al. 1980). TF and al-AT levels 
are predominantly serum derived and 
may be a more sensitive marker of vas­
cular leakage into the crevice. Much 
interest has focused upon the main func­
tions of these proteins i.e. protease inhi­
bition iu2-M. al-AT) and iron binding 
■TFi. Recent evidence however, sug­
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gests that these proteins are components 
of the acute phase of inflammation and 
modulate the immune responses via sev­
eral pathways. Apart from inhibiting 
proteolytic reactions. u2-M binds im­
portant effector molecules such as cyto­
kines. and cell receptors which inhibit 
immunological reactions (James 1980. 
James 1990). al-AT has been implicated 
in the inhibition of lymphocyte re­
sponses. complement activation and 
neutrophil migration (Breit & Penny- 
1980). TF is involved in T-cell trans­
formation and macrophage activation 
(Brock & Mainou-Fowler 1983. Hamil­
ton et al. 1984). Thus, detection of these 
acute phase proteins in GCF may be 
informative in determining host re­
sponses in periodontal disease. This 
study set out to determine suitable as­
says for the precise quantification of a2- 
M. al-AT and TF in GCF samples and 
to test their ability to differentiate be­
tween healthy, gingivitis and perio­
dontitis sites.
Material and Methods 
Clinical criteria
The Lobene gingival index (GI) (Lobe- 
ne et al. 1986) was used for the assess­
ment of gingival inflammation. Sites 
with gingival scoring of 0 or 1 and 
pocket depth (PD) not exceeding 2 mm 
were categorised as 'healthy'. GI be­
tween 2 and 4. and PD less than or 
equal to 3 mm were the criteria for the 
'gingivitis' sites, whereas sites with PD 
exceeding 3 mm were designated 'perio­
dontitis’ sites. The number of sites 
sampled for each protein is shown in 
the respective tables (Tables 1-3).
Gingival crevicular fluid sam pling and 
processing
Whatman grade 4 paper strips (2x13 
mm) were used for GCF collection 
(Griffiths et al. 1988). The individual 
crevicular site was gently air-dried and 
any supragingival plaque was removed. 
The area was carefully isolated to pre­
vent saliva contamination of the 
samples. The paper strip was inserted 
into the crevice until mild resistance was 
felt, and left for 30 s. Care was taken in 
order to avoid mechanical injury of the 
tissues. Strips contaminated by blood 
were discarded. After GCF collection, 
the paper strip was transferred to the 
cnairside-located Periotron 6000 (Harco 
Electronics. Winnipeg) for the quantifi­
cation of fluid voiume. The jaws of the
periotron were wiped with pure meth­
anol between sequential readings. The 
strips were then placed in individual 
sterile bijoux and stored at — 30 C until 
further processing. Subsequently, the 
strips were eluted into I ml of phosphate 
buffered saline containing 0.1" ■ bovine 
serum albumin and 0.05n'-> Tween 20. 
for 1 h at room temperature using a 
rotating mixer. The strips were then dis­
carded and the eluate aliquoted and 
stored at -7 0  C until used. 200 /<l ali­
quots were analyzed subsequently for 
the quantification of u2-M. al-AT or 
TF. Different GCF samples were used 
for each acute phase protein.
Calibration of the Periotron 6000
Prior to commencement of this study a 
calibration graph was constructed for 
the Periotron 6000 in order to transform 
the periotron digital readings for each 
paper strip into volumes and also to 
assess the accuracy of the instrument. 
ICnown volumes of serum dilution 1:1 in 
PBS were delivered to Whatman grade 4 
paper strips with a Hamilton microsy- 
ringe in volumes ranging from 0.2 to 1 
/d. in 0.2 /d increments. Each measure­
ment was performed 6 times and the 
mean value for each volume was used 
in a linear regression analysis from 
which the slope and intercept were used 
to determine the volumes of gingival 
crevicular fluid collected.
a2-M, a1-AT and TF quantification
All constituents were assayed by en­
zyme immunoassays. 2 types of assay 
were used.
(a) Indirect competitive immunoassay 
to quantify a2-M and TF. The method 
employed was a modification of the 
technique described previously by 
Altschuh & Van Regenmortel (l 982). 
Briefly, the antigen, human a2-M (Sig­
ma) or TF (Sigma), was coated onto 
a 96-well polystyrene microtitre plate 
(Immulon I, Dynatech laboratories. 
Virginia). The experimental samples 
and the corresponding antibody, goat 
anti-a2-M (Sigma) or sheep anti-TF 
(Scottish Antibody Production Unit 
(SAPU)). were added. The principle of 
this assay is that the solid and the liquid 
phase antigen will compete for the bind­
ing of the antibody which results in the 
sample concentration being inversely 
proportional to the amount of the anti­
body bound onto the solid phase anti­
gen. The sample antigen was quantified
indirectly by the addition of a peroxi­
dase conjugated anti-sheep - goat IgG 
(SAPU).
(b) Sandw ich immunoassay to quantify 
al-AT. A modification of the technique 
described by Hetherington et al. ( 1983) 
was appiied. Goat unti-ai-AT iCaibi- 
ochemi was coated onto the polystyrene 
microplate. The experimental sample 
was added and any antigen present was 
captured by the immobilised antibody. 
Incubation with the second anti-al-AT 
(rabbit) (Calbiochemi was followed by 
addition of peroxidase conjugated anti­
rabbit IgG (SAPU).
In both ELISA methods, each plate 
included positive and negative controls 
and serial dilutions of purified antigen 
(al-AT: Calbiochem). to permit con­
struction of a standard curve from 
which sample antigen quantities could 
be estimated. Visualisation at 490 nm 
was achieved by incubation with the 
substrate (o-phenvlenediamine) (Sigma) 
and stopping the reaction with H:S 0 4.
The results were expressed both as ng 
of the substance per 30 s sample and on 
a concentration basis as ng per /d of 
GCF.
Statistical analysis
Values for GCF levels of a2-M. al-AT 
and TF were markedly skewed and re­
quired logarithmic transformation prior 
to statistical analysis using the r-test. 
Due to this skewed distribution, confi­
dence intervals are shown rather than 
the standard error or standard devi­
ation. Significant differences of u2-M. 
al-AT and TF mean levels among the 
clinical groups were determined by a 
two-sample t-test on the log,0 trans­
formed data. Data was analyzed using 
the 'Minitab' statistical package on the 
IBM PC computer.
Results
The mean values and standard errors of 
the clinical indices and GCF volumes 
for the three clinical groups are shown 
in Tables l-3. Tables I-3 also demon­
strate the means and 95% confidence 
intervals of the levels of a2-M. al-AT 
and TF respectively, for both methods 
of expressing the results (ng per 30 s 
sample or ng /d  of GCF). Statistical 
analysis revealed higher absolute 
amounts of a2-M (ng per 30 s sample) 
in. samples from gingivitis 1/1 = 0.0004) 
and periodontitis in = 0.0001) sites than 
in samples from healthy sites. However.
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Table I. a2-macroglobulin content is expressed as ng./d of G C F and as ng/30 s sample, 




i// =  25)
gingivitis 
(/i =  25)
periodontitis 
1/1 =  28)
■ ;i 0 .28-0 .09 2.04-11.14 5.39-0 .13
PD I.12 = 0.0~ 2.28=0.15 4.89 =  0.28
GCF ' id i i).28 — 0.03 0.35 =  0.04 0.43 =o.o4
u2-M i nil: al) of G C F 420(218-807) 1368 i746-2506r 2612(1603-425nr
u 2-\l ing. 30 s) sample S3 (44-159) 386 (23 l-c>47)" 887 (516-1459)'
GCF volumes are expressed in /tl and standard errors are given. The mean clinical indices. 
GI and PD are shown with standard errors. Sample size is indicated under each clinical 
diagnostic category in parenthesis.
■ Significantly different from healthy sites p < 0 .0 l.
" Significantly different from healthy sites p <0.001.
there was no significant difference (/? = 
0.09) in al-M  levels (ng per 30 s sample) 
from gingivitis and periodontitis sites 
(Table 1). Significantly higher values of 
both al-AT and TF. in ng per 30 s 
sample, were obtained for gingivitis 
(p <0.005) and periodontitis sites 
(p< 0.0001) when compared to healthy 
sites. Although periodontitis sites had 
consistently higher mean al-AT and TF 
levels (ng per 30 s sample) than gingi­
vitis sites, no significant differences (p> 
0.2) were demonstrated between the two 
disease groups (Table 2. 3).
When the results were expressed on a 
concentration basis (ng///l of GCF). a2- 
M showed a statistically significant in­
crease at diseased (gingivitis and perio­
dontitis) over healthy sites (p < 0.01). 
When GCF TF concentration of the 
three clinical groups were compared, the 
periodontitis sites showed an increase
over healthy sites 1/7 = 0.03). but no 
other significant differences pertained 
(/7>0.1). al-AT concentration levels 
among the three clinical groups (Tables 
I were not significantly different i/> -■ 
n .  I ) .
D isc u ss io n
This study demonstrates that ELISA 
methodology can be used to quantify 
u2-M. al-AT and TF in GCF. At 
healthy sites the mean concentration of 
u2-M. al-AT and TF was about 10%. 
of their expected plasma concentration 
( 5:2-4 mg/ml) (Johansson 1979).
Our data also demonstrate that 
higher absolute amounts of a2-M. al- 
AT and TF are to be expected in GCF 
from diseased sites (gingivitis and perio­
dontitis). than from clinically healthy 
sites. This could be accounted for by 
increased crevicular fluid flow in the dis­
eased sites as a result of increased vascu­
lar permeability, and is strongiv sug­
gested by the higher GCF volume read­
ings obtained from diseased sites. The 
mean absolute amounts of u2-M. al- 
AT and TF. were not found to differ 
significantly between gingivitis and 
periodontitis sites. There was however 
a marked tendency for increased levels 
at periodontitis over gingivitis sites 
(Tables 1-3). As mean GI. PD and GCF 
volume were higher in the periodontitis 
group (Tables 1-3) the influence each 
factor has on the acute phase protein 
levels is unclear. Further investigation 
of the correlation of these proteins with 
detailed clinical indices may be profit­
able. especially if the GCF analysis for 
all the proteins could be performed on 
the same sample.
We could not detect the same statisti­
cally significant differences when results 
were expressed on a concentration basis 
and this is a reflection of the higher 
variability observed when the results are 
expressed in this way. al-AT exhibited 
a tendency for increasing values from 
health to disease (gingivitis and perio­
dontitis). although none of the differ­
ences were significant. TF however, 
only showed a statistically significant 
increased GCF concentration in perio­
dontitis over healthy sites. Gingivitis 
sites cannot be readily differentiated 
from healthy or periodontitis sues by 
GCF TF concentration. In contrast. 
GCF u2-M concentration was signifi­
cantly increased in both gingivitis and 
periodontitis sites when compared to 
healthy. There is evidence that ;2-\l
Table 7. a 1-antitrypsin content is expressed as ng///i of G C F and as ng/30 s sample, figures 




(/i =  24)
gingivitis
(/i =  22)
periodontitis
(/i =  22)
GI 0.17 =  0.08 2.64 =  0.12 3 .14-0 .17
PD 1.04 = 0.04 2.32 ±0.10 5 .02-0 .30
GCF (/d) 0.18 ±0.03 0 .2 7 -0 .0 4 0.37 =  0.07
al-AT (n g /d )  of G C F 192(113-326) 332 (224-492) 274(192-392)
al-AT (ng/30 s) sample 22(15-33) 68 (49-94)J 81 (49-134 )h
GCF volumes are expressed in /<1 and standard errors are given. The mean clinical indices. 
GI and PD are shown with standard errors. Sample size is indicated under each clinical 
diagnositc category in parenthesis.
J Significantly different from healthy sites p<  0.005.
” Significantly different from healthy sites p<  0.001.
Table 3. Transferrin content is expressed as ng//d of GCF and as ng/30 s sample, figures in 
parenthesis indicate the 95% confidence intervals
Site
healthv zinsivitis periodontitis
Parameter (n =  29) (n =  3I) (/i =  32)
GI 0.45 ±0.09 2.61=0.12 3.34-0.11
PD 1.13-0.08 2.39 =  0.13 5 .30-0 .36
GCF i/il) 0.27 = 0.03 0 .3 8 -0 .0 4 0 .4 5 -0 .0 4
TF (ng //I) of GCF 267(125-571) 551 (302-1005) 748 (426-1312)'
TF mg/ 30 s) sample 41 (21-78) 149 (S4—265 f 261 t 134-508fi
GCF volumes are expressed in /d and standard errors are given. The mean clinical indices. 
GI and PD are shown with standard errors. Sample size is indicated under each clinicai 
diagnostic category in parenthesis.
Significantly different from healthy sites n < 0.005.
’ Significantly different from healthy Mtes />■■■'0.001.
Significantly different from healthy sites /» = 0.03.
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may be produced locally by gingival 
fibroblasts (Condacci et al. 1988) and 
possibly macrophages (White et al.
1980) and this local contribution may be 
significant (Giannopoulou et al. 1990).
Our results are consistent with pre­
vious investigations of a2-M. Condacci 
et al. ( 1982) and Sengupta et al. ( 1988). 
which demonstrated that the absolute 
amounts of a2-M were increased at sites 
with higher degrees of gingival inflam­
mation. When however. Condacci et al.
( 1982) and in an another study Skaleric 
et al. ( 1986) expressed their results on a 
concentration basis (/ig/mg and g/I of 
GCF respectively) they reported, in con­
trast to our results, that the specific con­
tent of the inhibitor decreased as the 
gingival index and alveolar bone loss 
increased. This apparent inconsistency 
could be due to the different methods 
of GCF collection employed. Condacci 
et al. (1982) collected GCF using filter 
paper strips for 3 to 5 min and Skaleric 
et al. (1986) sampled using microcapil­
lary tubes. Both methods of GCF col­
lection are thought to irritate the gin­
gival tissues (Cimasoni 1983) and could 
thus increase vascular permeability in 
the area, resulting in a dilution of the 
static GCF. In our study we used a less 
invasive method of GCF collection 
(paper strips for 30 s) that minimises 
irritation and microleakage of the sub- 
epithelial micro vasculature. Expression 
of the results as amount of GCF con­
stituent per 30 s sample does not include 
the volume of GCF in its calculation 
and may thus be subject to less variance 
and is probably less sensitive to alter­
ations caused by evaporation or con­
tamination of the sample which would 
appear to be unpredictable, irrespective 
of the sampling technique used.
It is interesting to note that levels of 
al-AT in GCF are generally much lower 
than levels of both u2-M and TF al­
though its concentration in plasma is 
similar or higher than the concentration 
of these other proteins. We would have 
expected similar or higher amounts of 
al-AT in the inflamed gingival crevice, 
as its lower molecular weight would fa­
cilitate its extravasation. The increased 
levels of a2-M may be due to local pro­
duction by fibroblasts and macrophages 
(Condacci et al. I988. Giannopoulou et 
al. 1990, White et al. 1980) and a similar 
process may occur for TF within the 
gingival tissues. u2-M. al-AT and TF 
(Brock & Mainou-Fowler 1983. Breit & 
Penny 1980. James 1990) are now recog­
nised as being capable of regulating im­
mune responses and their presence in 
the gingival crevice may reflect their in­
volvement in local immune and inflam­
matory responses.
In conclusion, we have demonstrated 
that precise quantification of u2-M. al- 
AT and TF is possible in microlitre 
amounts of GCF. Although gingivitis 
and periodontitis sites could not be dif­
ferentiated by their a2-M. al-AT and 
TF leveis. they both had markedly 
higher levels than healthy sites. Gingival 
inflammation per se may be a major 
factor governing GCF a2-M. al-AT or 
TF levels rather than increased pocket 
depth.
Zusammenfassung
Die Moglichkeit von akute-Phase-Proteinen 
aus der Sulkusjliissigkeit :ur Unterscheiduitg 
von gesunden. Gingivitis- and Parodontitis- 
Zdhnen
Drei akute-Phase-Proteine. aus der lokalen 
gingivalen Entziindungsreaktion. wurden 
hinsichtlich ihrer Fahigkeit zur Unterschei- 
dung von gesunden. Gingivitis- und Paro- 
dontitis-Zahnen untersucht. Indirekte kom- 
petitive Immunoassays wurden lur die Quan- 
tifizierung von a2-Makroglobulin (u2-M) 
und Transferrin (TF) und fur al-Antitrypsin 
(al-AT) entwickelt. Ein doppel-Antikorper- 
Sandwichassav wurde hergestellt: bei gesun­
den (25). Gingivitis- (31) und Parodontitis-
(28) Ziihnen wurden mit Filterpapierstreifen 
(2 x 13 mm) Proben entnommen und das Vo- 
lumen mit dem Periotron 6000 gemessen. Die 
Proben wurden in Phosphat gebufferter 
Kochsalzlosung eluiert und auf a2-M. al-AT 
und TF hin analysiert. Die Ergebnisse wur­
den ais absolute Menge pro Probe (ng/30 s) 
und auf der Basis einer Konzentration (ng 
/d von GCF) ausgegeben. Hohere absolute 
GCF-Mengen von a2-.M, al-A T  und TF wur­
den einheitlicher von erkrankten (Gingivitis 
und Parodontitis) Zahnflachen erhalten als 
von gesunden Zahnflachen ip < 0.005). Abso­
lute GCF-Mengen von a2-M. al-AT und TF 
waren bei Parodontitis Zahnflachen iiber 
Gingivitis-Zahnen erhoht. obgleich diese Dif- 
ferenzen nicht statistich signifikant waren 
(p > 0 .l) . Sobald die Ergebnisse auf der Basis 
einer Konzentration ausgegeben wurden. war 
das a2-M Niveau von erkrankten Zahnfla­
chen signifikant hoher als von gesunden 
Zahnflachen (p< 0 .0 l). Zusatzlich war die 
GCF TF Konzentration bei Parodontitis. 
verglichen zu gesunden Zahnflachen. erhoht 
(p -0 .03).
Resume
Aptitude des proteines de la phase digue dans le 
jluide gingival d differencier les sites en bonne 
same, avec gingivite et avec parodontite 
L'aptitude de 3 proteines de la phase aigue. 
provenant de la reaction inflammatoire gingi-
vale locale, a dilTercncier les sites sains, avec 
gingivite et avec parodontite a ete etudiee. 
Des dosages immunologiques indirects com- 
petitifs ont ete conqus pour doser la 
maerogiobuline-<t2 ia2-M) et la transferrine 
(TF): pour l'antitrypsine-a I ial-AT'i. un dou­
ble dosage anticorps sandwich a ete produit. 
Dans des sites en bonne sante(25). avec gingi­
vite (3 1) et avec parodontite (28). des preleve- 
ments ont ete fans au moyen de bandelettes 
de papier tiltre (2 < 13 mm) et le volume re- 
cueiili a ete mesure avec le periotron M)()(). 
Les echantillons ont ete separes dans une so­
lution saiee tamponnee au phosphate et ana­
lyses pour rechercher u2-M. al-AT et TF. 
Les resultats ont ete exprimes en quantites 
absolues par echantillon ing/30 si et en 
concentrations (ng/.ni de tluide gingival). On 
a regulierement obtenu des quantites abso­
lues d"u2-M. al-AT et T F  plus elevees dans 
le tluide gingival de sites atteints (gingivite et 
parodontite) que dans celui des sites sains 
[p< 0.005). Les quantites absolues d'a2-M. 
al-A T et TF dans le fluide gingival etaient 
augmentees dans les sites avec parodontite 
par rapport aux sites avec gingivite. mais ces 
differences n'etaient pas statistiquement si- 
gnitlcatives (/? > 0.1). Quand les resultats 
etaient exprimes en concentrations, les ni- 
veaux d'a2-M dans les sites atteints etaient 
significativemeni plus eleves que ceux des si­
tes sains (g? < 0.01). Enfin. les concentrations 
de T F  dans le fluide gingival etaient augmen­
tees dans la parodontite par rapport aux sites 
sains ip = 0.03).
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Abstract - The dynamics of four acute-phase proteins were investigated in gingival 
crevicular fluid (GCF) during the course of a 21 day experimental gingivitis study. These 
acute-phase proteins were the protease inhibitors a2-macroglobulin (a2-M ) and a l -  
antitrypsin (a l-A T ) and the iron-binding proteins transferrin (TF) and lactoferrin (LF). 6 
healthy volunteers ceased all oral hygiene procedures for 3 weeks. GCF was sampled at 
seven day intervals from two sites per subject by paper strips for 30 s during the 
experimental gingivitis period and for two additional weeks after the reinstitution of oral 
hygiene. The mainly serum derived a2-M , a l-A T  and TF exhibited very similar dynamics 
which reflects their common origin in GCF. Their levels increased significantly from 
baseline and remained high for at least one week after the reinstitution of oral hygiene 
measures (repeated measures MANOVA; a2-M : p=0.015; a l-A T : p=0.012; TF: p=0.02). 
This probably reflects increased vascular permeability in the gingivae and, to a lesser 
degree, local production by gingival inflammatory cells. In contrast to the serum derived 
acute-phase proteins, the neutrophil derived LF rose significantly from baseline (repeated 
measures MANOVA; p=0.001) but dropped rapidly after the reinstitution of oral hygiene 
measures. This could be because dental plaque was removed and thus neutrophil 
chemotactic agents in the crevice were decreased.
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Chronic inflammation is a persistent feature of periodontal diseases 
and it is now established that accumulation of bacterial plaque is 
responsible for the initiation and maintenance of the inflammatory 
process. Loe, Theilade and Jensen’s (1) experimental gingivitis 
model has been applied extensively and has proven invaluable in the 
study of gingival inflammation.
Sampling gingival crevicular fluid (GCF) provides a non-invasive 
means of obtaining and quantifying site specific biochemical 
parameters which may provide useful information on the 
inflammatory state at specific sites (2). Four GCF acute-phase 
proteins were investigated in this study. These were the protease 
inhibitors a2-macroglobulin (a2-M ) and a  1-antitrypsin (al-A T), 
and the iron-binding proteins transferrin (TF) and lactoferrin (LF).
a2-M  and a l-A T  are the major serum protease inhibitors (serum 
concentration of approximately: 2-4 mg/ml) (3) accounting for 
approximately 90% of serum’s inhibitory capacity (4). Together 
they neutralise the majority of harmful proteases from each of the 
four catalytic classes (5) reflecting their considerable potential 
function in the protease rich GCF. TF and LF are iron-binding 
proteins with a very similar structure but of different origin. TF is 
mainly serum derived (serum concentration approximately 2 mg/ml) 
(3) and its main function in man is the transport of iron (6). LF is 
present in external excretions (milk, saliva, tears) (7). In addition, 
LF is found in abundance in PMN secondary granules (8) but not in 
other leucocytes (9), and only in trace amounts in serum (10). TF 
and LF in GCF might function as antibacterial agents by creating an 
iron limiting environment (2) although LF may also exert a direct
bactericidal effect independent of iron deprivation (11). Finally, 
the roles of the four acute-phase proteins in inflammation and their 
function in immune reactions is also recognised (12-15).
The above acute-phase proteins have been identified in GCF (16- 
21) and we have recently shown that their absolute amounts 
increase in diseased compared to healthy sites in cross-sectional 
investigations (22, 23). However, with the exception of the study 
of Giannopoulou and coworkers (19) who assessed a l-A T  and 
a2-M  in the same GCF sample no other studies have 
simultaneously measured a2-M , a l-A T , TF and LF in GCF. The 
present study aims to establish the dynamics of these acute-phase 
proteins in GCF during experimentally induced gingivitis and 
provide a biochemical profile of GCF.
MATERIAL AND METHODS
Subjects and design
Six healthy dental students (5 males, 1 female; age range of 22-23 
years) with no clinically detectable periodontal attachment loss or 
pocketing >3mm in any site were enrolled in the experimental 
gingivitis trial. Dental students were preferred because of their 
excellent oral hygiene and high degree of dental awareness and 
compliance. The experimental gingivitis model of Loe et al. (1) 
was adapted for use in this study. Subjects were enrolled in the 
trial 10 days prior to the commencement of the experimental 
gingivitis period (day -10) when clinical indices were recorded. 
Oral hygiene instruction and prophylaxis were then given. Ten 
days later (day 0/baseline) all oral hygiene procedures were ceased
for 3 weeks. The subjects were then followed on days 0, 7, 14 and 
21 of the experimental gingivitis period and 1 and 2 weeks after the 
reinstitution of oral hygiene measures. Clinical indices were 
recorded and GCF samples were obtained from the mesial aspect of 
the upper first premolars which were free of any dental restorations. 
Clinical indices included the Modified Gingival Index (MGI) (24) 
and the Plaque Index (PI) (25).
Gingival crevicular fluid sampling
Sterile Whatman grade 4 (Whatman Labsales Ltd., Maidstone, Kent) 
paper strips (2x13mm) were cut using a steel ruler and a scalpel and 
a line was drawn at 5mm indicating the length of the strip to be 
inserted between the Periotron jaws. The individual crevicular site 
was gently air-dried in an apico-coronal direction and any visible 
supragingival plaque was removed. The area was carefully isolated 
with cotton wool rolls and a saliva ejector, to avoid salivary 
contamination of the samples. The paper strip was introduced into 
the crevice until mild resistance was felt, whilst care was taken to 
avoid mechanical injury of the tissues. The strip was left in the 
crevice for 30 s and then transferred, for volume determination, to 
the chairside located, Periotron 6000 (Harco Electronics, Winnipeg, 
Canada). The Periotron was calibrated using the customised 
Whatman 4 paper strips each day GCF samples were collected. The 
strip was then stored in a labelled sterile 1ml microcentrifuge tube, 
and placed on ice until all sampling was completed. The strip>s were 
subsequently transported to the laboratory and stored frozen at -70°C 
until further processing. Prior to assaying, samples were eluted into 
lml of phosphate buffered saline containing 0.1% w/v bovine serum 
albumin and 0.05% Tween 20 (IB= incubation buffer) for lh  at 
room temperature.
Quantitation of GCF constituents
tt2-M, a l-A T , TF and LF in eluates of GCF were assessed using 
sandwich enzyme linked immunosorbent assays (ELISA). The 
sandwich ELISA methodology allowed the quantification of a2-M, 
al-A T , TF and LF in the same GCF sample. This permitted 
assessment of the levels of these proteins in GCF simultaneously 
during the development and reduction of gingival inflammation.
The four sandwich ELISAs (a2-M , a l-A T , TF and LF) are based 
Dn the technique described by Hetherington et al. (10). In brief, the 
96-well polystyrene microplate (Immulon IV, Dynatech 
Laboratories, Billinghurst, Sussex) was coated with the first 
antibody, a goat antiserum specific to the antigen to be quantified 
(1:6000 dilution in carbonate/bi-carbonate buffer for a2-M , TF and 
LF; 1:3000 for a l-A T ). The eluate of the sample was then added 
and any antigen present was captured by the immobilized antibody. 
This was followed by incubation with the second specific antiserum, 
developed in rabbit (1:4000 dilution in incubation buffer). Finally, 
the horseradish peroxidase (HRP) conjugated anti-rabbit IgG (goat) 
was added (1:4000 dilution in incubation buffer). Visualisation was 
achieved by incubation with the substrate and stopping the reaction 
with H2S 0 4. The plate was read at 490nm, and optical densities 
(ODs) obtained using the Dynatech Minireader II (Dynatech 
Laboratories, Alexandria, VA). Plates included serial two-fold 
dilutions of purified antigen for the construction of a standard curve. 
Only the central wells were used when running standards or samples 
(in triplicate). The peripheral wells were used for assaying the 
controls. All controls were run in duplicate except for the zero- 
antigen control which was run in quadruplicate. The working range 
of the standard for each of the above assays is shown in Table 1. 
Prior to assaying with the sandwich ELISAs, GCF sample eluates
were diluted further in IB in order to achieve an optimal final 
dilution for each assay. These optimal dilution ranges for each 
assay are shown in Table 1.
The recovery rates of the four acute-phase peoteins from Whatman 
grade 4 paper stripes are also shown in Table 1. LF demonstrated 
the lowest recovery rate compared to a2-M , a l-A T  and TF. GCF 
data, as presented in this report, were corrected to 100%, using the 
respective recovery rate for each acute-phase protein (Table 1).
Reagents
Purified a2-M  and TF were obtained from SIGMA (SIGMA 
Chemical Company Ltd., Poole, Dorset) whereas LF and a l-A T  
were purchased from Calbiochem (Novabiochem Ltd., 
Nottingham). Goat and rabbit anti-a2-M , and goat anti-TF were 
also obtained from SIGMA. Goat anti-LF as well as rabbit anti- 
LF and anti-TF were obtained from Nordic Immunological 
Laboratories (Maidenhead, Berkshire) whereas goat and rabbit anti- 
a l-A T  were purchased from Calbiochem. The horseradish 
peroxidase (HRP) conjugated anti-rabbit IgG (goat) was purchased 
from ICN Immunobiologicals (Lisle, IL, USA). Of the above 
antisera the rabbit antisera to a2-M , a l-A T , the goat anti-TF and 
the HRP conjugates were fractionated.
Statistical analysis
GCF constituent levels or MGI, PI scores and GCF volumes from 
the two sites (upper right and left first premolars) were averaged 
within each subject. GCF data were analyzed using the repeated 
measures analysis of variance and the MANOVA procedure on the 
SPSS/PC statistical package (26). The subject was considered as 
the experimental unit for the analysis of the GCF acute-phase 
protein data. This was justified as in experimental gingivitis 
studies gingival conditions are standardised at all sites within each 
subject prior to the initiation of the experimental period. In 
addition, preliminary analysis of the data demonstrated that 
incorporating the site in the analysis did not have a significant 
effect. Each pjrotein was tested separately for differences with 
time. In order to satisfy the distributional requirements of the 
GCF data for the tests, a log10 transformation was required 
(logio(l+x), x=original data value). In an attempt to investigate 
which days demonstrated significantly elevated GCF acute-phase 
protein levels since baseline, individual paired t-tests were 
employed on the log10 transformed data, comparing baseline levels 
of each protein to each subsequent day. A Bonferroni correction 
was applied and the significance level for the paired t-tests was set 
at 0.02 (0.05/V5, where 5=number of comparisons made) (27).
A further transformation of the logarithmically transformed data to 
z scores was used in this study. The z scores for each pwotein 
were produced by subtracting each data value from the grand mean 
of the protein and dividing by its standard deviation. This resulted 
in a new variable for each protein which had a grand mean of 0 
and standard deviation of 1. In this way differences in overall 
level among the four proteins were removed permitting a clearer 
focus on the pattern of change during the experimental gingivitis 
study.
RESULTS
MGI and PI scores and GCF volumes, for the 6 subjects (mean & 
SE), are shown in Figure 1. MGI and PI scores demonstrated the 
pattern typical of experimental gingivitis studies, rising when oral
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hygiene procedures ceased. After the reinstitution of oral hygiene 
measures, PI returned rapidly to haseline levels and MGI followed 
remaining, however, slightly higher than baseline. GCF volume 
rose, similarly to the clinical indices, with the accumulation of 
plaque and the development of gingival inflammation. GCF 
volumes remained higher than baseline after the reinstitution of oral 
hygiene measures.
The changes in GCF acute-phase protein levels over time for the 6 
subjects are depicted in Figure 2, a to d (geometric mean and 95% 
confidence intervals; semi-log scale). Repeated measures analysis 
af variance revealed that GCF acute-phase protein levels changed 
significantly over time during the experimental gingivitis trial (a2- 
M: p=0.0l5; a l-A T : p=0.012; TF: p=0.02; LF: p=0.001). The 
results of the follow up analysis comparing individual days to 
baseline, using paired t-tests, are also depicted in Figure 2. Figure 
3 demonstrates the z scores of the GCF acute-phase protein data 
[mean response for the 6 subjects). Figures 2 and 3 indicate that 
a2-M, a l-A T  and TF in GCF demonstrated a very similar pattern, 
rising and remaining significantly higher than baseline even after the 
reinstitution o f oral hygiene measures. In contrast, LF in GCF 
dropped rapidly after the reinstitution of oral hygiene measures 
returning to almost baseline levels.
DISCUSSION
The clinical findings of this study are consistent with previous 
experimental gingivitis trials. Upon cessation of oral hygiene 
measures plaque accumulated, gingival inflammation developed and 
simultaneously GCF volume rose. Interestingly, despite the 
’clinical’ improvement in gingival conditions during the healing 
period (days 2'8 and 35) vascular permeability persisted as shown by 
only a slight drop in GCF volumes.
In this study GCF data were reported as absolute amounts in ng/30s 
sample. The rationale for expressing results of GCF constituents as 
absolute amounts (ng/30s) has been discussed extensively (28, 29). 
Moreover, in the present study, GCF volumes were in the ultra low 
range, and thus minimal errors in GCF volume assessment would 
have created disproportionate flaws in concentrations of constituents
(29).
The mainly serum derived a2-M , a l-A T  and TF demonstrated a 
very similar pattern during the experimental gingivitis period, 
reflecting thear common origin in GCF (Figs. 2 and 3). The 
increase in their levels in the crevice could be attributed to the 
development o f gingival inflammation and to the resulting increased 
vascular permeability. This is supported by the simultaneous rise in 
GCF volume. In addition, increased local production could also 
contribute. Gingival fibroblasts synthesise a2-M  (30) whereas 
monocytes/macrophages can produce a2-M  (31), a l-A T  (32) and 
TF (33). Although we have shown that total macrophage numbers 
do not change within the gingivae during experimentally induced 
gingivitis (34) the proportion of activated macrophages increases 
(35), and this may enhance the local production of a2-M , a l-A T  
and TF. a l-A T  is produced and stored within PMN primary 
granules (36) and inducer T-lymphocytes, which increase with the 
severity of gingival inflammation (37), may also contribute to the 
synthesis of small amounts of TF within the tissues (38).
The dynamics of a2-M , a l-A T  and TF during the healing period 
(days 28 and 35) demonstrated a consistent pattern still, remaining
significantly higher than baseline for at least one week. This oould 
be attributed to the maintenance of increased vascular permeability 
as shown by the fact that GCF volumes demonstrated only a slight 
decrease during the recovery period. Sustained local production 
by resident cells of the periodontium may also be responsible for 
the high levels of a2-M , a l-A T  and TF after the reinstitution of 
oral hygiene measures, as it has been shown that clinical 
improvement precedes the histological resolution of gingival 
inflammation (39). In addition, in the case of protease inhibitors, 
lower degradation rates by microorganisms (40) or lower clearance 
rates (after binding to proteases) by macrophages/monocytes within 
the tissues (41), could also contribute.
GCF LF demonstrated a different overall pattern (Figs. 2 and 3), 
rising with the development of gingival inflammation and dropping 
after the reinstitution of oral hygiene measures. We have shown 
that LF correlates with the number of crevicular PMNs (23) and 
it has been shown that crevicular PMN numbers increase with the 
development of experimental gingivitis (42, 43). As LF is 
contained in only trace amounts in serum (10), the increase in its 
levels in GCF during the development of experimental gingivitis 
cannot be accounted for by increased vascular permeability. 
Migration of PMNs in the gingival crevice and degranulation 
therein is probably the major factor contributing to increased GCF 
LF levels. When chemotactic agents (dental plaque) are removed 
with the reinstitution of oral hygiene, PMN emigration rates drop 
and consequently LF in the crevice decreases rapidly in contrast 
to the mainly serum derived a2-M , a l-A T  and TF.
GCF acute-phase protein data as presented in Figures 2 and 3 
demonstrate the average response for the 6 subjects. Although 
there was small intra-subject variation in our clinical and 
biochemical data, a wide inter-subject variation was observed 
which might reflect individual variation in plaque accumulation or 
gingival inflammation in response to plaque. Alternatively, it 
could reflect an inherent variation in the local production of these 
acute-phase proteins. As far as a2-M  and a l-A T  are concerned, 
an interesting feature of this heterogenous response was obvious 
during the healing period; although most subjects sustained high 
levels of GCF a2-M  and a l-A T  after the reinstitution of oral 
hygiene measures, one subject demonstrated a definite drop to 
almost baseline levels. Interestingly, this type of response 
resembles the data presented by Giannopoulou et al. (19). These 
investigators showed that immunoreactive GCF a2-M  and a l-A T  
increased with the development of experimental gingivitis but, in 
contrast to the present study, inhibitor levels in the crevice dropped 
rapidly after the reinstitution of oral hygiene. Thus, there may be 
differences between individuals in the course and resolution of the 
inflammatory process and the resulting vascular permeability. This 
is supported by the fact that the serum derived GCF TF decreased 
at the same time as the inhibitors, in the subject participating in 
the present study. However, one could also speculate that some 
individuals may present with inherently higher clearance rates of 
protease-inhibitor complexes within the tissues during the 
resolution of gingival inflammation which would be reflected by 
a drop in crevicular a2-M  and a l-A T  levels. As the ELISA 
methodology used in this study assesses both bound and unbound 
inhibitor, subjects with lower protease/inhibitor complex clearance 
rates would maintain high GCF a2-M  and a l-A T  levels during 
the healing period. It has been suggested that assessing 
bound/unbound inhibitor ratio in GCF may provide useful 
information on the protease inhibitory status at specific sites.
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However, it should be borne in mind that in the crevioe where 
conditions for PMN proteinase release are favourable and 
monocytes/macrophages are scarce (44), bound inhibitors would 
predominate and protease/inhibitor complexes would persist for 
longer time periods than in the tissues where complexes are 
removed rapidly upon formation (41). Therefore, bound/unbound 
inhibitor ratio in GCF may not be reflecting the situation within the 
tissues. In the gingivae, the protease/inhibitor imbalance required 
for damage to occur, probably arises when PMNs are closely 
attached to their substrate (host-tissue surfaces) and release their 
proteinases within closed inter-phases. The close contact would 
inhibit the accessibility of substances of molecular weight greater 
than 50 kDa (45). a2-M  (Mwt: 725 kDa) would thus be completely 
excluded from the site of activity, whereas even if small amounts of 
a l-A T  (Mwt:55 KDa) could reach, they would be readily 
inactivated by oxidative mechanisms (46-48). In this context these 
protease inhibitors within the gingivae may act as homeostatic 
regulators, functioning when PMNs release their contents in open 
spaces, thus being essential in preventing excessive tissue damage.
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Fig. I. (a) modified gingival index (MGI), plaque index (PI) 
and (b) gingival crevicular fluid (GCF) volume during the ex­
perimental gingivitis trial. The mean and standard error (n = 6 
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Legends for figures
Figure 1. (a) modified gingival index (MGI), plaque index (PI) 
and (b) gingival crevicular fluid (GCF) volume during the 
experimental gingivitis trial. The mean and standard error (n=6 
subjects) at each time point are shown.
Figure 2. Acute-phase protein dynamics in gingival crevicular 
fluid during the experimental gingivitis trial. The geometric mean 
and 95% confidence intervals (n=6 subjects) at each time point are 
shown on a semi log scale. Data have been corrected to 100% 
according to the recovery rate of each acute-phase protein (Table 
1). (a) a2-macroglobulin (a2-M); (b) al-antitrypsin (al-AT); (c) 
Transferrin (IF); (d) Lactoferrin (LF)
** Significantly different from baseline p<0.01;
* Significantly different from baseline p<0.02;
-i- Difference from baseline failed to reach significance at p<0.02 
but p<0.05.
Figure 3. Total a2-macroglobulin (a2-M), al-antitrypsin (a l-  
AT), transferrin (TF) and lactoferrin (LF) changes in gingival 
crevicular fluid; average (n=6 subjects) z-scores of the log10 
transformed data during the experimental gingivitis trial.
Table 1. Working range of standard antigen for the a2- 
macroglobulin (a2-M), al-antitrypsin (al-AT), transferrin (TF) 
and lactoferrin (LF) sandwich ELIS As.
Assay Working range Dilution range of Recovery rate
ng/ml in IB GCF in IB from paper strips
a2-M 100 - 1.56 1: 25x10s to 5xl04 99.5%
al-A T  25 - 0.78 1: 5xl04 to 105 99.4%
TF 25 - 0.78 1: 5xl04 to 105 89.9%
LF 31 - 0.49 1: 105 to 2x10* 83.4%
IB= incubation buffer





217 14 20 3S0
■1-AT ng/30n
io-









0 7 14 21 35
Days Days
*. 2. Acute-phase protein dynamics in gingival crevicular fluid during the experimental gingivitis trial. The geometric mean and 
'/> confidence intervals (n = 6 subjects) at each time point are shown on a semi log scale. Data have been corrected to 100% 
:ording to the recovery rate of each acute-phase protein (Table 1). (a) a2-macroglobulin (a2-M); (b) al-antitrypsin (al-AT); (c) 
ansferrin (TF); (d) Lactoferrin (LF). ** Significantly different from baseline p <0.01; * Significantly different from baseline 
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• ^rl I G against P.gingivalis  in peri-implant crevicular fluid: A comparison with  
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The aim of the present investigation was two-fold: firstly, to determine the levels  
1 \  proteins and IgG against Porphyrom onas gingivalis in peri-implant crevicular 
„  their association with the clinical condition o f the peri-implant mucosa;
HIv to compare the inflammatory and im m unological responses at implants and 
fleeted by the gingival crevicular fluid (GCF) and PICF levels o f acute-phase 
d immunoglobulins. 31 partially edentulous subjects were recruited for this study. 
" was sampled from 1 healthy and 1 inflamed site from each patient; GCF was sampled  
an additional 2 1  healthy and 27 inflamed tooth sites o f the sam e patients. GCF and
y  were collected with paper strips (30s) and analysed using enzym e-linked
aoo
ft
-'osorbent assays for a2-m acroglobulin  (a2 -M ), a l-antitrypsin  (a l-A T ), transferrin 
actoferrin (LF) and IgG against P. gingivalis. This investigation demonstrated that 
absolute amounts o f the acute-phase proteins and IgG against P.gingivalis  are higher in 
and PICF from inflamed than healthy sites. N o significant differences were observed  
tveen PICF and GCF com ponents at either healthy or inflamed sites suggesting that 
■ammatory events are similar in the peri-implant mucosa and gingiva and that PICF and 
-production is governed by similar m echanism s.
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TRODUCTION
. ong-term success o f  osseointegrated dental implants relies, 
~ "g other things, on the maintenance o f the "biologic seal" and 
"tegrity of the peri-implant tissues (James and Lozada 1989). 
- oen-implant supracrestal tissues are in many w ays comparable 
"dr periodontal counterparts (Berglundh et al. 1991, Listgarten 
91)- Like the gingival crevice at a tooth, the peri-implant crevice 
a niche for the colonisation and growth o f oral 
- o^rganisms. The microflora around natural teeth and implants
• ken compared in partially edentulous patients, and were found
* analogous (Lekholm et al. 1986, A pse et al. 1989, Quirynen 
'sgarten 1990). In addition, an animal study has shown that
^Ionization and establishm ent on titanium osseointegrated  
-ants, from healthy mucosa to experimental m ucositis and peri- 
2^ntius, follow a very similar pattern to that o f natural teeth 
^ d t  et a l. 1992). "
* * 2  wkich has recently attracted attention, is whether 
(gingiva) and peri-implant mucosa share the same 
and im m unological responses. The inflammatory 
,."ans J^)en’,niplant healthy and inflamed mucosa biopsies from 
;'<:r.b]e s ^ n  im m unohistochem ically characterised and 
0^Und in the gingival tissue. It com prises mainly of  
'■ ’989s rnacroP^ages and only very few plasma cells (Seym our
' Moreover, histological studies on animals have 
.^ation l^at reaction o f the soft tissues to early plaque 
'^ 2). i Slm*Iar around teeth and implants (Berglundh et al. 
S term animal studies, however, have shown that
prolonged plaque accum ulation and inflammation may result in a 
greater apical extension o f  the inflammatory infiltrate around 
implants than teeth (Ericsson et al. 1992) and that in experimental 
peri-implantitis, inflammatory cells  may be found even in the 
adjacent bone marrow (Lindhe et al. 1992). Thus, a more intense 
inflammatory response may develop around implants when  
compared to teeth in response to prolonged plaque accumulation, 
although further human studies are needed to confirm this.
Gingival crevicular fluid (GCF) or peri-implant crevicular fluid 
(PICF) provides a non-invasive means o f  comparing the 
inflammatory and im m unological responses around natural teeth 
and implants. H owever, in contrast to GCF which has been 
w idely exam ined (Curtis et al. 1989), very few studies exist on 
PICF com ponents and their relation to the peri-implant status 
(A pse et al. 1989, Beck et al. 1992).
The protease inhibitors, a2-m acroglobulin  (a 2 -M ) and a l -  
antitrypsin (a l-A T )  play an important role in the neutralisation o f  
the proteases released in the gingival crevice (Sandholm  1986), 
whereas the iron-binding proteins transferrin (TF) and lactoferrin 
(LF) may act as antimicrobial agents in the area (Curtis et al. 
1989). These acute-phase proteins have been previously identified  
in GCF (Asm an et al. 1981, Condacci et al. 1982, Friedman et al. 
1983, Skaleric et al. 1986, Sengupta et al. 1988, Giannopoulou et 
al. 1992). In addition, it has recently been demonstrated that their 
absolute amounts are elevated in GCF from ’d iseased’ compared 
to ’healthy’ sites (A donogianaki et al. 1992, Adonogianaki et al.
that LF reflects polymorphonuclear leucocyte (PM N) 
,993). ^  crevice (Adonogianaki et al. 1993). Thus, these
b^ets in jgjns may also serve as markers o f peri-implant
,;^3tory
rf im m unoglobulin levels against putative periodontal 
v  -nCiuding P .gingivalis. may provide a measure o f the 
?«:^ Cn-I^ mune response at a specific site. Recently, Kinane et al.
i cl i ,
,1 imi
993) Sdeep pockets and inflamed sites than in shallow pockets or
that GCF antibody titres against P.gingivalis were
'r n d sites. A s P. gingivalis has been isolated also from the 
^  val microflora around implants in partially edentulous 
' ?n^ V(Lekholm et al. 1986, Apse et al. 1989, Quirynen & 
a^cntS 199O), PICF IgG levels against this periodontal pathogen 
^®aftC 'de useful information on the immunological status o f peri-
^ant sites.
aim investigation was two-fold: firstly, to determine the
e ai0f acute-phase proteins and IgG against P.gingivalis in PICF 
their association with the clinical condition o f the peri-implant 
jcoffl* anc^  secondly, to compare the inflammatory and 
Ideological reSponses at implants and teeth as reflected by the 
}CFand PICF levels of acute-phase proteins and immunoglobulins.
1ATERIAL a n d  m e t h o d s
Subjects, sites and clin ical indices 
rtvone partially edentulous patients (18 males, 13 females; age 
ngc: 23 to 84 years), who had previously been treated with 
reintegrated bridges at the Br&nemark Clinic (Gothenburg, 
'*eden) were selected to participate in this study. No subject had 
-v history of systemic conditions which could influence the course 
periodontal disease and had not been on antibiotics for the 
rrevious two months, were selected to participate in this study. The 
-cipants had at least two osseointegrated implants (ad modum 
'ineraarlc), which had been in function for a minimum o f one year 
•erage: 3.5 years; range: 1 to 10 years). PICF was sampled from 
' nealthy and one inflamed non-adjacent peri-implant sites. In 
Edition, 17 of the 31 patients contributed with one healthy and one 
arned tooth sites from which GCF was collected. Out o f the 
•lining 14 subjects, 4 contributed with one healthy and 10 with 
' '^m ed tooth site only. Hence, a total o f 21 healthy and 27 
fWnw t0°th sites were sampled for intra-subject comparisons 
^Cen *mplants and natural teeth (Table 1).
^ Str^ ut*on o f sites sampled in the subjects participating 
(n=31). The resulting total number o f sites in each 
Ithy/inflamed, implants/teeth) is also given.
of sites  
Implant Tooth








The non-invasive modified gingival index (MGI, Lobene et al. 
1986) was used to assess inflammation and categorise the 
mucosa/gingiva at implants or teeth as healthy or inflamed. Sites 
with an MGI score o f 0  or 1 were allocated to the clinically  
healthy group and sites with a score o f 2 to 4, to the inflamed 
group. Presence o f microbial deposits was assessed with the use 
of the Plaque Index system  (PII, Silness & Loe 1964). Following  
GCF and PICF sampling, probing depth (PD) and bleeding on 
probing (BOP) was assessed at implants and teeth using a 
pressure-sensitive periodontal probe with W illiams markines 
(0.25N; diameter: 0.45mm ; Electronic Periodontal Probe, Vine 
Valley Research, M iddlesex, NY, U SA). Dichotomous scoring 
was used for BOP.
G C F  and P I C F  sampling
Sterile Whatman grade 4 (Whatman Labsales Ltd., Maidstone, 
Kent) paper strips (2x13m m ) were cut using a steel ruler and a 
scalpel, and a line was drawn at 5mm indicating the length o f the 
strip to be inserted between the Periotron jaws. The individual 
crevicular site was gently air-dried in an apico-coronal direction 
and any visible supragingival plaque was removed. The area was 
carefully isolated with cotton wool rolls and a saliva ejector, to 
avoid salivary contamination o f the samples. The paper strip was 
introduced into the crevice until mild resistance was felt or to a 
maximum of 1mm in deeper pockets. The strip was left in situ for 
30s and then transferred, for volum e determination, to the chairside 
located Periotron 6000 (Harco Electronics, Winnipeg, Canada), 
which was calibrated at each session using known volum es of 
phosphate-buffered saline in a 1:1 dilution with serum. The strip 
was then stored in a labelled sterile 1ml microcentrifuge tube, and 
placed on ice until all sampling was completed. The strips were 
subsequently transported to the laboratory and stored frozen at - 
70°C until further processing. Prior to assaying, samples were 
eluted into 1ml o f phosphate buffered saline containing 0.05%  
Tween 20 for lh  at room temperature.
Quantitation of G C F  and P I C F  constituents
a2-M , a l-A T , TF, LF, albumin (Alb) and IgG against P. 
gingivalis in GCF and PICF eluates were assessed in the same 
sample using enzym e linked immunosorbent assays (ELISA).
The five sandwich ELISAs for a2-M , a l-A T , TF, LF and Alb are 
based on the technique described by Hetherington et al. (1983) and 
modified by Adonogianaki et al. (1993). In brief, the 96-w ell 
polystyrene microplate (Immulon IV, Dynatech Laboratories, 
Billinghurst, Sussex, England) was coated with the first antibody, 
a goat antiserum specific to the antigen to be quantified (1:6000  
dilution in carbonate/bi -carbonate buffer for a2-M , TF, LF and 
Alb; 1:3000 for a l-A T ). The eluate of the sample was then 
added and any antigen present was captured by the immobilized  
antibody. This was follow ed by incubation with the second 
specific antiserum, developed in rabbit at 1:4000 dilution in 
incubation buffer, containing either 0.1% bovine serum albumin 
for the a2-M , a l-A T , TF and LF ELISAs (IB) or 5% proprietary 
milk (M ARVEL) for alb (IB/M ). Finally, the horseradish 
peroxidase (HRP) conjugated anti-rabbit IgG (goat) was added 
(1:4000 dilution in the respective incubation buffer, IB or IB/M). 
Visualisation was achieved by incubation with the substrate and 
stopping the reaction with H2S 0 4. The plate was read at 490nm. 
Plates included serial two-fold dilutions of purified antigen for the 
construction of a standard curve. Only the central w ells were used
I. • ve an optimal final dilution for each assay. The optimal 
*1 tion ranges for the samples, the working range for the standard 
 ^U#j,e a2-M , a l - A T , T F and LF ELISAs as well as the recovery 
^  f0r each o f the acute-phase proteins from paper strips has been 
13 n elsewhere (Adonogianaki et al. 1992). The working range for 
* a]bumin ELISA was 125-1.95 ng/ml and the dilution ranges for 
6 sam ple are given in Table 2. Results were expressed either as 
^ O s  sample or ng/ug albumin.
fable 2. GCF sample dilution procedure prior to assaying by the 
lbUrT1in sandwich ELISAs. Samples were originally eluted in 0.5ml 
0f IB and further diluted, as shown below in IB/M, to yield a final 
jjlution of approximately at the range of 1/106 to l /p x lO 6)




v s  0.1 1/50
0,1 < v s  0.2 1/100
0,2 < v s  0.4 1/200
0.4 < v £ 0.8 1/400
0.8 < v 1/800
v= GCF or PICF volume
Specific antibody titres against P.gingivalis were measured by 
ELISA based on the method o f Ebersole et al. (1980, 1984), using 
formalinised w hole cells at an absorbance (OD600) which had 
previously been determined as optimum to coat microtitre plates. 
The bacterial strain used was P. gingivalis NCTC 11834. P. 
gingivalis was grown under anaerobic conditions (85% N2, 10% H2, 
5% CO^ at 37*C on Columbia blood agar. P. gingivalis was 
harvested after 5 days into phosphate-buffered saline (PBS, pH 7.4), 
with ImM Na2EDTA (PBSE), washed by centrifugation, and fixed 
i°r 1 hour in 10% formal saline. The cells were then washed twice 
,n PBS and once in 0.1M  Na carbonate-bicarbonate buffer 
containing 0.02% NaN3 at pH 9.6 (coating buffer). Fixed cells were 
s[ored in coating buffer at 4°C until use. Immulon 1 plates 
Ttynatech) were em ployed because o f their low protein-binding 
characteristics. After coating, the plates were treated with PBS 
Staining 0.1% bovine serum albumin (BSA), 0.05% Tween 20 and 
skimmed milk to remove background binding. Serum or GCF 
fluted in this buffer (excluding skimmed milk), to a concentration 
Vlthin the range o f the calibration graph, were then added for 2 
-ours at 37°C, and the plates were subsequently incubated with 
:‘°tin-anti-human IgG (150ng/m l) (Sigma) and thereafter with 
‘.^ g/rnl extravidin-peroxidase (Sigma). The reaction was visualized 
l^ng o-phenylenediamine substrate and stopped with 1M H2S 0 4. 
Optical densities were read at 490nm. Samples were assayed in 
ilJPlicate in the central w ells and peripheral wells were used as 
^trols. Correction was made for non-specific binding and results
were read from a reference line derived from serial dilutions o f a 
reference positive control serum. Results were expressed as 
absolute amounts in ELISA units (Gmur et al. 1986) per 30s 
sample (EU/30s) sample or as specific amounts in EU/^g Alb.
R eagents
Purified a2-M  ,TF and Alb were obtained from SIGMA (SIGMA  
Chemical Company Ltd., Poole, Dorset, England) whereas LF and 
a l-A T  were purchased from Caibiochem (Novabiochem Ltd., 
Nottingham, England). Goat and rabbit anti-a2-M  and anti-Alb. 
goat anti-TF, biotin-anti-human IgG and extravidin-peroxidase 
were also obtained from SIGMA. Goat anti-LF as well as rabbit 
anti-LF and anti-TF were obtained from Nordic Immunological 
Laboratories (Maidenhead. Berkshire. England) whereas goat and 
rabbit an ti-a l-A T  were purchased from Caibiochem. The 
horseradish peroxidase (HRP) conjugated anti-rabbit IgG (goat) 
was purchased from ICN Immunobiologicals (Lisle, IL, USA). Of 
the above antisera the rabbit antisera to a2-M , a l-A T , the goat 
anti-TF and the HRP conjugates were fractionated.
Statistical analysis
In order to control for inter-patient variability only within patient 
comparisons were made. GCF or PICF results were 
logarithmically transformed in order to satisfy their distributional 
requirements (log10 (1+x) where x= original data value). Four 
separate multivariate repeated measures analysis of variance 
(M ANO VA) procedures were applied to the logarithmically 
transformed data to test for all proteins simultaneously for 
differences between: a) healthy and inflamed peri-implant mucosa 
(n=31 pairs), b) healthy and inflamed gingiva (n=17 pairs), c) 
healthy gingiva and peri-implant mucosa (n=21 pairs) and finally 
d) between inflamed gingiva and peri-implant mucosa (n=27 
pairs). When a significant difference was detected by the analysis 
of variance, univariate paired t-tests were applied to the log 
transformed data to identify the location and direction of the 
statistically significant differences.
RESULTS
All of the implants that were selected for this study were well 
osseointegrated and none showed signs of increased rate of bone 
resorption.
The clinical data are depicted in Table 3. By definition, inflamed 
implant and tooth sites had higher MGI scores than healthy 
implant and tooth sites respectively. PLI was also higher at both 
categories of inflamed sites when compared to their healthy 
counterparts. Average probing depths were deeper at implants 
when compared to teeth, particularly at healthy sites, and in 
addition, average crevicular fluid volumes were higher. 67% of 
the healthy implant sites bled on probing compared to 14% of 
healthy tooth sites. The percentage of bleeding implant and tooth 
sites, allocated to the inflamed category was 93% and 85% 
respectively.
Multivariate repeated measures analysis of variance (M ANOVA) 
demonstrated a significant effect when healthy and inflamed tooth 
sites (p=0.021) were compared for their GCF absolute amounts of 
a2-M , a l-A T , TF, LF, Alb (ng/30s sample) and IgG against 
P.gingivalis (EU/30s). Follow-up analysis, using univariate paired 
t-tests, demonstrated significantly higher levels for all six proteins 
(a2-M , a l-A T , TF, Alb: pcO.001; IgG: p=0.036: LF: p=0.021) in
3
f inflamed compared to healthy tooth sites (Table 4). 
qCF ^ ^ p e a t e d  measures M AN O VA  demonstrated a significant 
^  3f hen the absolute amounts o f the six proteins in PICF from
and inflam ed sites were compared (p=0.004). Univariate 
cSts com paring the levels o f these proteins between healthy 
• fl med implant sites demonstrated that the levels o f a2-M , 
3fld ‘n (ng/30s) and IgG (EU /30s) were significantly
al'A (p<0*.01) 1° PICF from inflamed sites (Table 4). However,
s
'^■ficanee (p=0.097) (Table 4). When the absolute amounts of 
otein in fluid from healthy implant and tooth sites were 
ared no significant difference were noted (M ANOVA, 
:n1^ 99)1 Similarly, when absolute amounts from inflamed tooth 
" j^ mnlant sites were compared, the M A N O V A  did not 
-rnonstrate a significant effect (p=0.06) (Table 4).
SflF jj; levels showed a tendency towards increased levels in 
inflamed sites this increase just failed to reach statistical
e 3- Zl•meal indices at teeth and implants.
Implant sites Tooth sites
H e a l t h y Inflamed Healthy Inf 1amed
n= 31 n= 31 n=21 □ =27
Score n (%) n (%) a <%) n {%)
r 0 25 (81) - ! 17 (81) -
6 (19) - 4 (19) -
2 - 18 (58) * 10 (37)
1 - 12 (39) _ 16 (59)
4 - 1 (3) - 1 (4)
mean (SD) mean (SD) mean (SD) mean (SD)
0.193 (0.4) 2.452 (0.6) 0.190 (0.4) 2.667 (0.6)
Score n (%) n (%) a (%) n (%)
0 20 (65) 8 (26) 14 (67) 5 (19)
1 10 (32) 4 (13) 6 (29) 9 (33)
2 1 (3) 19 (61) 1 (4) 11 (41)
3 - - - 2 (7)
mean (SO) mean (SD) moan (SD) mean (SD)
0.387 (0.6) 1.355 (0.9) 0.381 (0.6) 1.385 (0.9)
an n (%) n* (%) a (%) a (%)
1 - - 4 (19) -
2 3 (10) 5 (17) 13 (62) 9 (33.3)
3 21 (68) 13 (43) 4 (19) 9 (33.3)
4 5 (16) 11 (37) - 9 (33.3)
S 2 (6) 1 (3) -
mean (SO) mean (SD) mean (SD) mean (SD)
3.193 (0.7) 3.27 (0.8) 2.00 (0.6) 3 (0.8)
n (%) n (%) a (%) n (%)
21 (67) 29 (94) 3 (14) 23 (85)
®ean (SD) mean (SD) mean (SD) mean (SD)
PTFt— r 0-156 (0.1) 0.335 (0.3) 0.111 (0.1) 0.276 (0.2)r vlr 
I ’*oing
ue missing 
gingival index: PI 1 =plaque index; PD=probing
on probing; GCF (PICF)=crevicular fluid
depth
T.bl. 4. Absoluta of o2-macro, 1 o b .Un U2-M). bl-.ntltrrp.ln (a l .
AT), traosf arnn <W >. U c t o f . r r m  H D .  Aibuaun <Alb) <„,/3o „  .nd Igo
»» crevicular fluid fro. health, and 



























































MANOVA healthy v infl— ed teeth. n=17 paxrs. p=0.021; .11 univ.nate coep.ri.ona 
significant p<0.05.
MANOVA healthy v inflaMd implants. n=31 pairs, p=0.00A; all univariate coBan.on. 
significant p<0.05 except for LP p=0.097.
MANOVA healthy implants v teeth, n=21 pairs. p=0.299.
MANOVA inflaMd implants v teeth, n=27 pairs, p-0.06. 
v=versua
When results were expressed as ng/^g Alb (a2-M , a l-A T , TF and 
LF) or EU/^g Alb (IgG) the picture was divergent (Table 5). 
Repeated measures M ANOVA demonstrated a significant effect 
when inflamed and healthy tooth sites (p=0.011) were compared. 
However, univariate analysis demonstrated that the only significant 
differences were the reduction in IgG and TF levels in GCF from 
diseased sites (p=0.001 and p=0.024 respectively, Table 5). GCF 
a2-M , a l-A T  and LF levels did not demonstrate a significant 
difference between healthy and inflamed tooth sites when 
expressed as ng/^ig Alb. Similarly, M A N O V A  demonstrated a 
significant effect when PICF levels o f these proteins from healthy 
and diseased implant sites were compared (p=0.007), but univariate 
analysis demonstrated a significant difference only in the reduction 
of the levels o f IgG in PICF from inflamed compared to healthy 
implant sites (p=0.03). Finally, M ANO VA did not demonstrate a 
significant effect when healthy or inflamed tooth and implant sites 
were compared (p=0.193 and p=0.137 respectively).
Table 5. Specific amounts of a2-macroglobulm (a2-M), al-antitrypsin (al- 
AT), transferrin (TF', lactoferrin ' LF) (ng/ug Alb) and IgG against 
P.gingivalis (EU/yg Alb) in crevicular fluid from healthy and inflamed tooth 
and implant sites. Geometric means (95% confidence intervals; are shown.









a2-M 17 20 17 19
(10-28) (12-32) (10-30) (11-30)
al-AT 33 42 52 51
(25-45) (30-60) (35-76) (36-72)
TF 34 35 56 36
(25-46) (24-51) (39-79) (27-48)
LF 17 14 44 23
(10-30) (3-23) (22-87) (12-41)
IgG 82 47 115 50
(53-126) (31-71) (72-182) (32-78)
MANOVA healthy v inflamed teeth, n=17 pairs, p=0.011; significant univ.riate comparisons 
TT:p<0.05 and IgG:p<0.01.
MANOVA healthy v inflamed implants, n-31 pairs, p=0.007; significant univariate comparisons 
IgC: p<0.05.
MANOVA healthy implants v teeth. n=21 pairs, p-0.193.




U S S IO N
data displayed som e interesting features. Very fewjjnical
^ implant tooth sites had an MGI score o f 4,
ting ^ at implants and teeth were relatively well 
fcft0 . ^  A s expected, inflamed implant and tooth sites 
^^strated  higher amounts o f plaque than healthy sites depicting, 
ihc limits o f this cross-sectional investigation, the w ell-know n  
of plaque accum ulation with inflammation of the 
tissues but also o f  the peri-implant tissues. When the 
— 'ally healthy sites w ere probed after all sampling was 




fo l lo w in g  the probing. This difference in bleeding frequencyjotnp
most likely due to the reduced resistance to probing offered by 
mucosa in com parison to that offered by the
. „ c  peri-itnpl3111
va as a consequence o f differences in terms o f tissue 
'^position, organisation and attachment to the root/implant surface 
Berglundh et al. 1991) as w ell as the shape o f  the anchorage unit, 
in fact, in a recent beagle dog study (Ericsson & Lindhe 1993), in 
- cn probing with standardised pressure (0.5N ; probe diameter 
5mm) at implants and teeth with non-inflam ed mucosa was 
•sioiogically evaluated, it was reported that the probe penetrated on 
„£ average 1.3mm (SD  0.3) into the supracrestal connective tissue 
[mplants, while at teeth the tip o f the probe was consistently  
a ted within the zone o f the junctional epithelium. The high 
-squency of bleeding found in the present study follow ing probing 
• ;ne ’clinically healthy’ implant sites, despite the use o f a probing 
-essure of only 0.25N , indicates that a pressure less than 0.25N  
-3V be needed in order not to traverse the apical termination o f the 
xn-implant junctional epithelium , and hence caution must be 
\srcised when comparing the probing data for teeth and implants 
n the present investigation.
:e assessment o f the four acute-phase proteins, Alb and also IgG 
:ainst P.gingivalis provides a profile for GCF and PICF 
mponents of different sources and with different functions. Such 
■ profile, especially when com ponents are assessed in GCF or PICF 
-om the same site, g ives a picture o f the inflammatory and 
-munological responses at a sp ecific  site. N one o f the constituents 
sorted in this study have been previously determined in PICF.
'milarly to GCF, PICF demonstrated protease-inhibitory capacity 
-Je to the presence o f  the potent protease-inhibitors a2-M  and a l -  
as well as general antimicrobial properties via the iron-binding 
-’Qteins TF and LF. The presence in PICF o f specific  
^unoglobulin against P.gingivalis , a putative periodontopathogen  
•at has been isolated from peri-implant sulci (Lekholm et al. 1986, 
et al. 1989, Quirynen & Listgarten 1990), could be due to 
*alised induction o f plasma ce lls  o f the peri-implant mucosa to 
production and/or leakage from serum. Specific  
Unoglobulin in the peri-implant crevice could be involved in the 
ionisation of m icro-organism s and also com plem ent activation 
enng further specific antimicrobial properties to PICF.
investigation w e decided to express results o f GCF and PICF 
,tl0^ ents *n two w ays, as ng/30s sam ple and as ng//ig Alb. The 
V  3 C ^°r exPress*ng results as ng/30s sam ple has been discussed  
(^ m ster  et a '^ 1986). Reporting results per unit Alb  
lni0rmalion on constituent levels relative to the serum 
^cat‘ C° mPonent o f GCF or PICF and may thus supply an 
0n of proteins derived through extravasation.
Tfc been \
snown in previous investigations that the levels of the
acute-phase proteins are higher in GCF from inflamed tooth sites 
compared to healthy sites (C ondacci et al. 1982, Giannopoulou et 
al. 1990, Adonogianaki et cd. 1992). Thus, when the results were 
expressed as ng/30s, the increase at inflam ed sites w as anticipated, 
for the protease inhibitors a 2 -M  and a l - A T  and the iron-binding 
proteins TF and LF (Table 4). For a 2 -M , a l - A T  and TF, which  
have high serum concentrations (2m g/m l) (Johansson 1979), 
increased vascularity and vascular permeability is probablv the 
major factor contributing to higher GCF or PICF levels at inflamed  
sites. This is supported by the sim ultaneous rise in GCF or PICF 
volum e as well as Alb at inflamed sites around both implants and 
natural teeth. Further support for the predominantly serum origin 
o f a2 -M  and a l-A T  is provided by the inability to demonstrate 
a significant difference between healthy and inflamed sites for both 
implants and teeth when the results were expressed relative to /Mb 
(Table 5).
When results were expressed as ng/30s LF demonstrated a 
statistically significant increase in GCF from inflamed compared  
to healthy tooth sites. A s LF may be considered a crevicular PMN  
marker (Adonogianaki et al. 1993) its increase in GCF at inflamed 
sites may be accounted for by increased PM N emigration. 
Although a significant difference was not show n when inflamed  
implant and tooth sites were compared, there was a tendency for 
inflamed implant sites to have lower levels o f LF than inflamed  
tooth sites. This tendency is in line with findings reported from 
a recent animal study show ing that lower PMN numbers may be 
found in inflamed peri-implant tissues compared to inflamed tooth 
sites (Ericsson et al. 1992).
The finding that inflamed tooth sites demonstrated higher antibody 
titres (E U /30s) o f IgG against P.gingivalis  than healthy tooth sites 
appears to contradict the findings o f  our previous study (Kinane et 
al. 1992). However, one has to consider that the present study 
refers to non-periodontally involved sites from well-m aintained  
patients, whereas the previous study was on a periodontitis affected  
population. The increase in the absolute amounts o f IgG against 
P.gingivalis  may be due to increased exudation from serum by 
similar m echanism s as for the acute-phase proteins.
An interesting observation was the drop in TF and IgG levels and 
the tendency for lower LF levels at inflamed tooth sites compared 
to healthy sites when results were expressed as ng//ig Alb (Table 
5). The drop in specific IgG levels in inflamed tooth sites may be 
related to the opsonisation and/or degradation by P.gingivalis 
resulting in consumption o f the im m unoglobulin (Kilian 1981). 
Furthermore, both TF and LF may bind to oral isolates, which may 
contribute to decreased levels o f the iron-binding proteins at 
diseased sites (Beighton et al. 1992; Ellison and Geihl 1991). 
These events would result in a relative dilution o f TF, LF and IgG 
compared to Alb. At diseased implant sites, however, only IgG 
showed a trend for lower levels when the results were expressed  
as ng/^g Alb, which may be related to the tendency for higher Alb  
levels (ng/3Gs) at healthy implants sites compared to healthy tooth 
sites. The tendency for higher albumin levels may suggest that 
structural and anatomical differences in implant sites result in 
greater leakage in healthy implant compared to healthy tooth sites. 
However, the fact that overall no significant differences were 
observed between implants and teeth (ng/30s or ng//ig Alb; Tables 
4 & 5) suggests that production o f PICF is probably governed by 
similar m echanisms to that o f GCF and that inflammatory events 
are similar in the peri-implant mucosa and the gingiva.
incon
the
dusion, this investigation suggests that great similarities exist 
ofile of GCF and PICF constituents and analogous
* 4 a  r v x  M  I a ■>« r 1 a>M — f t o  / “I a aw* ■ a m  1 y-v a r-\ 1seem to control inflammatory and immunological
^ ^ an S^n^ round both implants and natural teeth.nses
r
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Abstract
The relationships between various forms of periodontal disease 
and the avidities of serum antibodies of all three immunoglobulin 
classes (IgG, IgM and IgA) to Porphyromonas gingivalis and 
Actinobacillus actinomycetemcomitans were investigated. Twenty- 
four patients with untreated adult periodontitis (AP) and twelve 
untreated patients diagnosed as suffering from the early-onset 
form of periodontitis, rapidly progressive periodontitis (RPP) 
were studied. The latter group were age and sex matched to 
healthy controls. Measurement of antibody titre was made and 
avidity (expressed as molarity (M) ) was further assayed using the 
thiocyanate elution method. Avidity has previously been shown 
to relate to the biological function of antibody. IgM avidities 
to P. gingivalis were lower in the RPP group than in the AP group 
(0.54M compared to 0.74M, p<0.001). IgG avidities tended to be 
lower in the former than in the latter group (0.58M compared to
0.92M, p=0.065). In accordance with other workers,
seropositivity was defined as an immunoglobulin titre more than 
twice the median level of control sera. Only two of the RPP 
group were seropositive. Interestingly, the seronegative RPP 
patients were significantly different (0.53M compared to 0.92M,
p<0.01).
The data presented here that patients with various forms of 
periodontal disease appear to produce antibodies of differing 
avidity to P. gingivalis suggest that the quality of the humoral 
immune response to suspected periodontopathogens may have a 
bearing on the aetiology of periodontal disease.
2
Introduction
The Gram-negative obligate anaerobe, Porphyromonas gingivalis and 
the facultative anaerobe, Actinobacillus actinomycetemcomitans, 
are both considered important periodontopathogens within various 
forms of periodontal disease (32,37). A number of studies have 
demonstrated that increased serum antibody titres to one or more 
suspected periodontopathogens occur in periodontitis (18,27,36). 
However, others have reported titres that are similar to or lower 
than those found in control subjects (9,15,19). We have shown 
previously that local antibody levels are lower in deeper pockets 
and in more inflamed sites than in shallower pockets and less 
inflamed sites in adult periodontitis patients (23).
In this study we aimed to ascertain whether or not adult 
periodontitis (AP) could be distinguished from the early-onset 
form of periodontitis, rapidly progressive periodontitis (RPP) 
(3,28), in terms of patients' humoral immune response to these 
organisms. Wilton et al concluded in their review that the data 
currently available on antibody titre responses to suspected 
periodontopathogens, e.g. P. gingivalis and A • 
actinomycetemcomitans do not allow these responses to be 
diagnostic (35). But they suggested that the investigation of 
antibody avidity may be more fruitful. Thus antibody avidity and 
titre were examined for their potential to discriminate between 
these patient groups.
Antibody avidity, i.e. the net binding strength between 
antibodies and antigens, has been shown to be a useful indicator 
of the biological function of antibodies in acute and chronic 
infections (21), autoimmunity (29), B-cell activation (33) and 
vaccine development (4). Recently, it has been demonstrated that 
the effective binding of IgG to virulent P. gingivalis has a 
crucial role in the opsonization and phagocytosis of this 
organism and also in complement activation (6,7). In addition,
3
Lopatin et al showed that the avidity of IgG-class antibodies to 
P. gingivalis was significantly increased in adult periodontitis 
patients compared with healthy controls (24). No such elevation 
was detected in IgM-class antibodies. The authors suggested 
that, since human antibodies appear to be of generally low 
avidity compared with those in rabbits immunized with this 
organism, the presence of low avidity antibodies may contribute 
to the pathology associated with periodontal disease.
Chen et al demonstrated that IgG avidities to P. gingivalis 
were lower in rapidly progressive periodontitis patients than in 
control subjects. However, after treatment the avidities 
increased significantly to levels higher than in controls (5). 
They concluded that many rapidly progressive periodontitis 
patients do not produce protective levels of biologically 
functional antibody as a result of natural infection, but 
treatment may induce the production of such antibodies.
Whitney et al, in a recent study of the humoral immune 
response in rapidly progressive periodontitis, showed that these 
patients have lower IgG avidities to P. gingivalis (34). Our 
group has shown significantly higher IgG avidities to P. 
gingivalis in adult periodontitis patients than in seronegative 
control subjects (26).
These findings have prompted us to compare directly adult 
periodontitis and rapidly progressive periodontitis patients as 
well as healthy controls in order to establish whether there are 




P. gingivalis NCTC 11834 was grown under anaerobic conditions
4
(85% N2, 10% H2, 5% C02) and A . actinomycetemcomitans in C02 at 
37C on Columbia blood agar (Life Technologies, P.O. Box 35, 
Trident House, Renfrew Road, Paisley, PA3 4EF, Scotland, UK). 
P. gingivalis was harvested after 5 days and A . 
actinomycetemcomitans after 24 hours into phosphate-buffered 
saline, lmM Na2 EDTA, pH 7.4 (PBSE), washed by centrifugation, 
and fixed for 1 hour in 10% formal saline. The cells were then 
washed twice in PBSE and once in 0.1M Na carbonate-bicarbonate 
buffer containing 0.02% NaN3 at pH 9.6 (coating buffer). Fixed 
cells were stored in coating buffer at 4°C until use.
Subjects
Serum was collected from twenty-four adult periodontitis patients 
(AP), twelve rapidly progressive periodontitis patients (RPP) and 
twelve healthy control subjects who were age and sex matched to 
the rapidly progressive periodontitis patients. The mean age of 
the adult periodontitis patients was 40.3 years (25-53) and this 
group comprised 13 males and 11 females. The mean age of the 
rapidly progressive periodontitis patients was 32.8 years (20-40) 
and this group comprised 6 males and 6 females. Samples were 
collected from all patients before the commencement of therapy.
ELISA
Specific antibody titres were measured by ELISA based on the 
method of Ebersole et al (10,11), using formalinized whole cells 
at an absorbance which had previously been determined as optimum 
to coat microtitre plates. Immulon 1 plates (DynateCh 
Laboratories Ltd., Daux Road, Billingshurst, Sussex, RH14 9SJ, 
England, UK) were employed because of their low protein-binding 
characteristics. After coating, the plates were treated with PBS 
containing 0.1% bovine serum albumin (BSA), 0.05% Tween 20 and 
5% skimmed milk to remove background binding. Serum serially 
diluted in a similar buffer but without the 5% skimmed milk, was
5
then added and the plates were subsequently incubated with 
biotin-conjugated anti-human IgG, IgA or IgM (Sigma Chemical 
Company Ltd., Fancy Road, Poole, Dorset, BH17 7NH, England, UK) 
and thereafter with Extravidin-peroxidase (Sigma). Reaction was 
visualized using o-phenylenediamine dihydrochloride substrate and 
stopped with 1M H2S04. Samples were assayed in duplicate and 
results were calculated using a regression line and derived 
equation from serial dilutions of a reference serum. Results 
were expressed as ELISA units (EU) (17).
Dissociation Assay
The dissociation assay to determine antibody avidity was 
performed by incubating with serum as described above, and then 
the wells were treated with increasing concentrations of ammonium 
thiocyanate (0.2-8.0M). The concentration of thiocyanate 
required to dissociate 50% of bound antibody was determined by 
linear regression analysis. This was termed the ID50 and 
provides a measure of relative avidity as previously reported 
(25,30).
Statistical Analysis
Mann-Whitney U-tests were used in group comparisons of avidity 
where medians were employed and also in group comparisons of the 
non-normally distributed antibody titres. Student's paired t- 
tests were used to assess whether differences were significant 
between rapidly progressive periodontitis patient data and that 
of age/sex matched controls. Regression analysis was used to 
correlate avidities and titres of antibodies to P. gingivalis and 
A. actinomycetemcomitans in adult periodontitis, rapidly 
progressive periodontitis and control groups.
Results
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The median relative avidity, expressed as an ID50 or avidity 
index value equivalent to the molarity (M) of ammonium 
thiocyanate required to dissociate 50% of bound antibody, and 
median titre, expressed as ELISA units (EU), of antibody to both 
organisms for adult periodontitis and rapidly progressive 
periodontitis groups are given in Table 1. Statistically 
significant differences between groups were assessed using the 
Mann-Whitney U-test and p-values are given. The avidity of IgG 
tended to be higher and IgM avidity to P. gingivalis was 
significantly higher in adult periodontitis compared to rapidly 
progressive periodontitis patients, and also IgA titre was 
significantly lower in rapidly progressive periodontitis compared 
to adult periodontitis patients. In contrast, IgA avidity to A. 
actinomycetemcomitans tended to be higher in rapidly progressive 
periodontitis than in adult periodontitis and IgG and IgA titres 
were significantly higher in rapidly progressive periodontitis 
than in adult periodontitis. Similarly, the median avidity of 
antibody to both organisms for adult periodontitis and 
seronegative rapidly progressive periodontitis groups are given 
in Table 2, with p values for the comparisons between the two 
patient groups. Seronegativity here is as defined by Chen et al 
(5) (i.e. median titre < 2 X control median), and it should be
noted that the seronegative groups for P. gingivalis and A. 
actinomycetemcomitans are not identical, i.e. two patients were 
seropositive for P. gingivalis and a different two patients for 
A. actinomycetemcomitans.
A comparison between seronegative rapidly progressive 
periodontitis patients and their age/sex matched controls in 
terms of IgG avidity to P. gingivalis is also shown in Table 2 
and a paired t-test indicated that they were not significantly 
different.
The percentage of patients in both patient groups who were 
seropositive in terms of titre and avidity to P. gingivalis and
7
A. actinomycetemcomitans are shown in Table 3. The
seropositivity definition is extended here to include avidity,
i.e. avidity > 2x median control avidity.
A discriminant analysis of the IgG avidity for adult 
periodontitis and rapidly progressive periodontitis patient 
groups was performed (Table 4).. This analysis was performed with 
cross-validation thereby mimicking a prospective analysis 
(Minitab statistical software version 8). Data are shown for the 
analyses with the whole rapidly progressive periodontitis group 
and also the seronegative rapidly progressive periodontitis 
group.
Correlations between titre and avidity of antibody to P. 
gingivalis and A. actinomycetemcomitans are given in Table 5 for 
adult periodontitis, rapidly progressive periodontitis and 
control groups. Adult periodontitis and rapidly progressive 
periodontitis groups show different patterns in terms of these 
correlations, i.e. for adult periodontitis, IgG and IgA to P. 
gingivalis are correlated and IgM to A. actinomycetemcomitans, 
whereas for rapidly progressive periodontitis, IgG and IgM to P. 
gingivalis are correlated and IgG and IgA to A. 
actinomycetemcomitans. In addition, periodontitis patients are 
clearly different from control subjects in these correlations.
Discussion
The present study shows that IgG and IgM antibody avidities to 
P. gingivalis were lower in rapidly progressive periodontitis 
patients than adult periodontitis patients, with IgA titres 
being significantly lower than in adult periodontitis. However, 
a contrasting pattern could be discerned for A. actinomycetem­
comitans, with IgA avidity tending to be higher than in adult 
periodontitis and IgG and IgA titres also being significantly
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higher. In addition, median avidity of IgG antibody to P. 
gingivalis tended to be lower in seronegative rapidly progressive 
periodontitis patients than in age/sex matched controls. As such 
this study supports the hypothesis that there are differences in 
the humoral immune response to these two organisms in rapidly 
progressive periodontitis and adult periodontitis, and is 
consistent with previous studies demonstrating that avidities to 
P. gingivalis are lower than normal in rapidly progressive 
periodontitis (5,34) and higher than normal in adult
periodontitis (24,26) and extends our knowledge by indicating 
that this pattern differs for the humoral response to A. actino- 
mycetemcomitans.
Rapidly progressive periodontitis has been recognized as a 
distinct clinical condition (3,28). In addition, an association 
has been demonstrated between the occurrence of rapidly 
progressive periodontitis and the HLA system (1,20). A
correlation has been demonstrated between HLA A9 and rapidly 
progressive periodontitis. A number of studies have been
published showing that rapidly progressive periodontitis patients 
differ in their humoral immune response expressed as antibody 
titre to suspected periodontopathogens (2,16,18,36).
A recent study by Ebersole and Kornman (14) demonstrated 
that P. gingivalis emerges as an organism in the subgingival 
plaque during the conversion from gingivitis to progressing 
periodontitis in a non-human primate model, and that this elicits 
a systemic antibody response specific for this microorganism. 
Similarly, a study by Dahlen and Slots (8) in rabbits showed that 
animals co-inoculated with P. gingivalis and A. 
actinomycetemcomitans showed significantly more severe disease 
than animals which were monoinfected. They conclude that the 
immune system acting through systemic antibodies and/or cellular 
mechanisms may modulate the pathogenic potential of infecting 
periodontal pathogens. It may be that antibody avidity has a
9
crucial role in this modulation.
In the light of these findings and evidence of the 
importance of avidity as an aspect of the biological function of 
antibody (6,7,31), it may be that rapidly progressive 
periodontitis patients constitute a sub-group which is 
predisposed to early and rapidly progressive disease as a result 
of a mechanism blocking the production and/or deployment of 
strongly-binding antibody to suspected periodontopathogens.
To put the differences in relative avidity of antibody 
between different patient groups into context in terms of 
relative binding strength, the scale of relative antibody 
responses previously employed by Ebersole et al (13) may be used. 
The baseline avidity index to tetanus toxoid in that study of 
non-human primates was 0.9M, increasing to 1.72M (a 7-fold 
increase in binding strength) following primary immunization, and 
2.56M (a 45-fold increase in binding strength) following 
secondary immunization. Using the same scale of relative antibody 
responses, the avidity index of the RPP patients in the present 
study indicate that the binding strength is only 30-40% of that 
observed in the AP patients.
It must also be borne in mind that the mean age of the adult 
periodontitis patients was 40.3 years (25-53), whereas that of 
the rapidly progressive periodontitis patients was 32.8 years 
(20-40). Age matching of these groups was, by definition, 
impossible. However, a healthy control group age and sex matched 
to the rapidly progressive periodontitis patients was included 
since it was possible that any differences found between the two 
patient groups might be due to age alone.
Our findings of overall low-avidity antibodies in rapidly 
progressive periodontitis patients, and generally in humans, are 
in agreement with previous reports (5,24,26,34). However, they 
contrast with higher avidities of antibody to P. gingivalis and 
A. actinomycetemcomitans found in an early study in this field
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(12). It must be borne in mind, however, that these latter data 
were based on samples of five and four patients respectively in 
a mixed periodontitis group, and that these samples may have 
contained an unrepresentatively high proportion of seropositive 
adult periodontitis patients. As the present study shows, these, 
and a small percentage of seropositive rapidly progressive 
periodontitis patients can skew analyses unless measures are 
taken such as dichotomization into seropositive and seronegative 
groups or non-parametric testing based on medians rather than 
means•
The data presented in Table 5 on the relationship between 
titre and avidity are in agreement with our previous findings 
(26). A clear difference can be discerned between periodontitis 
patients and control subjects, and there is also an indication 
that these relationships in terms of the responses to P.
gingivalis and A, actinomycetemcomitans may also yield a useful 
distinction between adult periodontitis and rapidly progressive 
periodontitis patients. It is interesting to note that all of 
the correlations here were positive compared with the negative 
correlations between titre and avidity of antibody to Candida 
albicans found in a recent study (22). Care should, however, 
always be exercised in the interpretation of these correlations. 
For example, Table 5 also shows one significant correlation for 
control subjects in terms of IgM against A.
actinomycetemcomitans. However, as 3/6 correlations were 
statistically significant (p<0.05) for adult periodontitis
patients and 4/6 for rapidly progressive periodontitis patients, 
it is highly unlikely that these patterns of response are chance 
findings. On the other hand, the finding of one significant 
correlation out of six for control subjects could have arisen by 
chance.
If a precipitating factor or factors is necessary to
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initiate generalized, severe periodontitis at any age, and low 
avidity antibody is just another factor in its pathogenesis, then 
the current definition of rapidly progressive periodontitis based 
upon a cut-off age may appear even more arbitrary. This 
interpretation may appear particularly relevant in the light of 
the work of Joynson et al (21) on acute and chronic infection in 
relation to antibody avidity. In the present study the rapidly 
progressive periodontitis patients appear as a low avidity/acute 
infection group whereas the adult periodontitis patients appear 
as a higher avidity/chronic infection group.
Similarly, it may be that antibody avidity assessments could 
provide an indication of severity in adult periodontitis 
patients. Our group has previously shown a relationship between 
antibody avidity to P. gingivalis and attachment loss experience 
in a longitudinal study; in that IgM antibodies were of 
significantly higher avidity in adult periodontitis patients who 
did not experience further attachment loss than in those who did 
(26).
The data presented here that patients with various forms of 
periodontal disease appear to produce antibodies of differing 
avidity to P. gingivalis suggest that the quality of the humoral 
immune response to suspected periodontopathogens may have a 
bearing on the aetiology of periodontal disease.
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Table 2: Median avidities and titres of IgG antibodies to P. gingivalis and A  
actinomycetemcomitans for AP group, seronegative RPP group and controls age/sex 
matched to seronegative RPP group.











































































Table 4: Discriminant analysis of AP and RPP groups with cross-validation for entire RPP group 




Assigned group AP 11 3
RPP 13 9
% correct 46 75
AP (n=24) sero-negatlve RPP (n=10)
AP 14 1
seronegative RPP 10 9
% correct 58 90
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Table 5: Correlations between titres and avidities of IgG, IgM and IgA antibodies to P. 
gingivalis and A. actinomycetemcomitans for AP, RPP and Control groups.
P. gingivalis A.
actinomycetemcomitans
IgG IgM IgA IgG IgM IgA
AP 19.2%, 1.2% 36.4%, 6.8% 73.8%, 0.1%
0.03* 0.61 0.002* 0.22 0.003* 0.90
RPP 81.6%, 36.1%, 3.1% 80.5%, 1.4% 36.4%,
<0.001* 0.04* 0.58 <0.001* 0.72 0.04*
Control 1.5% 24.0% 9.1% 14.4% 61.2%, 9.6%
0.70 0.11 0.34 0.22 0.003* 0.33
Results given as R2 (%), p-value. Asterisks indicate statistical significance at p<0.05.
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